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1. Abstract 
 
Parasitic helminths share a large degree of common genetic heritage with their various hosts. This 
includes cell-cell-communication mechanisms mediated by small peptide cytokines and 
lipophilic/steroid hormones. These cytokines are candidate molecules for host-parasite cross-
communication in helminth diseases. In this work the function of two evolutionary conserved 
signaling pathways in the model cestode Echinococcus multilocularis has been studied. 
First, signaling mechanisms mediated through fibroblast growth factors (FGF) and their cognate 
receptors (FGFR) which influence a multitude of biological functions, like homeostasis and 
differentiation, were studied. I herein investigated the role of EmFR which is the only FGFR homolog 
in E. multilocularis. Functional analyses using the Xenopus oocyte expression system clearly indicate 
that EmFR can sense both acidic and basic FGF of human origin, resulting in an activation of the EmFR 
tyrosine kinase domain. In vitro experiments demonstrate that mammalian FGF significantly 
stimulates proliferation and development of E. multilocularis metacestode vesicles and primary cells. 
Furthermore, DNA synthesis and the parasite’s Erk-like MAPK cascade module was stimulated in the 
presence of exogenously added mammalian FGF. By using the FGFR inhibitor BIBF1120 the activity of 
EmFR in the Xenopus oocyte system was effectively blocked. Addition of BIBF1120 to in vitro 
cultivated Echinococcus larval material led to detrimental effects concerning the generation of 
metacestode vesicles from parasite stem cells, the proliferation and survival of metacestode vesicles, 
and the dedifferentiation of protoscoleces towards the metacestode. In conclusion, these data 
demonstrate the presence of a functional EmFR-mediated signaling pathway in E. multilocularis that 
is able to interact with host-derived cytokines and that plays an important role in larval parasite 
development. 
Secondly, the role of nuclear hormone receptor (NHR) signaling was addressed. Lipophilic and steroid 
hormone signaling contributes to the regulation of metazoan development. By means of in silico 
analyses I demonstrate that E. multilocularis expresses a set of 17 NHRs that broadly overlaps with 
that of the related flatworms Schistosoma mansoni and S. japonicum, but also contains several NHR 
encoding genes that are unique to this parasite. One of these, EmNHR1, is homolog to the DAF-
12/HR-96 subfamily of NHRs which regulate cholesterol homeostasis in metazoans. Modified yeast-
two hybrid analyses revealed that host serum contains a ligand which induces homodimerization of 
the EmNHR1 ligand-binding domain. Also, a HNF4-like homolog, EmHNF4, was characterized. Human 
HNF4 plays an important role in liver development. RT-PCR experiments showed that both isoforms 
of the EmHNF4 encoding gene are expressed stage-dependently suggesting distinct functions of the 
two isoforms in the parasite. Moreover, specific regulatory mechanisms on the convergence of NHR 
signaling and TGF-β/BMP signaling pathways in E. multilocularis have been identified. On the one 
hand, EmNHR1 directly interacted with the EmSmadC and on the other hand EmHNF4b interacted 
with EmSmadD, EmSmadE which are all downstream signaling components of the TGF-β/BMP 
signaling pathway. This suggests cross-communication in order to regulate target gene expression. 
With these results, further studies on the role of NHR signaling in the cestode will be facilitated. 
Also, the first serum-free in vitro cultivation system for E. multilocularis was established using 
PanserinTM401 as medium. Serum-free co-cultivation with RH-feeder cells and an axenic cultivation 
method have been established. With the help of this serum-free cultivation system investigations on 
the role of specific peptide hormones, like FGFs, or lipophilic/steroid hormones, like cholesterol, for 
the development of helminths will be much easier. 
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2. Zusammenfassung 
 
Parasitäre Würmer weisen eine große genetische Verwandtschaft mit ihren Wirten auf. Diese 
schließt auch Zell-Zell-Kommunikationsmechanismen ein, die sowohl durch Peptidhormone als auch 
durch lipophile/steroidale Hormone vermittelt werden. Man vermutet, dass diese Stoffe eine 
wichtige Rolle bei der Wirt-Parasiten-Kreuzkommunikation spielen. Deshalb untersuchte diese Arbeit 
die Funktion von zwei konservierten Signalwegen im Modellorganismus Echinococcus multilocularis. 
Der erste Teil dieser Arbeit beschäftigt sich mit den Fibroblast Growth Factors (FGF). Diese steuern 
durch die Bindung an spezifische FGF-Rezeptoren (FGFR) eine Vielzahl von biologischen Funktionen, 
wie beispielsweise Homöostase- und Differenzierungsprozesse. Zunächst wurde EmFR, das einzige 
FGFR-Homolog im Fuchsbandwurm in Xenopus Oozyten heterolog exprimiert. Dabei wurde 
nachgewiesen, dass der Rezeptor sowohl acidic als auch basic FGF erkennen kann und dies zur 
Aktivierung der Tyrosinkinasedomäne führt. Außerdem förderte im in vitro Experiment die exogene 
Zugabe dieser Wirtsfaktoren die Proliferation und Entwicklung von Metacestodenvesikeln und 
Primärzellen. Darüber hinaus wurden die DNA-Synthese und die Erk-MAPK-Kaskade des Parasiten 
stimuliert. Im Gegensatz dazu konnte durch die Hinzugabe des FGFR-Inhibitor BIBF1120 die Aktivität 
des Rezeptors im Xenopus Oozytensystem erfolgreich blockieret werden. Durch den Inhibitor wurde 
die Regeneration von Metacestodenvesikeln aus Stammzellen, die Proliferation und das Überleben 
von Metacestodenvesikeln verhindert und eine Dedifferenzierung von Protoskolizes verursacht. 
Zusammengefasst zeigen diese Daten, dass E. multilocularis einen funktionellen durch EmFR-
vermittelten Signalweg besitzt, welcher in der Lage ist, mit Wirtszytokinen zu interagieren und eine 
wichtige Rolle bei der Entwicklung von Echinococcus Larvenstadien spielt. 
Außerdem wurde die Bedeutung der Nukleären Hormon Rezeptoren (NHR) für den Parasiten 
untersucht. Lipophile und steroidale Hormone regulieren viele Entwicklungsprozesse in Metazoen. 
Mittels in silico Analyse konnten 17 Rezeptoren der NHR-Familie in E. multilocularis identifiziert 
werden, die größtenteils mit dem NHR Repertoire von Schistosoma mansoni und S. japonicum 
übereinstimmen. Allerdings wurden auch Rezeptoren identifiziert, die einzigartig für E. multilocularis 
sind. Einer dieser Rezeptoren, EmNHR1, ist homolog zur DAF-12/HR-96 Familie, die den 
Cholesterinstoffwechsel in Metazoen reguliert. Yeast-Two Hybrid Experimente zeigten, dass 
Wirtsserum den putativen Liganden von EmNHR1 enthält, da dessen Zugabe zur Homodimerisierung 
der EmNHR1-Liganden-bindungsdomäne führte. Außerdem wurde mit EmHNF4 ein weiterer 
Rezeptor charakterisiert, dessen humanes Homolog die Entwicklung der Leber beeinflusst. RT-PCR-
Experimente zeigten, dass die zwei entdeckten Isoformen von EmHNF4 stadienspezifisch exprimiert 
werden, was auf mögliche Funktionsunterschiede deutet. Darüber hinaus wurde sowohl für 
EmNHR1, als auch für EmHNF4 beobachtet, dass die DNA-Bindungsdomänen mit Komponenten des 
TGF-β/BMP-Signalwegs direkte Proteininteraktionen eingehen. Während EmNHR1 mit EmSmadC 
interagiert, zeigte EmHNF4b eine Reaktion mit EmSmadD und EmSmadE, was auf eine 
Kreuzkommunikation zwischen beiden Signalwegen deutet. Diese Ergebnisse werden zukünftige 
Studien bezüglich der Funktion von NHR-Signalwegen in Zestoden deutlich erleichtern. 
Weiterhin wurde in dieser Arbeit das erste serum-freie in vitro Kultivierungssystem für 
E. multilocularis etabliert. PanserinTM401 diente als Medium sowohl für die Kultur mit Fütterzellen als 
auch für eine axenische Kulturmethode. Mit Hilfe dieses Systems können in Zukunft Untersuchungen 
über die Rolle von Peptidhormonen wie FGF, oder lipophilen bzw. steroidalen Substanzen, wie 
Cholesterin, bei der Parasitenentwicklung besser untersucht werden. 
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3. Introduction 
3.1. The small fox-tapeworm Echinococcus multilocularis 
3.1.1. Phylogeny and epidemiology 
The small fox-tapeworm Echinococcus multilocularis belongs to the class of Cestoda (Fig. 1) and is the 
causative agent of Alveolar Echinococcosis (AE). 
 
 
 
Fig. 1: Phylogenetic position of the genus Echinococcus in the tree of life. Species marked in pink are parasitic 
worms, in green free living worms. Squares in red illustrate the term “helminths”, with the exception of non-
parasitc Nematoda [1]. 
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Like all small tapeworms of the genus Echinococcus, the adult worm of E. multilocularis is an 
endoparasite residing in the intestine of vertebrates. Its body is segmented into proglottids and 
comprises adhesive structures like the rostellum or the scolex. 
Echinococcus species belongs to the family of Taeniidae which is placed in the order of Cyclophyllidea 
and the subclass of Eucestoda. Overall, the phylum of Platyhelminthes consists of the classes 
Cestoda, Turbellaria and Trematoda. They share like all protostomes a bilateral symmetry, the 
development of three germ layers and during gastrulation the development of the mouth near the 
gut entrance. For the Turbellaria, all Platyhelminthes are parasites. Yet, the protostomes are divided 
into two branches: Ecdysozoa and Lophotrochozoa of which the Ecdysozoa include all moulting 
animals such as the arthropod Drosophila melanogaster and the nematode Ceanorhabditis elegans. 
In contrast, the Lophotrochozoa consist of flatworms (Platyhelminthes), Annelida and Mollusca. They 
are predominantly characterized by spiral cleavage and a prominent digestion system. In contrast to 
phylogenetic analyses the term “helminthes” is of historic origin and describes all endoparasitic living 
nematodes and platyhelminthes [1], like the study object of this thesis: E. multilocularis. 
The genus Echinococcus consists of different species causing a variety of clinical outcomes in various 
final host species. However, only the small fox-tapeworm E. multilocularis and the dog-tapeworm 
E. granulosus cause severe zoonotic diseases in humans, that is AE and cystic echinococcosis (CE), 
respectively [2]. Other species are: E. vogeli, E. shiquicus, E. oligarthrus, E. felidis [3].Throughout the 
last years, the taxonomic classification of the various E. granulosus strains (G1-G10) was extensively 
discussed and some strains are thought to be separate species [4]. In detail, E. granulosus strain G1 is 
termed E. granulosus sensu stricto, strain G4 E. equinus and strain G5 E. ortleppi, respectively [4,5]. 
Other strains like the cervid strain G10 and the pig strain G7 including G9 were grouped together 
with the non-European strains G6 in a single monophyltic group [2]. Yet, for the genotypes (G6, G7 
and G9) the term E. intermedius and for G8/G10 E. canadensis has been proposed [6,7]. In contrast 
to the E. granulosus strains, there is no evidence for species differentiation in E. multilocularis which 
is considered to be genetically conservative [8,9]. 
E. multilocularis is endemic in arctic and temperate zones of the Northern Hemisphere, namely in 
Europe, North America and Asia [10]. As depicted in Fig. 2 E. multilocularis, E. granulosus sensu 
stricto and E. granulosus strain G7 are endemic in Europe, however with different geographic 
distributions [11]. 
Since the last decade of the 20th century it was reported that E. multilocularis spread from south-
central Europe to central Europe including countries like Denmark, central France, northern Italy and 
the Balkan states. Most likely this recent spread is caused by high rabies vaccination rates in foxes 
which lead to an increase of survival rates and population density in foxes, resulting in a higher 
infection rate with E. multilocularis [11,12]. E. granulosus sensu stricto is present world-wide as 
concomitant of sheep farming and is present in Europe in the Mediterranean area, Wales and 
Bulgaria [11]. 
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Fig. 2: Distribution of the genus Echinococcus in Europe. Endemic areas of E. multilocularis (A), E. granulosus 
sensu stricto (B) and E granulosus G7(C) [11]. 
3.1.2. Biology and the life cycle of E. multilocularis 
E. multilocularis is characterized by a hermaphroditic life cycle which involves two host switches 
(Fig.3).  
 
Fig. 3: Life cycle of E. multilocularis. The adult worm of E. multilocularis (A) resides within the intestine of the 
definitive host, such as foxes, dogs or cats (B). The segmented worm is producing fertilized, infective eggs (C) in 
the gravid proglottid. The infective eggs harbor the first larval stage, the oncosphere (D) and are shed with the 
feces of the final host. Normally these are ingested by an intermediate host (F), mostly small rodents. Then the 
oncosphere gets activated by the passage through the stomach and the gut. Subsequently it actively penetrates 
the gut epithelium, and reaches small mesenterial veins, eventually being transported in the blood flow to the 
liver, where it develops to the third larval stage, the metacestode vesicle (G). After some time, protoscoleces 
develop in the metacestode vesicle. Once the final host takes up the intermediate host as a prey, the 
protoscoleces are activated and attach to the gut epithelium and develop into an adult worm. Thus, the cycle is 
closed. The oncosphere can also be taken up accidently by humans who are considered as dead end host (E). 
[2]. Schematic drawing taken from [2]. 
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The adult worm resides within the intestine of the carnivore final host and is about 2 - 4 mm in size. 
The scolex (head region) is comprised of the rostellum and adhesive organs with which the adult 
worm attaches to the gut wall of red and arctic foxes (genus Vulpes), but also dogs and cats as final 
hosts have been described. The estimated survival time of the E. multilocularis in the intestine is 
approximately six to twelve months and one fox can be infected with up to 200,000 worms without 
showing any sign of disease [13]. Characteristically, the adult platyhelminth is segmented in five 
proglottids. The last proglottid is termed gravid proglottid. It is usually enlarged and produces 
fertilized eggs. These infective eggs which harbor the first larval stage, the so-called oncosphere, are 
shed with the feces of the definitive host. Upon ingestion of contaminated diet the intermediate host 
takes them up. Habitually small rodents, but also deer, moose, reindeer and bison have been 
reported as intermediate hosts [13]. After ingestion the oncosphere hatches from the egg. The 
oncosphere becomes activated by the passage through the stomach and the intestine. Most likely, 
the acidic pH and bile salts are involved in this activation process [14] After activation it penetrates 
and invades the surrounding tissue and subsequently enters the mesenterial veins leading into the 
portal vein. From there, the oncosphere is transported by the blood flow to the liver. In the majority 
of all cases, the oncosphere develops within the liver to the second larval stage, the metacestode 
[15,16]. Characteristically, the metacestode is a fluid filled vesicle termed hydatid cyst which consists 
of an inner germinal layer and an outer acellular laminated layer. Main components of the laminated 
layer are carbohydrates [17,18] and high molecular weight glycans [19] which both are thought to be 
a protective shield against the intermediate host’s immune response [2]. The cells of the germinal 
layer proliferate, leading to the growth of the metacestode vesicle. By exogenous budding daughter 
cysts appear [13,20]. This leads to an infiltrative growth in the surrounding tissue and causes the 
typical tumor-like appearance inside the infected organs. Within the metacestode vesicle 
approximately 6 weeks post-infection with the oncosphere the third larval stage, the protoscolex 
develops in a so-called brood capsule and is characterized by its invaginated head structures. Once 
the intermediate host is taken up by the final host, as they are in a predator-prey-relationship, the 
protocoleces are activated and develop into the adult worm attached to the gut epithelium of the 
final host. The life cycle is closed. Signal triggering the evagination of protoscoleces are thought to be 
low pH and bile salts while passaging through the stomach and the gut [15]. Around one week after 
settlement, the first proglottids are produced and the first oncospheres are synthesized after 
another five weeks [15]. 
3.1.3. Clinical manifestation – Alveolar Echinococcosis 
When infective eggs are accidentally taken up by humans the life cycle is interrupted. Therefore, 
humans are considered as dead end hosts. Like in normal intermediate hosts the oncosphere will get 
activated by the passage through the stomach and the gut. Subsequently, it will manifest itself in the 
liver and develop into metacestode tissue, which is characterized by infiltrative, tumor-like growth, 
accompanied by metastasis formation in secondary organs like brain and lung during long-term 
infections [15,21]. Interestingly, only 10 % of all individuals exposed to E. multilocularis develop 
active AE [2]. However, for those that develop AE the lethality rate is about 96% if untreated [13]. 
The major obstacle in diagnosis of AE is that early infection appears clinically asymptomatic. 
Estimated time frame from infection to AE diagnosis is usually years to decades [13]. Therefore, the 
primary source of infection is hard to determine. People which have very high risk of transmission 
are individuals like hunters, farmers, and gardeners and particularly dog owners because of the close 
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contact to animals or contaminated material [22]. The prevalence of AE in central Europe is between 
two and 40 cases per 100,000 habitants [11]. 
While early infection is asymptomatic, the first signs of infection resemble that of a hepatic infection. 
Abdominal and pleural pain, vomiting, fever, anemia, weight loss and icterus are common symptoms. 
In this case, the metacestode tissue has extensively proliferated, has caused liver damage by inducing 
necrosis and has very likely formed metastasis. This phase of disease is characterized by an 
intensified inflammatory response of the immune system. While in the early stage of infection 
cytokines of a TH1 profile are predominant, namely IL-12, TNF-α and INF-γ, in the late phase of 
infection a TH2 immune response takes over with high levels of IL-4, IL-5, IL-6, IL-10 and INF-γ [2,23-
26]. 
The probability to be cured profoundly depends on the time point of diagnosis and adequate 
treatment. If AE is diagnosed within the first 10 years after infection, survival rates are above 30 %, 
while after 15 years they are 0 % [13]. Diagnosis is usually based on imaging techniques, like 
ultrasound or computer tomography and serological methods[13]. The detection of parasite specific 
antigens is of utter importance for primary diagnosis. For example the antigen Em2 which was 
isolated from the metacestode cyst is successfully used for the detection of human AE via enzyme-
linked immunosorbent assay (ELISA) [27]. 
Treatment options are very limited for AE patient. In the case of early diagnosis a radical surgery 
might be an option. However, due to the infiltrative growth of the metacestode tissue this solution is 
very complicated. Also liver transplantation harbors high risks, because residual material that might 
be present in the patient’s body will show an accelerated growth due to the immunosuppressant 
medication going along with transplantation. On the other hand chemotherapy is based on 
benzimidazole compounds. Unfortunately those drugs, like mebendazole and albendazole are rather 
parasitostatic than parasitocidal. Hence medication must be administered lifelong, also in case of 
incomplete resection[28]. Yet, the patients have to be examined over a long period of time by aiming 
tests and suffer from enormous side effects of the drugs, e.g. neurological deficit, gastrointestinal 
disorders, decreased numbers of leukocytes and thrombocytes, fever, urticaria, and bone marrow 
toxicity [29]. 
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3.2. Host-parasite relationship 
3.2.1. Biochemical and molecular biological approaches 
The clinical entity of AE was first described in 1852 and 1855 by the German pathologists Ludwig Buhl 
and Rudolf Virchow, respectively [30,31]. Virchow suggested AE to be of echinococcal origin, but did 
not recognize the causing agent as own Echinococcus species although the clinical manifestation was 
rather unusual. Later in 1863 Rudolf Leuckart stated the agent causing the pathology from the 
reported case by Virchow was a morphologically different form compared to the known 
echinococcosis disease and thus named it “Echinococcus multilocularis”. Nonetheless, it took almost 
140 years to get first insights into the molecular biology of E. multilocularis. First, investigations 
focused on the identification of diagnostic markers for AE. From these efforts, the recombinant 
antigens Em2, Em10, Em13, Em16 and Em18 were identified and verified as suitable indicators [32-
35]. Later on, also molecular studies were conducted. The Emelp (E. multilocularis ezrin-radixin-
moesin-like protein) gene locus was analyzed in 1999 and gave first knowledge about gene 
organization and expression of echinococcal genes [36]. EmElp, from which the recombinant antigens 
Em10, Em4, EmII/3 and Em18 derive, belongs to the ezrin-radixin-moesin (ERM) cytoskeleton family 
it is involved in the cytoskeletal organization and developmental processes dependent on Rho and 
PKB signal transduction [37,38]. In 2000, the mechanism of trans-splicing was described for 
E. multilocularis [39]. Next to the conventional cis-splicing process in which exons from a pre-mature 
mRNA are fused by excision of introns from the same RNA strand, trans-splicing is characterized by 
the fusion of a mini-exon of a small nucleolar pre-mRNA, the so-called spliced leader (SL) with the 5’ 
end exon of a different mRNA. In E. multilocularis only one 36 bp long SL is present and 
approximately 30 % of all transcripts are recognized as trans-spliced entities. Trans-splicing was first 
reported in kinetoplastide protozoans in 1986 where all mRNA carry an identical SL [40]. In contrast, 
in the nematode C. elegans two different SL, SL1 and SL2, are present and found at the 5´end of 60% 
and 10% of the mRNAs, respectively [41-43]. Meanwhile, among cestodes trans-splicing has also 
been reported for E. granulosus and T. solium [39,44,45]. While for trypanosomes trans-splicing is 
clearly needed to resolve polycistronic transcription units into monocistronic transcripts it is yet 
unsolved what the particular function in flatworms is. The mechanism of trans-splicing might serve as 
a yet unknown process of gene regulation in these organsims. Recent, preliminary data from the 
E. multilocularis genome project, however, clearly indicated that polycistronic transcription units are 
also present in cestodes and exclusively affect trans-spliced genes (Kiss F, Brehm K, unpublished 
results). 
3.2.2. Cultivation of E. multilocularis 
The establishment of an in vitro cultivation system for E. multilocularis considerably facilitated the 
molecular analysis of the parasite and its interactions with the host. In 1996, the first in vitro 
cultivation system was introduced by Jura et al. [46], in which metacestode vesicles were grown in 
the presence of either rat or human hepatocytes surrounded by two layers of collagen. Later, in a 
similar system hepatoma cell lines were applied as feeder cells [47]. Host factors which were 
secreted by the hepatocytes or hepatoma cell lines helped the parasite to proliferate and to 
differentiate in vitro. Within one or two weeks small vesicles of 1 - 2 mm in diameter developed. The 
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development of brood capsules and eventually protoscolex formation took up to three months. On 
the one hand the step-wise development of the metacestode vesicle was clearly observed by means 
of this system. But on the other hand it was not possible to discriminate between direct and indirect 
effects as the feeder cells were always present. Once peptide hormones or steroid / lipophilic 
hormones are applied they might also influence the feeder cells. Therefore, investigations have been 
made to establish an axenic cultivation system devoid of these feeder cells [48]. In this modified 
system the metacestode vesicles were kept under low oxygen and mild reducing conditions. In 
addition the vesicles were grown in medium which was preconditioned by hepatocytes and allowed 
growth for several months. This system helps to investigate the effect caused by host derived 
substances on the developmental process of E. multilocularis. More recently a culture system for 
E. multilocularis primary cells was introduced [49,50]. Upon isolation of primary cells an incubation 
period of approximately five weeks either under axenic conditions or in the presence of physically 
separated feeder cells resulted in newly formed metacestode vesicles. Those vesicles were infective 
as they caused lesions when applied into the peritoneum of mice. In the future, primary cells could 
possibly be a target for genetic manipulation in order to generate transgenic parasites. Altogether 
the cultivation methods at hand significantly facilitate studies on host-parasite communication and 
parasite development under in vitro conditions. 
3.2.3. Evolutionary conserved signaling cascades in E. multilocularis 
Parasitichelminths like E. multilocularis share a large degree of common genetic heritage with their 
various vertebrate or non-vertebrate hosts. This includes basic cellular functions, proteins and also 
conserved cell-cell-communication mechanisms which involve cytokines and hormones. A basic set of 
cytokine/hormonal cell-cell-communication systems already evolved in the most primitive animals 
like sponges and is still used by many animals. Therefore, in recent years studies have been 
performed to investigate the molecular signaling mechanisms in various parasitichelminths. For 
E. multilocularis it has successfully been shown that signaling systems involve surface RTK like the 
insulin- or the epidermal growth factor (EGF) receptors and serine/threonine kinases like the 
transforming growth factor-β (TGF-β) receptors. Not surprisingly homologues of proteins which are 
responsible for down-stream transduction of external stimuli of these surface receptors were also 
identified. Small GTP-binding proteins, members of the MAPK cascade and multiple Smad molecules 
are of significance, respectively [51-60]. All mentioned pathways are well conserved within the 
metazoa and are key players in developmental processes. Thus the theory was established that they 
might also be essential for parasite-host-communication. Indeed it was demonstrated that there are 
direct interactions between parasite-receptors and corresponding host cytokines: EmIR, a member of 
the insulin-receptor family with host insulin (Brehm, personal communication), EmER 
(E. multilocularis epidermal growth factor receptor) with host EGF (Gelmedin, personal 
communication) and EmTR1, a member of the transforming growth factor-β receptor family with 
host BMP2 [59]. This clearly confirms that E. multilocularis utilizes conserved signaling pathways and 
is, at least in vitro, able to sense host-cytokines via these evolutionary conserved signaling 
mechanisms [53,56,60]. Moreover, members of the evolutionary conserved NHR family are present 
in Echinococcus as well (section: 3.4.2) [61,62]. Of course, also these proteins could play a role in 
sensing steroid/lipophilic hormones of the host and influence parasitic development. Hence it is of 
utmost importance to study conserved signaling pathways to broaden the understanding how host-
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parasite interplay functions and thus it might explain the question how the parasite is able to survive 
within the host depending on host factors and the necessity to circumvent the host immune system. 
 
 
 
Fig. 4: Conserved signaling systems in E. multilocularis. Via EmFR (FGF signaling), EmER (EGF signaling) and 
EmIR1-2 (Insulin signaling) the MAPK cascade is triggered. Via EmTR1-4 the TGF-β/BMP signaling pathway is 
activated interacting with different Smad proteins. The presence of NHR signaling is indicated. Unknown 
ligands might bind to their putative NHRs which are influenced by co-regulators (e.g. EmSkip, EmAlien). EmFR: 
Echinococcus multilocularis FGF Receptor, EmER: Echinococcus multilocularis EGF receptor, EmIR1-2: 
Echinococcus multilocularis insulin Receptor 1 and 2, EmTR1-4 Echinococcus multilocularis TGF-β/BMP 
receptors 1 to 4. 
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3.3. Fibroblast growth factors (FGF) and FGF receptors (FGFRs) 
3.3.1. Diversity and function of FGF and FGFRs 
FGFs and their specific receptors are highly conserved throughout metazoan evolution [63,64]. They 
form a complex family of signaling molecules which are widely expressed in embryonic and adult 
tissue and play an important role in angiogenesis, cellular differentiation and tissue-injury repair [65]. 
FGFs are polypeptide growth factors interacting with heparin or heparan sulfate proteoglycans which 
is necessary for FGFs to activate FGRs effectively [66,67]. The human-mouse FGF family consists of 22 
members of which FGF1 (acidic FGF, aFGF) and FGF2 (basic FGF, bFGF) were originally isolated as 
mitogens for fibroblasts from the brain and pituitary [67]. 
FGFRs (Fig. 4) are receptor tyrosine kinases (RTK) that contain an extra cellular ligand-binding 
domain, a transmembrane domain (TM), a juxtamembrane domain (JM) and a split intracellular 
tyrosine kinase domain (TyrKc). The extra cellular region contains two or three immunoglobulin (Ig)-
like domains, and a heparin binding domain [68]. FGFs bind to FGFRs and induce their dimerization 
and the phosphorylation of specific cytoplasmic tyrosine residues. The fibroblast growth factor 
receptor substrate 2 (FRS2) is associated with the receptor at the JM domain. The phosphorylation of 
FGFRs and FRS2 triggers the activation of cytoplasmic signal transduction pathways such as the Ras-
MAP kinase pathway which include Erk 1/2, p38 and JNK kinases; the PIP3K/AKT pathway, and the 
PLCγ pathway [69]. The mentioned pathways are involved in promoting cell cycle progression as the 
expression of D-type cyclins (e.g. CCND1) is increased and CDK inhibitors such as p27KIP1 are 
repressed. Moreover, cell survival is affected by the repression of proapotptotic proteins or the 
increase of the antiapoptotic BCL2-family proteins [70]. 
Furthermore a fifth FGFR has been described, the fibroblast growth factor receptor like 1 (FGFRL1) 
[71]. Like the other human FGFR family members, it contains three Ig-like domains. However, the 
intracellular TyrKc is absent and instead a short histidine-rich motif is present. The gene was not only 
found in humans, but in all metazoans [72]. FGFs together with heparin also bind to FGFRL1 [73,74] 
and trigger effects in cell differentiation as well as block cell proliferation [75,76]. Interestingly, FGF1 
does not bind to FGFRL1, in contrast to all the other FGFRs [77]. A role in kidney development is 
suggested because mice with an Fgfrl1 gene deletion have a bilateral kidney agenesis [78]. Moreover, 
it is believed, that it plays a role in bone formation as human patient with frameshift mutations show 
craniosynostosis [79]. Most interestingly, FGFRL1 recently attracted attention regarding the fact that 
the gene shows genomic imprinting [80] and is a key player in stem cell renewal [81]. Considering 
these facts, the importance of FGFR signaling in developmental processes becomes clear. Still due to 
its level of complexity a lot of additional functions of the FGF-FGFR signaling pathway have to be 
understood. 
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Fig. 5: Schematic representation of the FGFR family (A) and the FGF/FGFR signaling pathway (B) in humans 
[70]. In this scheme the major tyrosine phosphorylation sites of FGFR1 are depicted. FGFR2, -3 and -4 harbor 
tyrosine phosphorylation positions which correspond to Y653, Y654, Y730 and T766 in FGFR1. The 
immunoglobulin-like domain (Ig), acidic box, transmembrane domain (TM), juxtamembrane domain (JM), the 
split tyrosine kinase domain and the C-terminal cytoplasmatic tail are shown. A trans-phosphorylation takes 
place upon ligand activation of the FGFR. Subsequently intracellular substrates, like FGFR substrate 2 (FRS2) are 
recruited and phosphorylated. This allows binding to GRB2, which is associated with the Ras guanine 
nucleotide exchange factor SOS1/2, and the molecule GAB1, resulting in the activation of the Ras and 
phosphoinositide-3 kinase (PI3K). Downstream the Raf–MEK1/2–Erk1/2, the PI3K–PKB and the phospholipase 
Cε (PLYε) pathways are activated. Independently of FRS2 also phospholipase Cγ (PLCγ) is linked to FGFR 
signaling. The mentioned pathways are involved in promoting cell cycle progression and cell survival. 
3.3.2. FGFRs in platyhelminthes and nematodes 
In the platyhelminth Dugesia japonica two FGFRs, DjFGFR1 and DjFGFR2, are present [82]. While 
DjFGFR1 is thought to be responsible for growth, migration and differentiation of undifferentiated 
and neuronal cells [82], DjFGFR2 plays a role in germ cell development and migration during 
sexualization [83]. Moreover a gene encoding a fibroblast growth factor receptor (FGFR)-like 
molecule, nou-darake (NDK), was described by Cebrià et al. [84]. It is specifically expressed in the 
head region of the planaria and is thought to modulate FGF signaling in stem cells to restrict brain 
tissues to the head region of planarians. 
In the nematode C. elegans a single FGFR (EGL-15) with two functionally exclusive isoforms, EGL-15 
5A and EGL-15 5B, and two FGFs, LET-756 and EGL-17, have been reported [85,86]. EGL-15 5B plays 
an important role in viability because null mutations are lethal for the first larval stage of C. elegans. 
This holds also true for LET-756 null mutants [87,88]. A distinct function in the guidance of the 
migration of sex myoblasts has been described for EGL-15 5A. Null mutations in EGL-15 5A and EGL-
17 show specific cell migration and axon maintenance defects [89-93]. Moreover, it was reported 
that the two different isotypes of EGL-15 are expressed in a tissue specific manner, leading to the 
assumption that is important in specifying the distinct functions [87,93]. 
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In E. multilocularis one FGF-like receptor has been identified EmFR [94]. The deduced amino acid 
sequence of 562 aa (63kDa) is 41% identical to the FGFR4 of Rattus norvegicus and to the FGFR1 of 
D. japonica (data not shown). EmFR shares all common structures of RTKs: a conserved intracellular 
region TyrKc (sequence alignment, see Fig. 6:), a TM, an extra cellular ligand-binding domain and a 
signal peptide (Fig. 7). Interestingly, EmFR exhibits only one Ig-like domain, instead of two or three 
which is accepted knowledge for all other FGFRs. 
 
 
 
Fig. 6: Amino acid sequence alignment of tyrosine kinase domains of Fibroblast Growth Factor Receptors. 
Shown are sequences of Echinococcus multilocularis EmFR (residues 288-555), Dugesia japonica DjFGFR1 (GI: 
20799117; residues 551-818), D. japonica DjFGFR2 (GI: 20799119; residues: 558-857), and human HsFGFR3 (GI: 
7533125; residues: 360-636). The threshold for identical amino acid residues, which are highlighted in white on 
black background, is set to 75 %. Similar residues are shaded in grey. 
 
 
 
Fig. 7: Schematic drawing of platyhelminth and nematode FGFRs. Domains are indicated as retrieved from the 
SMART annotation tool [95,96]. Sequences were taken from the original publications: EmFR [94], DjFGFR1 and 
DjFGFR2 [82], DjNDK [84] and CeEGL-15 [85]. Noteworthy, the membrane proximal Ig-like domain of DjNDK 
was not indicated by Cebrià et al. SP: Signal peptide, Ig: Immunoglobulin-like domain, TM: transmembrane 
domain, JM: juxtamembrane domain, TyrKc: Split tyrosine kinase domain. 
 
Expression analysis could show that EmFR is expressed in the metacestode larval stage and in 
protoscoleces. Furthermore, it was investigated whether human aFGF and bFGF influence the growth 
and development of metacestodes cysts in vitro. A more pronounced growth stimulating effect of 
host bFGF over aFGF was observed in a long-term experiment conducted under axenic conditions. 
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Moreover, after the exogenous addition of host aFGF and bFGF to in vitro cultivated metacestodes a 
specific phosphorylation of the Erk-like MAP-kinase EmMPK1 was detected. This data hints at the 
presence of a functional FGF-FGFRs signaling pathway in E. multilocularis next to the capability of 
E. multilocularis to sense host FGFs. 
 
Until now, there is no evidence of the existence of other FGFRs or FGFs in either platyhelminthes or 
parasitic and free-living nematodes. 
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3.4. Nuclear hormone receptor (NHR) signaling 
3.4.1. Function and structure of NHRs 
NHRs are DNA-binding transcription factors that are essential in development, differentiation and 
homeostasis [97]. Apart from their physiological importance these receptors are also involved in 
tumor genesis, diabetes, or hormone resistance syndromes [98-101]. 
NHRs form a superfamily of phylogenetically related proteins, encoded by 21 genes in the complete 
genome of D. melanogaster, 48 in humans [102] and, unexpectedly more than 270 genes in the free-
living nematode C. elegans [103]. In the parasitic trematode Schistosoma mansoni 21 members have 
been identified [104,105]. 
On the basis of regions of conserved sequence and function NHRs share a universal modular 
structure that consists of five to six domains, designated A to F, from N-terminus to C-terminus [98]. 
The N-terminal regulatory domain (region A/B) harbors the activation function 1 (AF1), the activity of 
which is independent of ligand binding. The DNA-binding domain (DBD, region C) has two zinc finger 
motifs and is highly conserved among NHRs. The first zinc finger contains the P-box which mediates 
binding to specific hormone responsive elements (HREs) in the promoter regions of target genes and 
the second one, known as D-box is involved in receptor dimerization. The so-called variable hinge 
stretch (region D) follows region C and allows conformational changes in the tertiary structure of the 
NHR upon ligand binding. It is thought to be responsible for the respective localization of the NHR 
that is the cytoplasm or the nucleus. The C-terminal ligand-binding domain (LBD, region E) is fairly 
conserved among NHRs and encloses the activation function 2 (AF2), the activity of which is 
dependent on the presence of bound ligand [105,106]. Moreover, the LBD is also site of heteromeric 
interactions with co-regulators, namely co-activators and co-repressors which modulate NHR 
activities [107]. The mode of action how NHR modulate transcription is quite diverse, involving 
activation or repression of genes in a ligand-dependent or independent manner [108-111]. It is also 
described that NHRs can be modified post-translationally [112,113] influencing its functions. In 
addition, it has been reported that NHR signaling and other signaling pathways, like the TGF-β/BMP 
pathway cross-communicate. For instance, it was shown that the human Smad3 interacts with the 
ligand-induced VDR [114].  
According to sequence alignments and phylogenetic tree re-construction, human, arthropod and 
nematode NHRs are divided into six evolutionary groups [115]. The members of the same group 
share at least 80 – 90 % identity in the DBD and at least 40 – 60% in the LBD. Among the first group 
the Homo sapiens vitamin D3 receptor VDR [116], the pregnane X receptor PXR [117,118] or the 
constitutive androstane receptor CAR [119] are found. The C. elegans DAF-12 receptor and its two 
paralogs NHR-8 and NHR-48 [120] can be sub-grouped to the ESCKA family of NHRs to which the 
H. sapiens VDR and PXR are the closest vertebrate homologs. Although they are highly related in the 
DBD, they differ in the DNA recognition helix (P-box) and the LBD. C. elegans DAF-12, NHR-8 and NHR 
48 also Pristionchus pacificus DAF-12 [121] and Strongyloides stercoralis DAF-12 [122] (both parasitic 
nematodes) as well as outside of the flatworms, the D. melanogaster DHR96 [123] receptor belong to 
the ESCKA family. The fact that they share an identical 13 amino acid sequence that comprises the 
above mentioned DNA recognition helix suggests the recognition of a unique HRE.  
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The important regulator for hepatocyte differentiation and regulation, the hepatocyte nuclear factor 
4 HNF4 [124] belongs to second group of NHRs. Generally, it is a positive transcriptional regulator of 
multiple heptocyte genes and involved in the regulation of enery metabolism or bile acid synthesis 
[125-128]. Interestingly, it binds to the DNA as a homodimer and its ligand are thought to be fatty 
acyl-CoA thiesters [129]. Its activity is influenced by phosphorylation or acetylation and it was 
reported that Smad3 and 4 are binding to HNF4, which suggests there is a cross-talk between 
different signaling pathways [130-132]. 
3.4.2. NHRs in parasitic helminths 
As already mentioned NHRs are present in S. mansoni, P. pacificus and S. stercoralis. Also, for 
S. japonicum NHRs have been reported [133] and it contains roughly the same set of NHRs as 
S. mansoni. 
In S. mansoni, for instance, members of the nuclear receptor subfamily I, e.g. SmNR1 [134], the 
retinoid X receptor RXR homologues, SmRXR1 and RXR2 [135-137] and other NHRs, like SmFTZ-F1α 
(Fushi tarazu-factor 1 α; [138] or SmCAR [139] have been described. Moreover, a novel subfamily - 
2DBD-NRs - of nuclear receptors containing two DNA-binding domains was reported in 2007 
[140,141]. The nuclear receptors of S. mansoni interfere with schistosome development as SmRXR1 
may have an important role in the regulation of the female-specific p14 genes [137]. Of course other 
functions are discussed since nuclear receptors regulate homeostasis, differentiation, 
metamorphosis and reproduction in metazoans. Long before the description of these NHRs in 
Schistosoma, it was recognized that host hormones, including steroids and thyroid hormone, affect 
parasite growth and metabolism as well as the maturation of larvae in vitro [142]. This indicates a 
cross-talk of host hormones with parasite receptors. 
For Taenia crassiceps a regulation of the parasite by host hormones was reported. Hormones such as 
17-beta estradiol, progesterone, testosterone or dihydrotestosterone do influence parasite growth 
and differentiation although only in vitro and at non-physiological concentrations [143,144]. 
However, no structural evidence for the expression of NHRs in T. crassiceps was found so far. 
For E. multilocularis, it was known that at least three NHRs are present [Brehm, unpublished data], 
yet these receptors have not been fully characterized. One of them, EmNHR1 [62] contains both a 
typical DBD and a LBD. It is homolog to the subfamily of NR1 receptors. The EmNHR1 encoding gene, 
Emnhr1, contains 8 exons spanning about 6.5 kb. The cDNA encoding EmNHR1 spans 2.5 kb and the 
deduced amino acid sequence (651 aa) results in a putative protein of 72 kDa [145]. Furthermore, 
members of the transcriptional co-regulators have been described in E. multilocularis. EmSkip [61] is 
a member of the SNW/SKIP family and EmNIP1 which is a homolog to the co-repressor Alien [62]. 
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3.5. Objectives 
Diseases caused by parasitichelminths result in millions of deaths each year, predominantly in low- 
and middle-income countries. Among those diseases schistosomiasis, filariasis and cysticercosis are 
of importance. Also, the zoonotic diseases caused by Echinococcus species, especially Cystic 
Echinococcosis which is due to E. granulosus infection, have a significant impact on the global 
economical situation in the world [146]. 
With the genome of E. multilocularis at hand, and the knowledge that E. multilocularis and 
E. granulosus share more than 99 % identity within their genomic sequence, E. multilocularis is 
considered a well-suited model organism to study helminth infections. Especially, with the 
accessibility of an in vitro cultivations system, E. multilocularis is of utter importance to learn about 
larval cestode development and host-parasite interactions. 
Using this system, both early parasite development [50,147], and also late developmental processes 
[48,49,148,149] can be studied. By these means, it was revealed that parasite development is either 
influenced by factors secreted by co-cultivated mammalian feeder cells or by substances present in 
host serum [20,149,150]. Moreover, it is now well established that several evolutionary conserved 
Echinococcus signaling systems for the EGF, the insulin, and the TGF-β/BMP pathways play a role in 
E. multilocularis development [20,150]. Yet, it was described that also a FGFR-FGF signaling pathway 
[94] as well as a NHR, namely EmNHR1 is present in E. multilocularis [145]. 
However, still a lot of answers regarding FGFR-FGF and NHR signaling have yet to be unraveled. 
Moreover, there is a constant need to improve the E. multilocularis in vitro cultivation system in 
order tackle even more complex developmental processes in vitro. 
 
 
Therefore, the following questions were addressed and investigated in this work: 
 How many members of the NR family are expressed by E. multilocularis? 
 What is the role and function of EmNHR1 in particular? 
 How do steroids/lipophilic proteins influence the development of the fox-tapeworm? 
 In contrast, how do the small FGF molecules influence parasite development? 
 Does E. multilocularis sense host FGFs, which would suggest parasite-host cross-
communication? 
 Is the established in vitro cultivation system of E. multilocularis adaptable to serum-free 
conditions applying PanserinTM401? 
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4. Materials and Methods 
4.1. Material 
4.1.1. Equipment 
Analytical Balance Sartorius, Göttingen, Germany 
Agitation Incubator G25 New Brunswick Scientific, Edison, NJ, USA 
Blotting Tanks: Mini Trans-Blot Cell (7.5 x 10 cm 
blotting area) 
BioRad, Munich, Germany 
Bruker Autoflex Mass Spectrometer Bruker Daltonics, Bremen, Germany 
Cooling Centrifuges: Sorvall RC-5B 
                   Beckman J2-21 
                   Sigma 3K30 
Thermo Scientific, Wilmington, DE, USA 
Beckman Coulter GmbH, Krefeld, Germany 
Sigma, Munich, Gemany 
DNA – Gel Electrophoresis Chamber BioRad, Munich, Germany 
Gel-Documentation System MidiDOC Herolab, Wiesloch, Germany 
Heating Block, Dri-Block Heater DB-3  Techne, Cambridge, UK 
Incubators: Heraeus B 6200 
           Autoflow 8500 
Thermo Electron GmbH, Karlsruhe, Germany 
NuAire Plymouth, MN, USA 
Laminar Air Flow Hoods: NU-437-400E / Series 3 
                       MSC-Advantage (1.2) 
NuAire Plymouth, MN, USA 
Thermo Scientific, Wilmington, DE,USA 
Light Optical Microscope, Leica DM IL LED Leica, Wetzlar, Germany 
Magnetic Stirrer, RCT basic IKAMAG IKA Werke GmbH & Co. KG, Staufen, Germany 
Neubauer Counting Chamber (0.1 mm) Hartenstein Laborversand, Würzburg, Germany 
Overhead Agitation Wheel  Renner GmbH, Dannstadt, Germany 
pH Meter WTW GmbH, Weilheim, Germany 
Pipettes, Eppendorf Research 
(10 µl, 100 µl, 1000 µl) 
Eppendorf Deutschland, Hamburg, Germany 
Power Supplies Power Pack P25 and P24 Biometra, Göttingen, Germany 
Protein Separation Chambers: Mini-Protean II BioRad, Munich, Germany 
Sequencer, ABI Prism™ Sequencer 377 Perkin Elmer, Weiterstadt, Germany 
Spectrophotometer: NanoDrop™ 1000 
                   U-2000 
                   Multiskan EX 
Thermo Scientific, Wilmington, DE,USA 
Hitachi, NY, USA 
Thermo Scientific, Wilmington, DE,USA 
Speed Vac Plus SC110A Savant, NY, USA 
Table Centrifuge Mikro 200 Hettich GmbH & Co.KG, Tuttlingen, Germany 
Tabletop Processor, Curix60 Agfa HealthCare GmbH, Cologne, Germany 
Thermocycler: Trio-Thermoblock 
              T-Gradient 
Biometra, Göttingen, Germany 
Biometra, Göttingen, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Ultrasonication Apparatus: Sonifier®II 
Desintegrator Modell 250  
Branson, Danbury, CT, USA 
Vortexer: Power Mix Hartenstein Laborversand, Würzburg, Germany 
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4.1.2. Consumables 
0.5 – 2.0 ml reaction tubes Sarstedt, Nümbrecht, Germany 
15 ml and 50 ml sterile centrifugation tubes Greiner, Nürtingen, Germany 
6-, 12- and 24-well plates for cell culture Nunc, Roskilde, Denmark 
96-well plates ELISA Nunc, Roskilde, Denmark 
400 µm Anchor Plate Bruker Daltonics, Bremen, Germany 
Blotting paper Schleicher & Schüll, Dassel, Germany 
Cell culture flasks from 25 to 175 cm² Sarstedt, Nümbrecht, Germany 
Cell scraper (25 cm) Sarstedt, Nümbrecht, Germany 
Centrifuge beaker, 15 and 50 ml, Quickseal Beckman, Munich, Germany 
Centriprep YM-10 10kDa and 30kDa Millipore Billerica, MA, Germany 
Pipette tips (10 µl, 100 µl, 1000 µl) Hartenstein Laborversand, Würzburg, Germany 
Positively charged nylon membrane 
porablot NY plus 
Macherey & Nagel, Düren, Germany 
 
Petri dishes (various diameter) Hartenstein Laborversand, Würzburg, Germany 
Sterile filters, 150 ml bottle top filter, 0.45 μm  Nalgene, Rochester, NY, USA 
Syringes and needles, sterile 
(0.45, 0.6, and 0.9 diameter) 
Braun Melsungen AG, Melsungen, Germany 
X-Ray film hyperfilm MP Amersham, Braunschweig, Germany 
4.1.3. Chemicals, Enzymes and Solutions 
Acetonitrile Sigma-Aldrich GmbH, Steinheim, Germany 
Activated Charcoal Sigma-Aldrich GmbH, Steinheim, Germany 
Agarose NEEO Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Agar-Agar, Bacto-Peptone, Yeast Extract, 
Glucose, Yeast Nitrogen Base w/o Amino Acids 
Difco Laboratories, Augsburg, Germany 
 
Aldosterone Sigma-Aldrich GmbH, Steinheim, Germany 
Alpha-Cyano-4-Hydroxycinnamic Acid Sigma-Aldrich GmbH, Steinheim, Germany 
Ammonium Persulfate (APS) Sigma-Aldrich GmbH, Steinheim, Germany  
Antibiotics (ampicillin, kanamycin, 
chloramphenicol)  
Sigma Chemie GmbH, München, Germany 
Benchmark™ Prestained Protein Ladder Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany  
BIBF1120 Selleck Chemicals LLC, Houston, TX, USA 
Biotin Sigma-Aldrich GmbH, Steinheim, Germany 
Bile Salts (BS) Sigma-Aldrich GmbH, Steinheim, Germany 
Broad Range Prestained Protein Marker  New England Biolabs GmbH, Frankfurt, Germany 
Calf Intestinal Phosphatase (CIP) New England Biolabs GmbH, Frankfurt, Germany 
Chenodesoxy Acid (CDA) Sigma-Aldrich GmbH, Steinheim, Germany 
Cholic Acid (CA) Sigma-Aldrich GmbH, Steinheim, Germany 
Coomassie Brilliant Blue (SimplyBlue SafeStain) Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany 
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Desoxycholic Acid (DCA) Sigma-Aldrich GmbH, Steinheim, Germany 
Developer 153, Part A + B Agfa HealthCare GmbH, Cologne, Germany 
Dextran T70 Sigma-Aldrich GmbH, Steinheim, Germany 
Diethylpyrocarbonate (DEPC) Sigma Chemie GmbH, München, Germany 
DNase I, Rnase-free Roche Deutschland Holding GmbH, 
Grenzach-Wyhlen, Germany 
dNTPs, lyophilized Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Dulbecco´s Minimal Essential Medium (DMEM), 
(4.5 g glucose/L) 
Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany 
Dulbecco´s Phosphate Buffered Saline (PBS) 
without Ca2+ /Mg2+ 
Biochrom AG, Berlin, Germany 
Fetal Bovine Serum Superior (FBS) Biochrom AG, Berlin, Germany 
Fixer G354 Agfa HealthCare GmbH, Cologne, Germany 
FGF (aFGF and bFGF), recombinant human ImmunoTools, Friesoythe, Germany 
Heparin Sigma-Aldrich GmbH, Steinheim, Germany 
Immunoglobulin G, rat Biomol GmbH, Hamburg, Germany 
Insulin solution, human Sigma-Aldrich GmbH, Steinheim, Germany 
Lithocholic Acid (LCA) Sigma-Aldrich GmbH, Steinheim, Germany 
Low Molecular Weight Marker (N3233) New England Biolabs GmbH, Frankfurt, Germany 
ONPG (ortho-nitrophenyl-β-galactoside) Sigma-Aldrich GmbH, Steinheim, Germany 
Panserin 401 PAN Biotech, Aidenbach, Germany 
Penicillin / Streptomycin (P/S) Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany  
Polysorbate 20 (TWEEN 20) Merck KGAA, Darmstadt, Germany 
Phusion High-Fidelity DNA Polymerase New England Biolabs GmbH, Frankfurt, Germany 
Pierce ECL Western Blotting Substrate Pierce Protein, Rockford, IL, USA 
ProBond Resin Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany 
Progesterone Sigma-Aldrich GmbH, Steinheim, Germany 
Restriction Enzymes New England Biolabs GmbH, Frankfurt, Germany 
Serotonin (5-Hydroxytryptamine Creatinine 
Sulfate Complex) 
Sigma-Aldrich GmbH, Steinheim, Germany 
SMART ladder, molecular weight marker Eurogentec GmbH, Cologne, Germany 
Sodium Taurocholate Sigma Chemie GmbH, München, Germany 
Sterile Water Fresenius, Bad Homburg, Germany 
SU5402 Tocris Biosciences, Bristol, UK 
T4 DNA Ligase New England Biolabs GmbH, Frankfurt, Germany 
Tavanic (Levofloxacin) Sanofi-Aventis GmbH, Frankfurt, Germany 
Trifluoroacetic Acid (TFA) Sigma-Aldrich GmbH, Steinheim, Germany 
TRIzol (15596-018) Life Technologies GmbH, Invitrogen Division, 
Darmstadt, Germany 
Trypan Blue, 0.5 % Biochrom AG, Berlin, Germany 
Trypsin, 0.05% (1X) with EDTA 4Na, liquid Life Technologies GmbH, Invitrogen Division 
  Materials and Methods 
 
21 
 
Vitamin B12 Sigma-Aldrich GmbH, Steinheim, Germany 
X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) 
AppliChem GmbH, Darmstadt, Germany 
4.1.4. Commercial Kits 
Ambion AM1906 Kit Life Technologies GmbH, Applied Biosystems 
Division, Darmstadt, Germany 
BCA Protein Assay Pierce Protein, Rockford, IL, USA 
ECL Chemiluminescence Kit  Amersham, Braunschweig, Germany 
Matchmaker Two Hybrid System 3 Clontech, Heidelberg, Germany 
Montage In-Gel-DigestZP Kit Millipore Billerica, MA, Germany 
NucleoBond® PC 100 Midi Kit Machery-Nagel GmbH & Co.KG, Düren, Germany 
OmniScript RT PCR Kit Qiagen GmbH, Hilden, Germany 
pBAD/Thio expression Kit Invitrogen, Groningen, Netherlands 
QIAEX II Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
QIAgen Gelextraction Kit Qiagen GmbH, Hilden, Germany 
QIAgen PCR Cloning Kit Qiagen GmbH, Hilden, Germany 
QIAgen Plasmid Midi Kit  Qiagen GmbH, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen GmbH, Hilden, Germany 
QIAquick Nucleotide Removal Kit Qiagen GmbH, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen GmbH, Hilden, Germany 
QIAquick RNEasy Mini Kit Qiagen GmbH, Hilden, Germany 
TOPO-TA Cloning®KIT Invitrogen, Groningen, Netherlands 
 
All buffers and solutions were prepared with distilled water, autoclaved and sterile filtrated, 
respectively. For RNA purposes, either DEPC-treated or commercially available RNase-free water was 
used. For enzymatic reactions, double distilled and autoclaved water was used. 
4.2. Oligonucleotides 
All oligonucleotides were ordered from Sigma-Aldrich/Sigma-Genosys in lyophilized form and were 
reconstituted with PCR grade water at a final concentration of 50 μM. 
Vector Oligonucleotide Name Oligonucleotide Sequence 5' - 3' 
pBAD/Thio-TOPO® pBAD forward GCTATGCCATAGCATTTTTATCC 
 pBAD reverse GACTAAATTAGACATAGTCCG 
 Trx forward GTTCCTCGACGCTAACCTG 
 pBAD up 60 CTGATTTAATCTGTATCAGGC 
pCR®2.1® TOPO-TA Topo M13 CAGGAAACAGCTATGACCAT 
 Topo T7 TACGACTCACTATAGGGCGA 
pDrive pDrive T7 TAATACGACTCACTATAGGG 
 pDrive SP6 ATTTAGGTGACACTATAGAA 
pET30c(+) T7 priming site AATACGACTCACTATA 
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 T7 Terminator CTAGTTATTGCTCAGCGGTGG 
pGADT7 Y2H T7 seq TAATACGACTCACTATAGGGC 
 Y2H AD seq AGATGGTGCACGATGCACAG 
pGBTK7 Y2H T7 seq TAATACGACTCACTATAGGGC 
 Y2H BD seq TTTTCGTTTTAAAACCTAAGAGTC 
 Y2H BD up TAAGAGAGTCACACTTTAAAATTTGTAT 
pGEX-5X pGEX 5' Sequencing Primer GGGCTGGCAAGCCACGTTTGGTG 
 pGEX 3' Sequencing Primer CCGGGAGCTGCATGTGTCAGAGG 
pJG4-5 JG4-5' CTTATGATGTGCCAGATTATG 
 JG4-5' nest CTCCCGAATTCGGCACGAG 
 JG45-3' TTGGAGACTTGACCAAACCT 
 JG45-3'nest CTGGCGAAGAAGTCC 
pQE30 pQE seq dw CCCGAAAAGTGCCACCTG 
 pQE seq up GTTCTGAGGTCATTACTGG 
pRSETA T7 pRSET AATACGACTCACTATA 
 T7 Terminator CTAGTTATTGCTCAGCGGTGG 
pSecHygroA T7 pSec TAATACGACTCACTATAGGG 
 BGH reverse TAGAAGGCACAGTCGAG 
 
cDNA Oligonucleotide Name Oligonucleotide Sequence 5' - 3' 
 CD3  ATCTCTTGAAAGGATCCTGCAGG 
 CD3nest CTCTTGAAAGGATCCTGCAGGACT 
 CD3RT ATCTCTTGAAAGGATCCTGCAGGTTTTTTTTTT
TTTTTTTTTTTTTTTTV (T26,V= G+C+A) 
 
gene Oligonucleotide Name Oligonucleotide Sequence 5' - 3' 
emact EmAct2 dw TCAATCCTAAAGCCAATC 
 EmAct2up CGTACAACGACAGCAC 
emelp em10-15 AATAAGGTAATCAGTCGATC 
 em10-16 TTGCTGGTAATCAGTCGATC 
 siRNA-EmElp AACCUUUCUAAGACUGGAUAAGA 
 siRNA-EmElp-as UCUUAUCCAGUCUUAGAAAGGUU 
emfr EmFR-exp-dw GTTCATCGAGACCTGGCGG 
 EmFR-exp-up CAAAAGACCATATGTCGGATTT 
 EmFR-seq-ORF-1212-dw GCTCGTCAAATCGCCATTGGG 
 EmFR-Iso-A-up CAAAAGACCATATGTCGGATTT 
 EmFR-Iso-B-up CAAAAGACCATCTGAAGGAGTG 
 EmFR-Iso-dw GTTCATCGAGACCTGGCGG 
 EmFR-Iso-up GTTTGACCTTCCTCTCGGAG 
 EmFR-Iso2-dw GTGTTCCTCTAAAGTGGATGG 
 EmFR-Iso2-up GATTGGCTGCTGGTGAATCGC 
 EmFR-pSecHygroA-BamH1-dw GCGGATCCGCATCAACACCCTCCACCCTTC 
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 EmFR-pSecHygroA-Not1-up GAGCGGCCGCACACCCCTGTAAGAACTT 
 EmFR-TK-mut-dw  GTCGCAAAAATCGCCGATAACGCTCTCAC 
GCGCAAGGTG 
 EmFR-TK-mut-up  CACCTTGCGCGTGAGAGCGTTATCGGC 
GATTTTTGCGAC 
 siRNA EmFR-74 UUCAGUCUUAACGGGCUCGUCUU 
 siRNA EmFR-74-as AAGACGAGCCCGUUAAGACUGAA 
 EmFRin-pBAD/Thio-dw CGTCCCCAACGAATGATTTTC 
 EmFRin-pBAD/Thio-up AATGTCCTTGGAGGCGAGGTAGAC 
 FRin-BD-BamH1-dw1 ACTGCGGGATCCGTCCCCAACGAATG 
 FRin-BD-PstI-up TCAACCTGCAGGTAAGAACTTTGACAGTGT 
 FRin-AD-XmaI-dw TGCGCCCCGGGTCCCCAACGAATG 
 FRin-AD-ClaI-up TCAACATCGATGTAAGAACTTTGACAGTGT 
 FRex-pET30a(+)-BamH1-dw TCTGGGATCCCGCATCAACACCCTCCACCC 
 FRex-pET30a(+)-Sal1-up GGCGTCGACTACCTGAGAGACACTGTGTCATG 
 EmFRin_pGEX5X_BamH1_dw CTGGATCCGTCGTCCCCAACGAATG 
 EmFRin_pGEX5X_Not1_up GTGCGGCCGCACAATGTCCTTGGA 
 EmFR-qRT-3-dw GATGAAGAAGTCTTCTCTGG 
 EmFR-qRT-3-dw TAAGAACTTTGACAGTGTAGC 
 pQE30-FRin-BamH1-dw CGGATCCCGTCCCCAACGAATGATTTTC 
 pQE30-FRin-Sal1-up GTCGTCGACTCAAATGTCCTTGGAGGCGAG 
emfyn EmFyn-dw CCGAGAGAATGCTTTTG 
 EmFyn-up GCTTTATTGCATACATATTCC 
emhnf4 c3313-pos-15555-dw GGACATCTCACACTCTGG 
 c3313-pos-15704-dw GTTCGTCACTTAACGATCTG 
 c3314-pos-209-up GCCCAGTAGCACTATCG 
 c3314-pos-5552-up GACATGCGTAATCAATGCCG 
 EmHNF4-fullcDNA-dw GAGCCTCCAGAGTAGACATG 
 EmHNF4-fullcDNA-up ACTTCCGTACATTCTTCATAATG 
 EmHNF4-ORF-dw ATGGACCTCTACAATAGCAGCAG 
 EmHNF4-ORF-up TCATTGCTTTTCAACGTCCTCTTG 
 HNF4-put-ORF-dw1 ATGTCATTCTTCTACAACGTCCG 
 HNF4-put-ORF-dw2 TGAACTCAGAATCAGGAATCG 
 HNF4-put-ORF-dw3 ATGCTGACAGCTATTGTCAATG 
 HNF4-put-ORF-dw4 ATGGCCTCTTTTGAAGTCA 
 HNF4-put-ZnF-up TGCTGATTTTATCGCGCTCG 
 HNF4-put-ORF-up1 TCAATCACCTGAAAGTAGTATG 
 HNF4-put-ORF-up2 GCAGCAGAAGTAGTGGCAACG 
 HNF4-put-5RACE-nes-up1 GATGGATAGAGAGGCAGAACCCGAGG 
 HNF4-put-5RACE-up1 GACAGTTGGAGATGGATAGAGAGG 
 HNF4-put-5RACE-nes-up2 GAAGTGTTCACGAATTGTTGTG 
 HNF4-put-5RACE-up2 GAACTCCTCGCCTGAAGTG 
 HNF4-put-5RACE-nes-up3 GATGCCACCGCTGCTGCTATTGTAGAG 
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 HNF4-put-5RACE-up3 GTAGAGGTCCATTTCAAAGTTGTGTGG 
 HNF4-put-3RACE-dw1 CAAAGGATCTTTCCTCTACTGG 
 HNF4-put-3RACE-nest1-dw CAATTGGGCAAGACAGCTGG 
 HNF4-put-3RACE-dw2 GAACTCCTCGCCTGAAGTG 
 HNF4-put-3RACE-nest2-dw GAAGTGTTCACGAATTGTTGTG 
 HNF-DBD-Pool-mut-dw CCGTTTTTGCCGGCTGAAAAAGTGCTTCC 
GGGTGG 
 HNF-DBD-Pool-mut-up CCACCCGGAAGCACTTTTTCAGCCGGCAA 
AAACGG 
 HNF4-DBD-AD/BD-NdeI-dw ATCCATATGTGTCTTATTTGTGGAG 
 HNF4-DBD-Pl-AB/BD-EcoR1up GCTGAATTCATCGCGCTCGTTTTGG 
 HNF4-DBD-Pa-AB/BD-EcoR1up GGTGAATTCCCCCACCGGAAAGCAC 
 EmHNF4-LV-4/5-dw CCGCGCAGCGGTCCAAAAC 
 EmHNF4-SV-4/8-dw CCGCGCAGGTCACCTTAAC 
 EmHNF4-e8-up CCACAAGAAATCCTGAAACCCG 
 EmHNF4-qRT-5-dw CAAGTTGGATGCTATTCTC 
 EmHNF4-qRT-5-up GAGGCAAATAAACTCTGTC 
emmpk3 EmMPK3-exp-dw TGGGTAGTGATGGTAATCTCG 
 EmMPK3-exp-up AGGGCGCGATGAAGTCG 
emnhr1 EmNHR-ab-dw GACTATCACTCACACTCTCTAG 
 EmNHR-ab-up GAGAAGGATATGACCATAGTTGTC 
 EmNHR-ab2-NcoI-pRSET-dw CCGCCATGGCATCAACAGACACCACCCTC 
 EmNHR-ab2-HindIII-pRSET-up GTGAAGCTTTTCCAGATAGTGCTTCAACAG 
 EmNHR1-NTS-NcoI-fwd GTACCATGGTGAATACTTCTGGTTTTTTG 
GTACGG 
 EmNHR1-ALT-XmaI-rev TAGCCCGGGGTCAGAGCCTGTAACTCCG 
 EmNHR1-LHQ-NcoI-fwd TGCCCATGGATCTTCATCAGGATCGCTTACC 
 EmNHR1-FIE-XmaI-rev CACCCCGGGCACTCGATAAACATATGTACC 
 EmNHR1-SLV-XmaI-rev CCACCCGGGTTCACCAAACTACTTATAG 
 EmNHR1-DNY-NcoI-fwd CTCCCATGGACAACTATGGTCATATCC 
 EmNHR1-LHQ-dw  CTTCATCAGGATCGCTTACCTAC 
 EmNHR1-SLV-up TCACCAAACTACTTATAGTAATATTTGAG 
 NHR1-H95-ATG-NdeI-dw AATCCTCATATGACGTCCCAAAAGCAAG 
 NHR1-H95-TAA-up TTAGGAGGAATTAGTCATGTTAG 
 NHR1-H95-DBD-Y2H-XmaI-up CCGTGGCCCGGGGAGATGCTGAGATCAAAGG 
 NHR1-H95-DBD-SHS-up TTATGAGATGCTGAGATCAAAGG 
 NHR1-DBD-RERK-up TTTCGCTCCCGATTACGCTG 
 EmNHR1-qRT-2-dw TCAATCGGTATCCAATATC 
 EmNHR1-qRT-2-dw ATTAGTCAACACGGCAG 
 EmNHR1-ATG-UP1-dw ATGTCTAGTGTGATTCATGACG 
 SL-ATG-dw CTTACCTTCGAGTTTTGTATG 
gfp siRNA eGFP-658 CAUAGCGUUGGCUACCCGUGAUA 
 siRNA eGFP-658-as UAUCACGGGUAGCCAACGCUAUG 
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Hstub12 Tub12up CCCCAAGTGTATGATACTGG 
 Tub12ST CTGGGCAGTGCGGCAACCA 
 
4.3. Determination of nucleic acid concentration and purity 
The nucleic acid concentration was photometrically determined at a wavelength of 260 nm using the 
spectrophotometer NanoDrop 1000. The purity of the nucleic acids was analyzed on the basis of the 
ratios of 260 nm/280 nm (for protein impurity) and 260 nm/230 nm (for salt impurity). DNA 
concentration was further estimated by comparing the intensity of ethidium bromide staining 
between a DNA fragment of unknown concentration with DNA size marker fragments of known 
concentrations (SmartLadder, Eurogentec). 
4.4. RNA applications 
4.4.1. Isolation and purification of total RNA from E. multilocularis 
RNA isolation from in vitro cultivated axenic metacestode vesicles and protoscoleces was performed 
with TRIzol Reagent as described in [52]. Briefly, about 3-4 metacestode vesicles or 20 µl purified 
protoscoleces were washed three time in pre-warmed 1x PBS. Vesicles were mechanically disrupted 
by sucking them through a syringe (G20, 0.9 cm diameter). Subsequently the material was subjected 
to 1 ml of TRIzol Reagent. The following steps were performed according to the manufacturer’s 
protocol. RNA isolation of in vitro axenic primary cells followed the protocol as published by Förster 
et al. [145]. 
For purification of the RNA solution either the Ambion AM1906 Kit was used according to the 
manufacturer’s instructions or the RNA was subjected to a DNAse digest with 0.2 U/µl RNAse-free 
DNAse (Roche) for 1 h at 37 °C in the presence of 0.05 M sodium acetate (CH3COONa) and 0.05 M 
Magnesium sulfate (MgSO4). Then the RNA was purified applying the RNEasy Mini Kit (QIAgen) 
following the manufacturers recommendations. 
4.4.2. First strand cDNA synthesis 
For reverse transcription the Omniscript RT-PCR kit (QIAGEN; Hilden, Germany) was used. However, 
the manufacturer’s protocol was slightly altered. Between 0.5 µg and 2 µg total RNA in a volume of 
12 µl were mixed with 1 µM of the CD3-RT oligonucleotide [44] and incubated for 10 min at 65 °C. 
Subsequently after letting the solution cool to room temperature, the remaining components 
(Reverse Transcriptase, RNase Inhibitor, dNTPs and RT buffer) were supplemented. The reaction 
(20 µl) was allowed to incubate for 90 min at 37 °C. 
 
  Materials and Methods 
 
26 
 
4.5. DNA procedures 
4.5.1. Isolation and purification of chromosomal DNA from the metacestodes 
Metacestode vesicles were washed three times in 1xPBS, disrupted by pipetting with a 1ml tip. After 
centrifugation (short spin, full speed) the supernatant was removed and lysis buffer (100 mM NaCl, 
10 mM Tris-HCl, pH 8.0, 50 mM EDTA, pH 8.0, 0.5 % SDS, 20 μg/ml RNase A; 1.2 ml per 100 mg pellet) 
supplemented with 0.1 mg/ml Proteinase K was added. To ensure that samples were totally digested 
an overnight incubation at 50 °C under constant agitation was the method of choice. DNA was 
extracted by 1 volume of phenol-chloroform-isoamyl (25:24:1) alcohol. After centrifugation (25 min, 
2000 g, room temperature) the upper aqueous phase was transferred to a new tube and phenol-
chloroform-extraction was repeated. Subsequently the DNA was precipitated with 2 volumes of 96% 
ethanol in the presence of 0.1 volumes LiCl (5 M stock; pH 4.5) and incubated at -20C° overnight. The 
DNA was completely precipitated at 20,000 rcf for 30 min at 4 °C. After carefully removing the 
supernatant, and washing with 70 % ethanol, the DNA pellet was dried at room temperature and 
resuspended in 1xTE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). The Quality of the DNA was assessed 
with a photo spectrometer and with agarose gel electrophoresis. 
4.5.2. Isolation of plasmid DNA from E. coli 
The isolation of plasmid DNA from E. coli strains was performed with the QIAprep Spin Miniprep Kit 
(QIAgen), the Plasmid Midi Kit (QIAgen) or the NucleoBond® PC 100 Midi Kit (Machery-Nagel) 
following the exact instructions of the producer. 
4.5.3. Gel electrophoresis of DNA 
Agarose gels were prepared as 0.7 % - 1.0 % 1xTAE (40 mM Tris, 1 mM EDTA, pH 8.0, 0.11 % glacial 
acetic acid ad 1 l dH2O, pH 8.5) for fragments between 0.25 kb and 7 kb or 2 % 1xTBE (89 mM Tris 
base, 89 mM Boric acid, 2 mM EDTA, pH 8.0) gels for fragments smaller than 0.25 kb. The 
corresponding amount of agarose was dissolved by heating in 1xTAE or 1xTBE, respectively. 
Subsequently, the agarose-buffer solution was allowed to cool down to 50 °C – 60 °C and was then 
poured into a horizontal gel sleigh in which loading wells were left by appropriate combs. The DNA 
sample to be analysed was mixed with a 6 x agarose buffer containing 0.25 % bromo phenol blue, 
0.25 % xylene cyanol, 40 % saccharose and 30 % glycerol. The DNA was allowed to separate on the 
gel for about 30 – 50 min at room temperature at voltages between 70 V and 100 V until the dyes 
included in the loading buffer were sufficiently separated. In a 1 % agarose gel, the bromo phenol 
blue band and the xylene cyanol correspond to a 0.3 kb and 3 kb fragments, respectively. Later the 
DNA was visualized by incubating the gel in ethidium bromide (2 mg/l ethidium bromide in 1xTAE or 
1xTBE, respectively) for about 10 min and exposing the gel to UV light. The SmartLadder (Eurogentic) 
or the Low Molecular Weight DNA Ladder (NEB, N3233) were used as marker to estimate DNA 
fragment size. 
4.5.4. Purification and DNA precipitation 
PCR amplicons and DNA treated with restriction enzymes was purified with the help of the QIAquick 
PCR Purification Kit or the QIAquick Nucleotide Removal Kit, while DNA in an agarose gel was 
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extracted either with the QIAEX II Gel Extraction Kit or the QIAgen Gelextraction Kit (all QIAgen) 
following the instructions of the manufacturer. 
DNA from a sample solution was precipitated with 2.5 volumes of 96 % ice-cold ethanol and 0.1 
volume of 3 M sodium acetate (pH 5.2). After incubation for up to 24 h at -20 °C the DNA was fully 
precipitated by centrifugation (30 min, 15,000 rpm, 4 °C). Then the supernatant was removed, the 
DNA was washed with 70 % ethanol and dried at room temperature. When the pellet resumed a 
white colour, the DNA was dissolved either in DNAse-free water or 1xTE buffer (10 mM Tris, 1 mM 
EDTA, pH 8.0). 
4.5.5. Sequencing of DNA 
DNA was sequenced according to Sanger employing an ABI prism 377 DNA sequencer (Perkin-Elmer; 
Rodgau-Juegesheim, Germany). The DNA sample (300 ng plasmid DNA; 50 ng PCR purified amplicon) 
was mixed with 1 µl of a 50 µM oligonucleotide, 2 µl of a 5 x sequencing solution to a final volume of 
10 µl. The PCR protocol was a follows: 25 cycles of 96 °C for 10 s, 45 °C –60 °C for 5 s and 72 °C for 
1 min. The annealing temperature for the sequencing oligonucleotide was calculated with the 
equation Ta [°C] = 4x (G+C) + 2x (A+T) – 5. 
4.5.6. Amplification of DNA via PCR 
Defined DNA fragments were amplified by utilizing sequence specific oligonucleotides in a 
polymerase chain reaction (PCR) with either the Trio-Thermoblock or the T-Gradient (both Biometra). 
Depending on the purpose of PCR either the non-proofreading Taq DNA polymerase (NEB) or the 
proofreading enzymes PfuTurbo (Stratagene) and Phusion High-Fidelity DNA Polymerase (Finnzymes) 
were applied. 
Following the equation Ta [°C] = 4x (G+C) + 2x (A+T) to calculate the oligonucleotide annealing 
temperature, usually oligonucleotides with an approximate Ta of 58 °C and a G/C content between 40 
– 60 % were designed. 
In detail, cycling and reaction conditions were as follows depending on which enzyme was used for 
the reaction: 
 Taq DNA polymerase (NEB): initial denaturation for 30 - 60 seconds (s) at 94 °C, 30 cycles of a 
denaturation, primer annealing and a elongation step (30 s at 94 °C, 30 s at Ta-5 °C, 60 s/1000 
bp at 72 °C) and with a final elongation for 10 to 30 min at 72 °C. The PCR mix comprised 1-5 
μl template, 2 μl 10 x buffer, 0.2 μl 10 mM dNTPs, 0.2 μl 50 μM oligonucleotide I, 0.2 μl 
50 μM oligonucleotide II, 0.2 μl Taq DNA polymerase (2 U/μl) ad a final volume of 20 μl. 
 Phusion High-Fidelity DNA Polymerase (F-531S) and PfuTurbo were used according to the 
manufacturer’s instructions and with the supplied reagents. 
4.5.7. Rapid amplification of cDNA ends (RACE) 
In order to define the 5’ and 3’ ends of target genes RACE experiments were conducted. As template 
an already existing cDNA library was chosen [39]. For the first PCR one specific oligonucleotide of the 
respective 5’ or 3’ end of the target gene and one oligonucleotide complementary to the vector 
backbone were used. For the second PCR - nested PCR - a pair of oligonucleotides was chosen, which 
binds between the first set of primers. 
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4.5.8. Semi-quantitative RT PCR 
Total RNA was isolated as described earlier (4.4.1) from metacestode vesicles, primary cells and both 
activated and dormant protoscoleces. Equal amounts of RNA were reverse transcribed using the 
Omniscript RT-PCR Kit (QIAgen) and the oligonucleotide CD3-RT. Subsequently, equivalent amounts 
of cDNA were subjected to PCR expression analyses. In detail, ten-fold serial dilutions were analyzed 
by this mean. Different PCR protocols were used for the genes of interest: 
 Emnhr1: The oligonucleotides EmNHR1-LHQ-dw (5’-CTT CAT CAG GAT CGC TTA CCT AC-3’) 
and EmNHR1-SLV-up (5’-TCA CCA AAC TAC TTA TAG TAA TAT TTG AG-3) were used. The 
constitutively expressed gene Emelp [44]served as control using the primers Em10-15 (5’-
AAT AAG GTC AGG GTG ACT AC-3’) and Em10-16 (5’-TTG CTG GTA ATC AGT CGA TC-3’) The 
protocol was chosen as specified: initial denaturation of 1 min at 94 °C, 35 cycles of 30 s at 
94 °C, 30 s at 57 °C and 50 s at 72 °C with a final elongation step of 10 min at 72 °C. 
 Emfr: the primers EmFR-exp-dw (5’-GTT CAT CGA GAC CTG GCG G-3’) and EmFR-exp-up (5’-
CAA AAG ACC ATA TGT CGG ATT T-3’) were utilized. As control Emact-dw (5’- TCA ATC CTA 
AAG CCA ATC-3’) and Emact-up (5’- CGT ACA ACG ACA GCA C-3’) for Emactin2 [147] 
employing a protocol of initial denaturation of 1 min at 94 °C, followed by 30 cycles of 30 s at 
94 °C, 30 s at 56 °C and 30 s at 72 °C with a final elongation step of 10 min at 72 °C. 
 Emmpk3: The oligonucleotides EmMPK3-exp-dw (5’-TGG GTA GTG ATG GTA ATC TCG -3’) and 
emMPK3-exp-up (5’-AGG GCG CGA TGA AGT CG -3’) were used. Again, the constitutively 
expressed gene Emelp [44] served as control using the primers Em10-15 and Em10-16. The 
protocol was chosen as specified: initial denaturation of 1 min at 94 °C, 28 cycles of 30 s at 
94 °C, 30 s at 56 °C and 30 s at 72 °C with a final elongation step of 10 min at 72°C. 
4.5.9. PCR based mutagenesis 
In a PCR based mutagenesis approach specific mutations to a particular DNA sequence were 
introduced using oligonucleotides which harbor the desired mutation. The procedure first involved 
the amplification of the entire plasmid vector, in which the mutation was introduced. Then, the 
mixture of original and mutated vector was digested with the dam-methylation sensitive restriction 
enzyme DpnI. Thus, the original plasmids were digested, but not the newly amplified plasmids 
because methylations of plasmids are only introduced when plasmids are expanded in bacteria. After 
the DpnI digest bacteria were transformed with this DNA mixture. Single colony bacteria were 
harvested after overnight incubation, plasmid DNA was isolated and subjected to sequencing to 
verify the introduced mutations. 
 Design of oligonucleotides: The length was between 25–45 nucleotides and the mutation site 
was situated in the middle of the sequence. The average CG content numbered 40 %. 
 Annealing temperature for PCR: To calculate Ta the following equation was used: Ta = 81 5 x 
0.41 (% GC) – 675/N - % mismatch was used; (% GC : number of G and C nucleotides of the 
primer; % mismatch: percentage of non-binding nucleotides; N : total number of nucleotides 
of the primer) 
 PCR reaction mix: The PCR was conducted in total volume of 50 µl with 10 ng of the 
respective plasmid as template, 0.2 mM dNTPs and 125 ng each of the respective 
oligonucleotides. All other ingridients were added according to the manufacturer’s protocol 
(Phusion High-Fidelity DNA-Polymerase, NEB) 
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 PCR protocol: initial denaturation of 1 min at 98 °C, 18 cycles of 30 s at 98 °C, 30 s at Ta+3 °C 
and 5 min at 72 °C with a final elongation step of 10 min at 72 °C 
 DpnI digest: 0.5 µl (10 U/µl) directly added to the PCR mix after PCR reaction; incubation for 
3 h at 37 °C. 
 Transformation: 2 µl and 5 µl of the reaction mixture following the transformation protocol 
(see section 4.7.3) 
 DNA plasmid preparation (see section 4.5.2) and sequencing (see section 4.5.5). 
4.5.10. TA cloning 
When amplifying DNA with Taq DNA Polymerase (NEB) the resulting amplicons possess an additional 
3’ A. This overhang was used for cloning into the pCR®2.1®TOPO-TA vector or the pBAD/Thio-TOPO® 
vector (both Invitrogen) which both harbor a complementary 5’T overhang. Successful ligation of the 
insert into the vector results in white colonies on the agar plate, while blue colonies represent 
bacteria with religated vectors. Purified DNA fragments which lack a 3’ A overhang from PCR 
reactions with Phusion High-Fidelity DNA Polymerase were incubated with Taq DNA polymerase and 
dATP for 1 h at 72 °C to add a 3’ A, thus allowing TA cloning. 
4.5.11. Colony-PCR 
To check whether the DNA insert integrated into the multiple cloning site (MCS) of the respective 
plasmid backbone, bacterial clones were analyzed in a colony PCR. Single bacterial colonies were 
picked with a sterile tip from the agar plate and resuspended in 20 µl sterile water. The suspension 
was incubated on a shaker for 10 – 20 min at room temperature. For PCR analysis 2 µl of the 
suspension was used as template with Taq DNA polymerase (NEB; see section 4.5.6). 
4.5.12. Restriction digest of DNA 
DNA restriction digests were conducted using NEB restriction enzymes following the manufacturer’s 
instructions. The reaction volume was 20 µl. Simultaneous double digests of DNA inserts were the 
method of choice when needed for directional cloning only if enzymes met the same temperature 
and buffer specificities. After a single restriction digest, the DNA fragment was dephosphorylated at 
the 5’ end using Antarctic Phosphatase (NEB) or CIP as recommended by the producer before the 
subsequent ligation step. 
4.5.13. Ligation of DNA fragments  
DNA fragments were ligated using the T4 DNA ligase (NEB). In detail, the reaction was carried out in 
total volume of 20 µl at 16 °C over night. The vector-insert ratio was 1:3 with usually 50–100 ng of 
plasmid vector. 
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4.6. Protein analysis 
4.6.1. Determination of protein concentration 
The BCA Protein Assay Kit (Pierce Biotechnology) was used to determine the protein concentration of 
samples late used for SDS-PAGE (see section 4.6.2). The working solution was obtained by mixing 
Reagent A and B in a ration 50:1. As protein standard bovine serum albumin (BSA) was chosen in the 
following concentrations (µg/ml): 50, 100, 200, 400, 600, 800, 1000 und 1200. From each 
concentration and from the samples of unknown concentration 50 µl were taken and mixed with 
1 ml working solution. Then the mixture was incubated for 30 min at 37 °C. Subsequently the 
absorption at 562 nm was measured in the ELISA reader Multiscan Ex Primary EIA V.2.1-0 (Thermo). 
4.6.2. SDS-PAGE 
The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted in the 
Mini-Protean separation chambers by BioRad. The following working solutions were used: 
 
 PAA:    30 % acrylamide / 0.8 % bis-acrylamide (Roth) 
 4x Lower-Tris:   1.5 M: Tris-HCl, pH 8.8, 0.4 % SDS 
 4x Upper-Tris:   0.5 M Tris-HCl, pH 6.8, 0.4 % SDS 
 TEMED:   N,N,N',N'-tetramethylethane-1,2-diamine (Merck) 
 APS:    16 % ammonium persulfate dissolved in H2O 
 Running buffer:  192 mM glycine, 25 mM Tris base; 1 % SDS 
 2x stop mix:  2 ml 0.5 M Tris-HCl pH 6.8 
1.6 ml glycerol 
1.6 ml 20 % SDS 
1.4 ml dH20 
0.4 ml 0.05 % (w/v) bromophenol blue 
7 μl β-mercaptoethanol / 100 μl 
 5x sample buffer: 25 % v/v 250 mM Tris pH 6.8 
50 % v/v glycerin 
10 % w/v SDS 
25 % v/v β-mercaptoethanol) 
 
 Resolving gel composition: 
 
 5 % 7.5 % 10 % 12 % 15 % 17.5 % 
PAA 4 ml 6 ml 8 ml 10 m 12 ml 14 ml 
4x Lower Tris 6 ml  6 ml 6 ml 6 ml 6 ml 6 ml 
dH2O 14 ml  12 ml 10 ml 8 ml 6 ml 4 ml 
 
 Stacking gel composition: 1.5 ml PAA; 2.5 ml 4x Upper-Tris, 6.5 ml dH2O 
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The polymerization of the acrylamide of either the resolving or the stacking gel was initiated by the 
addition of 40 µl TEMED and 120 µl APS or 40 µl TEMED and 70 µl APS, respectively. The 
polymerization took approximately 25–30 min at room temperature. For the stacking gel combs with 
either 10 or 15 wells were applied. The volumes mentioned above for the stacking and the running 
gel are sufficient for six Mini gels (100 mm x 75 mm x 1 mm). Before loading the samples onto the 
gel, they were mixed with 2x stop mix, heated at 100 °C for 5–10 min and subsequently centrifuged 
(short spin, full speed at room temperature). Separation was allowed at 150 V for about 30–90 min 
depending on the resolution needed. To determine the protein size of the separated samples the 
broad range prestained protein marker (NEB) was loaded in one lane of the gel. 
After discarding the stacking gel, the resolving gel was either subjected to Coomassie staining, silver 
staining or Western blot analysis. 
4.6.3. Coomassie staining of protein gels 
Coomassie staining of the PAA gels was conducted for approximately 30 min at room temperature 
with Coomassie staining solution (0.25 % Coomassie R250, 50 % methanol, 10 % glacial acetic acid). 
For destaining of unspecific stained areas and visualization of protein bands the Coomassie 
destaining solution (45 % methanol, 45 % H20, 10 % glacial acetic acid) was used. The destaining 
solution was renewed several times, until the optimal result was obtained. 
When needed for mass spectrometry analysis PAA gels were stained according to Bente et al. [151]. 
Briefly, gels were colloidal Coomassie brilliant blue stained overnight in 1.6% ortho phosphoric acid 
(Fluka), 8 % ammonium sulfate (Fluka), 0.12 % Coomassie blue G 250 (Merck), and 20 % methanol 
(Merck) and destained in 25 % methanol. 
4.6.4. Silver staining of protein gels 
Silver staining of PAA gels was conducted according to a previously described protocol published by 
Rabilloud [152]. First, the gel was fixed in fixing solution (50 % ethanol, 12 % acetic acid, 38 % dH2O) 
for 1 h at room temperature. After washing for 20 min in 30 % ethanol, the gel was sensitized in 
sensitizing solution (66 µl 37 % formaldehyde, 25 µl 43 % Na2S2O3 in dH2O, ad 100 ml dH2O) for 1 min. 
Subsequently the gel was washed three times in dH2O for 1 min each and then impregnated with 
silver staining solution (66 µl 37 % formaldehyde, 0.2 g AgNO3, ad 100 ml dH2O) for 30 min at room 
temperature. Again, the gel was washed two times for exact 30 s. Finally, the gel was incubated in 
developer (50 µl 37 % formaldehyde, 1.8 µl 43 % Na2S2O3, 6 g Na2CO3, ad 100 ml dH2O) until the gel 
was optimally developed. The Reaction was stopped with freshly prepared EDTA-solution (13.7 g/l). 
4.6.5. Western blotting 
For transferring the resolved proteins onto nitrocellulose membranes the Mini Trans-Blot Cell 
(BioRad) was used. The transfer was conducted for 1 h at 350 mA. Subsequently to blotting, the 
nitrocellulose membrane was blocked with blocking solution and then incubated with the desired 
antibody overnight at 4 °C. Then, the membrane was washed three times for 10 min with washing 
buffer before being incubated with secondary antibody solved in blocking buffer for 1 h at room 
temperature on a seesaw. The washing steps were repeated and the proteins were visualized by 
chemiluminescence (ECL, Pierce) and exposing to X-ray films. The films were developed with a Curix 
60 automated developer (Agfa). 
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The following buffers and setups were applied for Western blotting: 
 
 Western blot buffer:  25 mM Tris-HCl 
192 mM Glycin 
20 % Methanol 
 Western blot setup: Sponge, Whatman paper, PAA-gel, nitrocellulose, Whatman paper 
Sponge 
 Cooling block:   mounted in the transfer chamber for blotting 
 Blocking buffer:  5 % skim milk (SM) or 5 % BSA dissolved in 1x TBST (20 mM Tris, 
150 mM NaCl, pH 7.5, 0.1 % Tween20) 
 Washing buffer: 1x TBS / 0.1 %Tween20 (TBST) 
 
Primary Antibody Dilution Buffer Company Source 
anti-β-actin 1:1000 5 % BSA-TBST Cell Signaling rabbit 
anti-Erk1/2 1:1000 5 % SM-TBST Stressgen rabbit 
anti- Erk (pTpY 185/187) 1:1000 5 % SM-TBST Invitrogen rabbit 
anti-elp 1:1000 5 % SM-TBST mAb2810 [153] mouse 
anti-HA 1:1000 5 % SM-TBST Santa Cruz Biotechnologies rabbit 
anti-IGF-I clone Sm1.2 1:500 5 % SM-TBST Millipore mouse 
anti-insulin 1:500 5 % SM-TBST Sigma mouse 
anti-myc 1:1000 5 % SM-TBST Santa Cruz Biotechnologies mouse 
anti-phospho-Akt 1:1000 5 % BSA-TBST Cell Signaling (#9275) rabbit 
anti-phospho-FGFR 
(Tyr653/654) 
1:500 5 % BSA-TBST Cell Signaling rabbit 
anti-V5  1:5000 5 % SM-TBST Invitrogen mouse 
anti-His 1:1000 5 % SM-TBST Cell signaling mouse 
Secondary Antibody     
anti- mouse IgG – HRP  1:10,000 blocking buffer Jackson ImmunoResearch  
anti–rabbit IgG – HRP 1:5000 blocking buffer Jackson ImmunoResearch  
anti-rat IgG - HRP 1:1000 5 % SM-TBST BioLegend goat 
4.6.6. Mass spectrometry 
Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS) of 
protein spots was conducted essentially as described [154]. The desired protein spots were cut from 
the Coomassie brilliant blue stained gel with a wide-bore pipet tip. Then the gel pieces were places 
into single wells of a ZipPlate (Montage In-Gel-DigestZP Kit, Millipore) and according to the 
manufactures instructions the proteins in the gel plugs were destained, digested with trypsin 
(Promega), extracted, purified on a C18 reverse phase matrix, and eluted in 8 µl of 60 % acetonitrile, 
0.1 % trifluor-acetic acid (TFA). 
Then, 2.5 µl of the eluted peptides were spotted onto a 378-well, 400 µm Anchor Plate (Bruker 
Daltonics). Shortly before the solvent was completely evaporated, 1 µl of matrix solution (saturated 
α-cyano-4-hydroxy-cinnamic acid (Sigma) solution in 50 % acetronitrile, 0.1 % TFA) was added. After 
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the plate was air-dried, MALDI-TOF-MS was conducted on a Bruker Autoflex Mass Spectormeter 
(Bruker Daltonics, Bremen). The experiments were run in the reflection mode applying the following 
settings: Ion source 1 voltage: 19 kV; ion source 2 voltage: 16.5 kV; reflector voltage 20 kV; lens 
voltage 8 kV; 40 ns pulse time, 120 ns pulse extraction time, matrix suppression <500 Da. For internal 
calibration a mix of peptides (Nr. A9525 Angiotensin II MolMass 1046.5; Nr. A9650 Angiotensin I Mol. 
Mass 1296; Nr. A109 ACTH clip 1-10 Mol. Mass 1299; Nr. A2407 ACTH clip 1-17 Mol. Mass 2093; 
Sigma) was used. Analysis of obtained spectra was conducted by means of Mascot 
(www.matrixscience.com; Peptide Mass Fingerprint; MSDB 20060831). 
4.7. Working with bacteria 
4.7.1. Bacteria strains and media 
Bacteria Strains Company Genotpye 
E. coli DH5α Invitrogen F-Φ80dlacZΔM15 Δ(lacIZY-argF) U169 recA1 endA1 
hsdR17(rk-,mk-) phoA supE44 thi-1λ gyrA96 relA1 tonA 
 
E. coli TOP10 Invitrogen F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara-leu)7697 galU galK rpsL 
 
E. coli BL21  Amersham F-, ompT, hsdSb(rB
-mB
-), gal, dcm 
 
E. coli BL21(DE3) pLysS Novagen F- ompT hsdSb(rB
-mB
-) gal dcm (DE3) pLysS (camR) 
Media   
Luria-Broth (LB) Invitrogen  
LB agar plates   LB medium with 1.5% Bacto-Agar 
SOC  Invitrogen  
 
Bacteria cultures were grown at 37 °C either in LB liquid medium under constant shaking (225 rpm) 
or on LB agar plates. The appropriate selective antibiotic was supplemented depending on the 
propagated plasmid (100 µg/ml ampicillin, 50 µg/ml kanamycin or 100 µg/ml chloramphenicol). 
4.7.2. Chemically competent E. coli 
Chemically competent bacteria were produced using the CaCl2 method. Briefly, 50 ml LB medium 
were inoculated with 1 ml overnight culture of the respective E. coli strain. The bacteria were then 
incubated approximately 2–3 h at 37 °C at 225 rpm until an OD600nm of 0.5 -0.7 was reached. In the 
next step, the culture was separated into 2 aliquots, centrifuged at 4000 rpm for 10 min at 4 °C. After 
decanting the supernatant the pellet directly placed on ice. Each pellet was carefully resuspended in 
12 ml ice cold 100 mM CaCl2 and the centrifugation step was immediately repeated. Then the 
resulting pellet was dissolved in 1 ml fresh CaCl2 by gently resuspending. After incubating the bacteria 
for 30 min up to 60 min on ice, glycerol was added to a final concentration of 20 %. The bacteria 
were immediately stored at -80 °C in 50 μl aliquots. 
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4.7.3. E. coli transformation 
For each transformation 25 μl competent cells were incubated with the respective plasmid or ligation 
mixture for 30 min on ice. Subsequently, heat shock at 42 °C for 1 min followed. After addition of 
125 μl SOC medium, the bacteria were incubated between 30 min and 60 min at 37 °C under 
constant shaking (225 rpm). Then the bacteria were transferred on LB agar plates supplemented with 
the corresponding antibiotic (100 μg/ ml ampicillin, 50 μg/ ml kanamycin or 100 µg/ml 
chloramphenicol) and incubated at 37 °C overnight. 
4.7.4. Heterologous expression in E. coli and purification of the recombinant 
proteins 
 
pBAD/Thio-TOPO® vector system 
 
In this work, recombinant EmNHR1-ab and EmFRin were expressed in DH5α E. coli using the 
pBAD/Thio expression Kit (Invitrogen). The vector was designed to express fusion proteins under the 
control of an inducible araBAD promoter with an N-terminal thioredoxin tag which can be cleaved at 
the enterokinase site. Moreover, a V5 epitope tag is fused to the C-terminus followed by a His(6)-tag. 
The former was used to detect fusion proteins by means of Western Blot (anti-V5-antibody) and the 
latter was used for native affinity chromatography. As stated by the manufacturer, the V5 epitope 
tag and the His(6)-tag contribute 16 kDa to the size of the fusion protein. After ligation of the vector 
and the respective PCR amplicon (EmNHR-ab: EmNHR-ab-dw and EmNHR-ab-up; EmFRin: EmFRin-
pBAD/Thio-dw and EmFRin-pBAD/Thio-up) the construct was introduced in E. coli, selected under 
ampicillin pressure and checked for correct insertion by means of sequencing. Positive clones were 
used for pilot expression studies according to the manufacturer’s specifications.  
For large scale recombinant expression, an overnight culture (LB medium, 100 µg/ml ampicillin) of 
the respective clones was used as inoculum (1:200). The culture was propagated until the bacteria 
reached an OD600nm of 0.5. Then the induction of protein expression was started by adding 0.2 % L-
arabinose and the culture was incubated for 6 h at 37 °C under constant shaking (225 rpm). 
Subsequently, the bacteria were harvested by centrifugation (4 °C, 6000 g, 20 min) and the pellet was 
resuspended in native lysis buffer (300 mM NaCl, 50 mM sodium phosphate-buffer pH 8.0, 10 mM 
imidazol) supplemented with 5 mg/ml lysozyme and incubated on ice for 30 min. Then suspension 
was stored at -20 °C until protein purification. Upon thawing the lysed pellet was treated with 
sonification for a least three times for 30 s (continuous output of 4-5, duty-cycle of 40-50 %) until the 
mixture was viscous. Subsequently an RNase (5 µg/ml) – Dnase (5 µg/ml) treatment followed for 
15 min at 30 °C before centrifugation at 4 °C and 6000 g for 20 min. Then the supernatant was 
transferred to FastPrep® Lysing Matrix B tubes (Qbiogene, Bio 101 Systems, Heidelberg, Germany) 
and transferred to a FastPrep® for 45 s at speed 6.5. After centrifugation for 15 min at 4 °C 
(maximum speed) the supernatant was pooled and 4 ml Nickel beads (ProBond Resin, Invitrogen) 
which had earlier been equilibrated with lysis buffer were added. This mixture was incubated at 4 °C 
overnight under constant but slow rotation. After washing three times in 300 ml native washing 
buffer (300 mM NaCl, 50 mM sodium phosphate-buffer pH 8.0, 20 mM imidazol) the beads were put 
on a PD-10 column (GE Healthcare) and the protein was eluted in a first step with 6 ml elution 
buffer I (300 mM NaCl, 50 mM sodium phosphate-buffer pH 8.0, 250 mM imidazol) and in a second 
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step with 6 ml elution buffer II (300 mM NaCl, 50 mM sodium phosphate-buffer pH 8.0, 500 mM 
imidazol). The eluted fractions were analysed by Western blot or Coomassie staining of the PAA-gel 
run in an SDS-PAGE. Fractions which harbored the desired protein were collected, pooled and 
dialysed overnight in 5 l 1xPBS at 4 °C. 
 
pGEX-5X Vector System 
 
The pGEX-5X system (Amersham) was used to express recombinant EmFRin. Recombinantly 
expressed fusion proteins have an N-terminally fused glutathione-s-transferase (GST) of S. japonicum 
which is about 26 kDa in size. The fusion protein expression is under the control of an IPTG 
(isopropyl-β-Dthiogalactopyranoside) inducible promoter. For cloning EmFRin the following 
oligonucleotides were used: EmFRin_pGEX5X_BamH1_dw and EmFRin_pGEX5X_Not1_up and 
positive clones were verified by sequencing. 
Protein expression was conducted as follows: LB-medium containing 100 μg/ml ampicillin was 
inoculated 1:50 with E. coli BL21 from an overnight culture. The suspension was incubated at 37 °C 
and constant shaking (225 rpm) until an OD600nm of 0.5. Subsequently the protein expression was 
induced by the addition of 1 mM IPTG and allowed to for 2 h. Then the bacteria were centrifuged at 
4 °C at 6000 g for 20 min. After resuspension in 10 ml pre-chilled 1xTBS containing 5 mg/ml lysozyme 
the suspension was frozen at -20 °C overnight. Upon thawing the lysed pellet was treated with 
sonification for a least three times for 30 s (continuous output of 4-5, duty-cycle of 40-50 %) until the 
mixture was viscous. Next an RNase (5 µg/ml) and DNase (5 µg/ml) treatment followed for 15 min at 
30 °C before 1 % Triton-X—100 was added. After an incubation period of 1 h at 4°C, the cell debris 
was pelleted by centrifugation (4 °C, 6000 g for 20 min). The supernatant was transferred to a new 
reaction tube and mixed with glutathione sepharose beads that had been previously equilibrated 
with 1x PBS 1 % Triton X-100. After 4 h constant agitation at 4 °C, the beads were washed three time 
with 1x TBS, 1 % Triton-X-100 and then the protein was eluted in several fractions by using the 
elution buffer I (25 mM glutathione in 1x TBS) and II (50 mM glutathione in 1x TBS), each trhee times. 
The eluted fractions were analysed by Western blot or Coomassie staining of the PAA-gel run in an 
SDS-PAGE. Fractions which harbored the desired protein were collected, pooled and dialysed 
overnight in 5 l 1xPBS at 4 °C. 
 
pET30c system 
 
The pET30 vector (Novagen) was used to express recombinant EmFRex. For cloning EmFRex the 
following oligonucleotides were used: FRex-pET30a(+)-BamH1-dw and FRex-pET30a(+)-Sal1-up and 
positive clones were verified by sequencing. Protein expression was conducted in E. coli BL21(DE3) 
pLysS cell und ampicillin and chloramphenicol selection according to the manufacturers 
specifications.  
 
pRSET-A 
 
The pRSET-A vector (Invitrogen) was used to express recombinant EmNHR-ab. For cloning EmNHR-ab 
the following oligonucleotides were used: EmNHR-ab2-NcoI-pRSET-dw and EmNHR-ab2-HindIII-
pRSET-up and positive clones were verified by sequencing. Protein expression was conducted E. coli 
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host strain BL21(DE3)pLysS under ampicillin and chloramphenicol selection and IPTG induction 
according to the manufacturer’s instruction. Protein purification was done as described for 
pBAD/Thio-TOPO® fusion His(6)-tag proteins.  
 
pQE30 
 
The pQE30 vector (QIAexpressionist, QIAgen) was used to express recombinant EmFRin. For cloning 
EmFRin the following oligonucleotides were used: pQE30-FRin-BamH1-dw and pQE30-FRin-Sal1-up 
and positive clones were verified by sequencing. Protein expression was conducted E. coli host strain 
M15[pREP4] under ampicillin selection and IPTG induction according to the manufacturers 
specifications. Protein purification was done as described for pBAD/Thio-TOPO® fusion His(6)-tag 
proteins. 
4.8. Working with yeast  
4.8.1. Yeast strains and media 
Yeast strains   
AH109 BD Biosciences 
Clontech 
MATa, trp1-901, leu2-3, 112, ura3-52, his3- 200, 
gal4Δ, gal80Δ, LYS2::GAL1UASGAL1TATA- HIS3, 
GAL2UAS GAL2TATA-ADE2, URA3::MEL1UAS-, 
MEL1TATA-lacZ 
 
Y187  
 
BD Biosciences 
Clontech 
MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-
3, 112, gal4Δ, met -,gal80Δ, URA3::GAL1UAS-
GAL1TATA-lacZ, MEL1 
 
Media   
YPDA  
 
20 g/l Difco peptone 
10 g/l Yeast extract 
20 g/l Bacto agar (for plates) 
dH20 ad 950 ml 
 
pH 6.5 adjusted by adding 25 % HCl 
After autoclaving 50 ml of 40 % glucose and 15 ml of 0.2% adenine 
hemisulfate solution were added. Both solutions were filter sterilized. 
 
SD 6,7 g Difco™ Yeast Nitrogen Base w/o Amino Acids 
20 g Difco™ Bacto Agar 
x g of the corresponding drop out supplement (DOS) (Clontech) 
dH20 ad 930 ml or 950 ml 
 
pH 6.5 adjusted by adding 25 % HCl 
After autoclaving 50 ml of 40 % glucose were supplemented. 
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SD - Trp + 0.64 g/l -Leu/- Trp DOS 
+ 20 ml 50x Leu (5 mg/ml) 
 
SD - Leu  + 0.64 g/l -Leu/- Trp DOS 
+ 20 ml 50x Trp (1 mg/ml) 
 
SD - Leu/- Trp + 0.64 g/l -Leu/- Trp DOS 
 
SD - Leu/-Trp/ -His 
 
+ 0.6 g/l -Ade/- His/- Leu/-Trp DOS 
+ 0.003 % (v/v) adenine hemisulfate 
 
SD - Leu/- Trp/ -His/-Ade + 0.6 g/l Ade/ - His/ - Leu/ - Trp DOS 
 
4.8.2. Yeast-two hybrid analysis 
In a yeast-two-hybrid approach protein-protein interactions were analysed. For that, the 
MATCHMAKERTM-system (Clontech) was used and the experiments were performed as previously 
described [60]. Briefly, translational fusions of the proteins or protein domains of interest with the 
Gal4 DNA-binding domain (pGBKT7; BD) or the Gal4-activation domain (pGADT7; AD) were 
generated. These fusion constructs were co-transformed into the yeast strain AH109. For 
transformation YPDA medium was inoculated with AH109 and cultured at 30 °C overnight and 
200 rpm. Then the culture was collected and centrifuged (700 g, 5 min, 4 °C) and subsequently the 
pellet was resuspended in freshly prepared transformation buffer (40 % PEG 3350, 200 mM lithium 
acetate, 100 mM DTT; 100 µl for 1 ml yeast culture). 100 µl aliquots of the yeast-transformation-
buffer solution were subjected to reaction tubes and 200 ng DNA of each plasmid construct were 
added. The suspension was incubated for 30 min at 45 °C before being transferred on 
leucine/tryptophan-deficient selective plates. Selection was allowed for 4 d at 30 °C. Then the proper 
expression of the fusion proteins was verified by Western blot analyses utilizing antibodies against 
the Gal4-AD (anti-HA; SantaCruz Technologies) and Gal4-BD (anti-cmyc; SantaCruz Technologies). 
Interaction trap analysis of the double-transformants was conducted according to the 
MATCHMAKERTM instruction specifications using selective agar plates lacking leucine, tryptophan (as 
plasmid selection markers) and either histidine in the presence of 7.5 mM 3-amino-triazole (3-AT) for 
medium stringency or histidine plus adenine for high stringency selection. Colony formation was 
assessed after 3 days of incubation at 30 °C. 
The AD and BD constructs for the full-length EmNHR1 coding sequence, the DBD, the complete and 
the truncated forms of the LBD have been obtained by directional cloning. First, the full-length 
Emnhr1 was cloned into the pDrive (Qiagen PCR cloning kit) plasmid amplified from H95 
metacestode cDNA using the primers NHR1_H95_ATG_NdeI_dw and NHR1_H95_TAA_up. Second, 
the respective fragments were PCR amplified from the pDrive plasmid. The DBD was amplified using 
NHR1_H95_ATG_NdeI_dw and NHR1_H95_DBD_Y2H_XmaI_up and for the constructs of the LBD the 
following primers were chosen: EmNHR1-LHQ-NcoI-fwd/EmNHR1-FIE-XmaI-rev; EmNHR1-LHQ-NcoI-
fwd/EmNHR1-ALT-XmaI-rev; EmNHR1-NTS-NcoI-fwd/EmNHR1-FIE-XmaI-rev; EmNHR1-LHQ-NcoI-
fwd/EmNHR1-SLV-XmaI-rev; EmNHR1-NTS-NcoI-fwd/ EmNHR1-ALT-XmaI-rev; EmNHR1-DNY-NcoI-
fwd/EmNHR1-FIE-XmaI-rev. EmNHR1-FL was introduced to pGADT7 via NdeI/SacI and to pGBKT7 via 
NdeI/SalI restriction digest. To introduce EmNHR1-DBD into pGADT7 and pGBKT7 an NdeI/XmaI 
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restriction digest was applied. All LBD constructs were introduced to pGBKT7 by NcoI/XmaI 
restriction digest. For the respective LBD AD clones the LBD inserts were cut from the positive BD 
clone with the following enzymes: NdeI for and NdeI/XmaI and inserted into pGADT7, cut with the 
same restriction enzymes, respectively. 
The ORF for EmFR was amplified from cDNA with the primers EmFR-pSecHygroA-BamH1-dw and 
EmFR-pSecHygroA-Not1-up. Then the intracellular domain (EmFRin) was PCR amplified using the 
following oligonucleotides: FRin-AD-XmaI-dw/FRin-AD-ClaI-up and FRin-BD-BamH1-dw1/FRin-BD-
PstI-up, respectively. The inserts were cloned via the restriction sites XmaI/ClaI and BamHI/PstI into 
the AD and BD yeast vectors, respectively. Using the oligonucleotides HNF4-DBD-AD/BD-NdeI-dw and 
HNF4-DBD-Pl-AB/BD-EcoRI-up or HNF4-DBD-Pa-AB/BD-EcoRI-up, the different EmHNF4 DBD 
isoformes were amplified from the respective pDrive clones, which had resulted from amplifying 
EmHNF4 (EmHNF4-ORF-dw/EmHNF4-ORF-up) from cDNA Pools and activated protoscoleces DNA. 
EmHNF4 DBD isoformes were amplified and cloned via NdeI and EcoRI into the expression vectors. 
All the clones were fully sequenced to ensure that no unwanted mutations had been introduced due 
to incorrect PCR amplification. Yeast-two hybrid fusion plasmids for EmSmadA, EmSmadB, EmSmadC, 
EmSmadD, EmSkip, EmAlien, EmGt198, EmElpN, EmElpC, EmPDZ have been previously described 
[37,58,60-62]. 
4.8.3. Liquid culture β-galactosidase assay 
The liquid culture β-galactosidase assay was performed as described by Förster et al. [145]. For that, 
the plasmid constructs (see section 0) were co-transformed into the yeast strain Y187. The assay was 
conducted according to the MATCHMAKERTM specifications. Briefly, co-transformants were grown in 
leucine/tryptophan deficient medium over night, diluted and let grown again for 5 h. The cultivation 
was conducted either in the presence or absence of certain substances which were analysed for their 
impact on protein-protein interactions. The optical density at OD600nm was measured before 
harvesting the yeast cells and washing them in Z buffer (16.1 g/L Na2HPO4• 7H2O; 5.50 g/L 
NaH2PO4•H2O; 0.75 g/L KCl; 0.246 g/L MgSO4•7H2O; pH 7.0). After three freeze-and-thaw cycles with 
liquid nitrogen, first Z buffer/0.27% v/v β-mercaptoethanol and then 0.67 mg/ml o-nitrophenyl β-D-
galactopyranoside were added. The reaction was stopped immediately after the yellow colour had 
developed with 1 M Na2CO3. 
Analysed substances have been: 5 % FBS, 10 % FBS, 20 % FBS, 20 % heat inactivated FBS, 5 % human 
serum, 10 % human serum, 20 % E. multilocularis hydatid fluid, 20°% FBS treated with dextran coated 
charcoal, 10 % FBS <10 kDa, 10 % FBS >10 kDa, FBS <30 kDa, 10 % FBS >30 kDa (Centriprep YM-10 
10 kDa and 30 kDa), 0.013 mg/l Biotin, 0.013 mg/l Vitamin B12, 10 % DMEM with/without FBS, 10 % 
Panserin or conditioned Panserin, 10 % Panserin without lipids, 10 % Panserin without 
lipids/cholesterol, 10 % Panserin without lipids/cholesterol/vitamins, 10 % conditioned A4 medium 
and 400 µg/ml Proteinase K treated FBS. 
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4.9. Working with mammalian cell lines 
4.9.1. Cell lines and media 
Cell lines Acronym ATCC no. Media 
Rat Reuber hepatoma cells  RH- CRL-1600 Dulbecco’s minimal essential medium 
(DMEM; GIBCO BRL); 
PanserinTM 401 
Human embryonic kidney 
cells 
HEK293 CRL-1573 DMEM; GIBCO BRL 
4.9.2. Cultivation of RH- cells under serum-free conditions: PanserinTM 401 
RH- cells were gradually adapted to serum-free conditions according to the manufactures 
suggestions. Briefly, RH- cells cultivated in DMEM supplemented with 10 % FBS were taken from the 
logarithmic growth phase and seeded in PanserinTM 401 enriched with 5 % FBS. After two passages 
the amount of serum was reduced to 1 %. Subsequently, the step was repeated and the 
concentration of FBS was lowered to 0.5 % and finally to 0 % FBS. Passaging regime was conducted in 
parallel with RH- growing in DMEM/10 % FBS. 
4.9.3. Transfection of HEK293 cells 
HEK293 cells were cultured in DMEM containing 10 % fetal bovine serum (FBS), 1 % penicillin and 1 % 
streptomycin (1 % P/S) at 37 °C with 5 % CO2. HEK293 cells were transfected with constructs of the 
vector pSecHygroA encoding wild-type EmFR and mutant EmFR TkD-, a dead box kinase in which the 
amino acid motif DFG was mutated to DNA. As mock control the empty vector was used.  
One day prior to the transfection, the medium from the HEK293 cells was removed and the cells 
were detached by trypsin/ETDA treatment for 5 min at 37 °C. 8 x 104 cells were seeded per well into 
a 6-well plate containing 5 ml DMEM, 10 % FBS, 1 % P/S and incubated overnight at 37 °C and 5 % 
CO2. Then, the medium was replaced by 4 ml fresh medium and the transfection solution (DNA-salt-
complex) was added drop wise. The transfection solution consisted of 7.5 μg of plasmid DNA mixed 
with 62 μl 2 M CaCl2 and was supplementted to a final volume of 500 μl with dH2O. After mixing, 
500 μl 2x HBS buffer (50 mM HEPES, 1.5 mM Na2HPO4, 280 mM NaCl, 10 mM KCl, 12 mM α-D-
glucose, pH 7.1) were added. Then, the suspension was inverted for 2-4 times and incubated for 30 
min at room temperature. After 7 h, the medium was carefully replaced with fresh medium and the 
incubation was continued for 24 h. Yet, another medium change was performed, letting the cells 
grow again for 24 h before harvesting. For CIP treatment (NEB) the cells were harvested, and 
adjusted to 100 µl with NEB Buffer 3. 20 U (2 µl) of CIP were added and the suspension was 
incubated for 45 min at 37 °C. Then 5x western blot sample buffer was added in a 1:5 dilution. Also, 
1 mM Na3VO4, 10 mM NaF and 1x phosphatase inhibitors (PhosSTOP, Roche Applied Science, 
Mannheim, Germany) were included. Other samples for the analysis of protein expression by 
western blotting were treated as follows. The medium was removed and the cells were adjusted to 
150 μl 1xPBS with a final concentration of 1 mM Na3VO4, 10 mM NaF and 1x phosphatase inhibitors 
and mixed 40 µl 5x western blot sample buffer. All samples were heated to 100 °C for 10 min, shortly 
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spun down to pellet the debris and the supernatant was subjected to SDS-PAGE and Western blot 
analysis. The remaining supernatant was frozen at -20 °C for further analysis. 
4.10. Transfection and treatment of Xenopus laevis oocytes 
All experiments with Xenopus laevis oocytes were part of a joint project and have been conducted by 
E. Browaeys-Poly and K. Cailliau at the Laboratoire de Régulation des Signaux de Division, University 
Lille 1 Sciences and Technology, Villeneuve d’Ascq Cedex, France as a joint project. 
Briefly, capped messenger RNA (cRNA) encoding the full-length sequence of EmFR was synthesized in 
vitro utilizing the T7 mMessage mMachine Kit (Ambion, Austin, TX, USA). Stage VI oocytes were used 
for microinjection [155] of EmFR cRNA (60 ng in 60 µl) 48 °h before the addition of 1, 5 or 10 nM 
human aFGF or bFGF (R&D systems, Abingdon, UK) to the medium. As a positive control cRNA of 
pleurodeles FGFR1 which was identified as homologous to human receptor [156] (gift of Shi D.L. 
CNRS UMR 722, Paris VI) was microinjected. Additionally, BIBF1120 (stock solution 10 mM in DMSO) 
was added (0.1 to 20 µM final concentration) 1 h before ligand stimulation (10 nM aFGF or bFGF) on 
EmFR and FGFR1 expressing oocytes. Subsequently, 15 h after FGF stimulation the oocytes, either 
treated or untreated with inhibitor, were analyzed for their stat of progression in the cell cycle. G2/M 
transition or Germinal Vesicle Breakdown (GVBD) is visible by the detection of a white spot at the 
animal pole of the oocytes. Non-injected oocytes treated or untreated with 10 µM progesterone 
served as positive and negative controls of GVBD, respectively. In each assay, 20-30 oocytes which 
were taken from three animals have been used. 
For Western blot analysis the oocytes were handled as follows: The oocytes were subjected to lysis 
buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 0.05 % SDS, 5 mM MgCl2, 1 mg/ml BSA, 10 µg/ml 
leupeptin, 10 µg/ml aprotinin, 10 µg/ml soybean trypsin inhibitor, 10 µg/ml benzamidine, 1 mM 
PMSF, 1 mM Na3VO4). Then the lysates were centrifuges for 15 min at 10,000 g and 4°°C. 
Subsequently, the membrane pellets were resuspended in lysis buffer supplemented with 1 % Triton 
X-100, were incubated for 15 min at 4 °C and again centrifuged as before. Finally, the supernatants 
were subjected to SDS-PAGE analysis. Proteins were transferred to a Hybond ECL membrane 
(Amersham Biosciences, Orsay Cedex, France). For detection, the membranes were treated with anti-
c-myc (1/50 000, Invitrogen, Cergy Pontoise Cedex, France) or anti-p-tyr (1/8000, BD Biosciences, 
France) antibodies. An HRP-coupled anti-mouse IgG antibody (1/50 000, Biorad, Marnes-la-Coquette, 
France) served as secondary antibody. Signals were detected with the use of ECL advance Western 
blotting detection kit (Amersham Biosciences, Orsay Cedex, France). 
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4.11. Working with E. multilocularis 
4.11.1. E. multilocularis isolates 
Isolate Source Use 
H95 primary infection of M. unguiculatus by 
oncosphere uptake 
metacestode cultivation in vitro 
isolation and cultivation of primary cells 
GH09 
 
Java monkey as intermediate host, 
secondary infection of M. unguiculatus 
metacestode cultivation in vitro 
isolation and cultivation of primary cells 
protoscoleces isolation and cultivation 
J31  Java monkey as intermediate host, 
secondary infection of M. unguiculatus 
protoscoleces isolation and cultivation 
4.11.2. In vivo cultivation of metacestode larvae and isolation from Mongolian jirds 
Maintenance of E. multilocularis metacestodes strictly requires constant passages in Mongolian jirds 
(Meriones unguiculatus). For that, the animals were infected with homogenized larval material by 
means of intraperitoneal injection. The jirds developed a secondary alveolar echinococcosis within 2–
3 months and were then sacrificed with CO2. The larval material was isolated under sterile conditions 
and the sterile instruments were repeatedly substituted while also avoiding injuring the digestive 
tract of the animals or touching the animals’ fur hair. Subsequently the parasite material was cut into 
small tissue blocks and subjected onto a metallic tea strainer for sieving. The ground material was 
washed at least three times with 1xPBS in order to get rid of host cells. Next, the material was 
subjected to different actions depending on the needs for the following experiment. For the isolation 
of protoscoleces (see section 4.11.3). For other purposes, the suspension was incubated overnight at 
4 °C in the presence of Tavanic (1 mg/ml). After washing out the antibiotic with 1xPBS, the 
suspension was used for injection of a new laboratory animals (0.3 – 0.9 µl inoculums) or the 
material was taken to start a new in vitro culture of metacestode larvae [49,50,54]. 
4.11.3. Isolation and activation of protoscoleces 
Protoscoleces were isolated from in vivo cultivated parasite material according to a previously 
established protocol [44]. For that, one volume of freshly isolated and ground parasite material (see 
section 4.11.2) was diluted with three volumes of 1xPBS. Then the suspension was vigorously shaken 
for approximately 10 min in order to release the protoscoleces from the metacestode larvae 
material. Subsequently the suspension was sieved through polyester gauze (150 µm pore size) and 
the flow-thru was taken to be sieved through a second polyester gauze (30 µm pore size). The 
protoscoleces do not pass the 30 µm gauze and thus were collected from the gauze by resuspension 
with 1xPBS. The material was transferred to a petridish (diameter: 10 cm). By horizontal rotation of 
the petridish, the protoscoleces concentrate in the middle and were transferred with a 1000 µl 
pipette into a fresh reaction tube for further applications. 
The freshly isolated protoscoleces were activated by pepsin/low pH treatment as described by [52]. 
In detail, 0.5 -1 ml protoscoleces were transferred to 25 ml 0.05 % pepsin in DMEM without FBS at 
pH 2 to mimick the gastrointestinal passage. After 30 min at 37 °C under constant shaking (125 rpm) 
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the material was allowed to precipitate by gravity. After three washing steps with 1xPBS, the 
protoscoleces were resuspended in 0.2 % sodium taurocholate (solved in DMEM without FBS, pH 7.4) 
and an incubation period of 3 h at 37 °C and 125 rpm followed. Finally, after three washing steps, the 
protoscoleces were either subjected to RNA isolation (see section 4.4.1) or in vitro cultivation with 
and without treatment (see section 4.11.5). 
4.11.4. In vitro cultivation of metacestode larvae 
Metacestode larvae were cultured in vitro in the absence or presence of host cell as described 
[48,148]. For that, the homogenized material which was freshly isolated form animals (see section 
4.11.2) was used. 
In the co-cultivation system 1 ml of ground parasite material was incubated in 50 ml standard culture 
medium (see table below) in a 75 cm2 flask together with 1x107 trypsinized RH- feeder cells. The 
suspension was cultivated at 37 °C and 5 % CO2 for approximately ten days. Then the parasite 
material was poured into 50 ml tubes and was allowed to precipitate by gravity. The supernatant was 
decanted and replaced by fresh standard medium. Over the next weeks of incubation (up to three 
months) the medium was replaced weekly by precipitation. Each time the medium was changed, 
fresh feeder cells were supplemented while using the same flask several fold. Once the metacestode 
vesicles reached a diameter of 3–5 mm, the vesicles were taken for experiments. 
Axenic cultivation: Metacestode vesicles (3–4 mm in diameter) from co-culture were transferred to 
A4 or B2 medium supplemented with reducing agents for axenic cultivation [48]. To eliminate 
transferred host cells, the vesicles were washed three times with 1xPBS. The medium was renewed 
every 48 h to 72 h and the vesicles were incubated at 37 °C under nitrogen atmosphere. During the 
first week of axenic culture the vesicles were washed once in 1xPBS. For the following passages only 
the medium was renewed. After two or three weeks, the vesicles were subjected to experiments. 
Media Medium / FBS content antibiotics 
normal culture medium DMEM, 10 % FBS  1 % P/S 
starvation medium DMEM, 0.2 % FBS or 0 % FBS  1 % P/S 
pre-conditioned 
medium (cDMEM-1 = 
A4) 
filter sterilized supernatant of RH- culture (1x106 RH- in 
50 ml DMEM, 10 % FBS; for seven days in a 75 cm2 flask) 
1 % P/S 
pre-conditioned 
medium (cDMEM-2 = 
B2) 
filter sterilized supernatant of RH- culture (2x107 RH- in 
50 ml DMEM, 10 % FBS, for three days in a 75 cm2 flask) 
1 % P/S 
axenic culture medium 
(nitrogen atmosphere) 
A4 or B2, 1 μl/ml β-mercaptoethanol, 1 μl/ml batho-
cuproine disulfonic acid (BAT), 1 μl/ml L-cysteine (L-Cys) 
1 % P/S 
PanserinTM401 (Pan) 0 % FBS 1 % P/S 
Conditioned 
PanserinTM401 (cPan) 
filter sterilized supernatant of PanserinTM401 RH- culture 
(1x106 RH-/50 ml Panserin, for seven days in a 75 cm2 flask) 
1 % P/S 
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4.11.5. In vitro cultivation and treatement of activated protoscoleses 
Activated protoscoleces (20 µl) were transferred to A4 or DMEM (10 % FBS, 1% P/S) medium 
supplemented with reducing agents for axenic cultivation. The medium (1 ml) in the 24-well plate 
was renewed every 48 h to 72 h. The protoscoleces were incubated at 37 °C under nitrogen 
atmosphere with the substances in different concentrations or in the presence of the respective 
solvent (DMSO or water) at identical concentration. In all experiments the viability of the 
protoscoleces which is indicated by active movement was repeatedly analyzed by means of light 
microscopy. The experiments were conducted in duplicates and repeated three times. 
4.11.6. Treatment of the metacestode vesicles 
In order to analyze the effect of drugs or growth factors axenic metacestode (3–4 mm in diameter) 
were manually picked and washed one time in 1xPBS. In all experiments the viability of the cysts 
which is indicated by an intact cyst wall was repeatedly analyzed by means of light microscopy. 
 
Assessment of multiple metacestode vesicles in 12-well culture plates 
Vesicles were cultured in groups of five to eight per well in a final volume of 2 ml. As medium either 
DMEM (10 % FBS, 1% P/S) or A4 supplemented with reducing agents and the respective drugs was 
chosen. In order to examine the effect of growth factors, metacestode vesicle were incubated under 
starving condition (DMEM 0.2 % FBS 1 % P/S) for 4 days prior to the stimulation. The vesicles were 
incubated at 37 °C under nitrogen atmosphere with the substances in various concentrations or as a 
control in the presence of the respective concentration of the solvent (DMSO, ethanol, methanol, 
chloroform, HCl or water). The experiments were conducted in duplicates repeated three times. 
 
Assessment of single metacestode vesicles in 15 ml centrifugation tubes: 
The metacestode vesicles were singled out in 15 ml tubes and either DMEM (10 % FBS, 1% P/S), B2, 
A4, PanserinTM401, or conditioned PanserinTM401 supplemented with reducing agents and the 
respective drugs were used. As a control the metacestode vesicles were cultured either in untreated 
medium or medium supplemented with the respective solvent: water, ethanol, methanol and 
chloroform. Medium was replaced every 48 h to 72 h and the tubes were incubated at 37 °C under 
nitrogen atmosphere. For each group 5 to 10 replicates were prepared. 
4.11.7. Isolation and cultivation of E. multilocularis primary cells 
E. multilocularis primary cells were isolated from axenic two to three months cultivated metacestode 
vesicles according to a previously published protocol [49] with slight alterations. Metacestode 
vesicles (30 ml volume) were washed three times with 1x PBS before being disrupted by sucking 
them into a 10 ml pipette and carefully resuspending. Then the vesicles were pelleted for 5 min at 
800 g, the supernatant was discarded, and still intact vesicles were disrupted using a 1 ml tip. 
Subsequent to a washing step with 1x PBS, the cells were subjected to centrifugation for 3 min at 
600 g. Then the pellet was resuspended in 8 volumes of pre-warmed trypsin/EDTA solution an 
incubated for 15 min at 37 °C. Every 2 minutes the solution was thoroughly mixed until it became 
turbid. The cells from the germinal layer were obtained and separated from debris by shaking 
intensively for two min before placing the solution on top of a 150 µm gaze. The flowthrough was run 
over a 30 µm gaze. Subsequently the second flow through was centrifuged for 1 min at 80 g in order 
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to pellet the calcium bodies leaving the isolated germinal cells in the supernatant. Consequently the 
supernatant was poured into a new tube and was now centrifuged for 10 min at 400 g and 5 min at 
600 g. The resulting cell suspension was taken up in 1x PBS to a total volume of 0.75 ml. Cells were 
seeded on 12-well plates at a concentration of 60 μl suspension in 2 ml culture medium per well. A4, 
B2 or conditioned PanserinTM401 supplemented with reducing agents served as medium. The plates 
were incubated at 37 °C under a nitrogen atmosphere for three weeks with medium change every 
48 h to 72 h. For the cells were allowed to settle for about 10 min before carefully sucking up half the 
medium and replacing it with 1 ml fresh medium supplemented with reducing agents calculated to 
the total volume of 2 ml. 
4.11.8. Treatment of E. multilocularis primary cells 
For the drug treatment experiments, the primary cells were seeded as into A4 or conditioned 
PanserinTM401. Also, for the stimulation with growth factors, the primary cells were incubated in A4 
or conditioned PanserinTM401. The respective drug or growth factor was added for short periods of 
time (seconds up to 24 h) before subjecting the samples to SDS-PAGE and Western Blot. Long-term 
observation studies took place for three weeks with replacing the medium and supplementing with 
the substance of interest as described for metacestode vesicles or protoscoleces. Control samples 
with the respective concentration of solvent were also analyzed. The experiments were conducted in 
duplicates and repeated three times. 
4.11.9. Verification of purity of Echinococcus material 
In order to exclude, that DNA/cDNA had been isolated from feeder cells, the synthesized 
echinococcal cDNA was analyzed in a PCR using oligonucleotides specific for host tubulin cDNA: 
Tub12up (5' CCC CAA GTG TAT GAT ACT GG-3') and Tub12ST (5' CTG GGC AGT GCG GCA ACC A-3'). 
4.11.10. BrdU-Proliferation Assay 
Proliferation of E. multilocularis metacestode vesicles and primary cells was assessed in a 
bromodesoxyuridine (BrdU)-based method. For that, axenic metacestode vesicles (2-4 mm in 
diameter) were manually picked and starved for 2 days in 12-well plates with 8 vesicles per well 
(Greiner BioOne, Kremsmünster, Germany) in 2 ml DMEM (Invitrogen; Karlsruhe, Germany) under 
5 % CO2 atmosphere. Freshly isolated primary cells from metacestode vesicles were plated on 12-
well plates and grown for 2 days under axenic conditions in 2 ml Ax-cDMEM-A [49]. Then in both 
cases the medium was changed by removing 1 ml volume and replacing it with 1 ml DMEM or 1 ml 
Ax-cDMEM-A for vesicles and primary cells, respectively. BrdU (SigmaAldrich, Taufkirchen, Germany), 
recombinant human aFGF and bFGF (Immunotools, Friesoythe, Germany) were supplemented at 
1 mM, 100 nM and 100 nM final concentrations, respectively. The cultures were incubated for 
48 hours at 37 °C under 5 % CO2 for metacestode vesicles or under nitrogen atmosphere in the case 
of primary cell culture. Samples were prepared in duplicates in three independent experiments. As 
control, the metacestodes and primary cells were incubated in either DMEM or Ax-cDMEM-A with 
1 mM BrdU, without the addition of FGFs. 
Then cells were harvested for the isolation of genomic DNA. In detail, the metacestode vesicles and 
primary cells were washed with 1x PBS. The vesicles were disrupted by pipetting and both vesicles 
and primary cells were subsequently pelleted and transferred to lysis buffer (100 mM NaCl, 10 mM 
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Tris-HCl, pH 8.0, 50 mM EDTA, pH 8.0, 0.5 % SDS) supplemented with 20 μg/ml RNase A and 
0.1 mg/ml Proteinase K. For total digestion of Echinococcus cells, the samples were incubated for 4 h 
at 50 °C under constant shaking. The DNA was extracted by two rounds of phenol chloroform 
extraction (1 volume of phenol-chloroform-isoamyl-alcohol 25:24:1). Subsequently, the DNA was 
precipitated with 2 volumes of 96 % ethanol and 0.1 volumes 5 M LiCl pH 4.5 over night at -20 °C. The 
following day, the DNA was completely precipitated at 20,000 rcf for 30 min at 4 °C. After washing 
with 1 volume 70 % ethanol, the pellet was air-dried for 15 min and was resuspended in 1x TE buffer 
(10 mM Tris, 1 mM EDTA pH 8.0)  
Then the DNA was prepared for coating onto a 96-well plate (96 Well Optical Bottom Plates, Nunc, 
Langenselbold, Germany). For that, 1 volume of DNA (at 1-5 µg) were combined with 1 volume of 
Reacti-Bind DNA Coating solution (Pierce Biotechnology, Rockford, IL, USA) and mixed for 10 min. 
The DNA mixture was added to the microplate in duplicates and incubated overnight at room 
temperature with gentle agitation. The TE/Reacti-Bind DNA Coating Solution mix served as negative 
control. Unbound DNA was removed by washing three times with 1xPBS. After blocking with 5 % 
nonfat dry milk in 1xPBS for 1 h at room temperature and an extensive washing step with 1xPBS, 100 
μl of anti-BrdU-POD (Cell Proliferation ELISA, BrdU; Roche Applied Science, Mannheim, Germany) 
was added and incubated for 90 min at room temperature. After the incubation period, microplates 
were washed three times with 1xPBS buffer and 100 μl substrate solution (Cell Proliferation ELISA, 
BrdU; Roche Applied Science, Mannheim, Germany) was added and incubated for 30-60 min. Stop 
solution was added (25 μl of 1 M H2SO4) and absorbance of the samples was measured using ELISA 
reader at 450 nm. 
4.11.11. siRNA knock-down of EmFR 
Preliminary siRNA knock-down experiments were performed as described [147] with some 
alterations. 30 ml of axenic metacestode vesicles were washed one time with 200 ml 1x PBS. Then 
vesicles were disrupted by slowly passaging them once through a 10 ml plastic pipette. Subsequently, 
the broken vesicles were transferred into a 50 ml tube and centrifuged for 5 min at 400xg. After 
decanting the supernatant and the residual, still intact vesicles the broken vesicles were washed one 
time by filling the tube with 1x PBS, loosening the pellet by gentle agitation, incubating for 5 min at 
room temperature and centrifugating 5 min at 400xg brfore decanting the supernatant. Then eight 
volumes of pre-warmed 0.05 % Trypsin-EDTA were added and a careful agitation followed to loosen 
the vesicle pellet. After incubation at 37 °C for 20 min and careful agitation every 3 min the primary 
cells were detached from the laminated layer. Carful shaking was performed until the liquid became 
turbid. Subsequently, the cells were filtered through a 30 µm gaze sieve using a self-made sieving 
device (30 µm polyester filters, A. Hartenstein, Germany, PES5). The calcium bodies were removed by 
centrifugation for 1 min at 100 g. The supernatant which contained the primary cells was centrifuged 
at 300xg for 15 min. Then the still turbid supernatant was discarded by decanting and resuspending 
the cells very carefully in the residual fluid using a 1 ml tip. Now, the cells were seeded drop-wise 
into 3 wells of a 6-well plate (1 well per 10 ml starting material) each containing 4 ml cDMEM-1 
supplemented with BAT only. Then the cells were resuspended by slowly pipetting up and down. 
After waiting 3 min the clumpy cell aggregates were removed. Then the cells were incubated over 
night at 37 °C, 5 % CO2. After checking microscopically for mini-aggregate formation these mini-
aggregates were carefully collected with a pipette, transferred into a 15 ml tube and filled up to 14 
ml with DMEM / 10 % FBS. Under constant shaking (100 rpm) the cells were allowed to settle for 
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20 min at room temperature. After decanting the supernatant the step was repeated. The still turbid 
supernatant was entirely removed by pipetting and the pellet was carefully resuspended in 
electroporation buffer (siPortTM siRNA electroporation buffer, Ambion) by pipetting very slowly up 
and down. 50 µl electroporation buffer for 1 ml vesicle starting material was used. Then 50 µl of 
mini-aggregate/ electroporation buffer suspension was added to 50 µl of electroporation buffer 
containing 3 µg of double stranded 23 bp siRNA (for either EmFR, EmElp, control RNA: QIAgen 
1022564 or no siRNA). Subsequently, the mixture was filled into a 1 mm gap electroporation cuvette 
and electroporated at 200 V, 25 µF, 13 Ohm using a saw-wave electroporator. Then the 
electroporated cells were incubated for 10 min at 37°C, 5% CO2 and transferred to 1 ml of 
DMEM/10 % FBS with BAT with 1x 104 freshly trypsinized RH- feeder cells. 50% of the medium was 
changes every 3-4 days and monitored light-microscopically. 
4.12. Computer analyses and statistics 
For amino acid sequence comparisons the basic local alignment search tool (BLAST) [157,158] on the 
nr-aa database collection (http://blast.genome.jp) was used. CLUSTAL W alignments were generated 
with the help of the BioEdit Sequence Alignment Editor (version 7.0.0) applying the BLOSUM62 
matrix. MUSCLE alignments were generated using the following platform: 
http://www.ebi.ac.uk/Tools/msa/muscle/. Domain predictions were implemented by using the 
simple modular architecture research tool (SMART) [96,159] available under 
http://smart.emblheidelberg.de. Predictions for protein localization in cells were done with PSORT II 
(http://psort.hgc.jp/form2.html). For the analyses of genomic and gene loci as well as BLAST searches 
against the latest assembly version of the E. multilocularis whole genome the respective resources of 
the Sanger Institute (Hinxton, UK) available under http://www.sanger.ac.uk/cgi-
bin/blast/submitblast/Echinococcus were used. From this resource also transcriptome data has been 
made public and was taken for gene loci analyses, screening for transcription units. 
Two-tailed, unpaired student’s T-tests were performed for statistical analyses (GraphPad Prism, 
version 4). Error bars represent standard error of the mean. Differences were considered significant 
for p-values below 0.05 (indicated by *) 
4.12.1. Iterative BLAST for the identification of putative E. multilocularis NHRs 
The identification of putative E. multilocularis NHRs was carried out as described [145]. Briefly, an 
iterative tBLASTN was performed against the E. multilocularis genome assembly using the deduced 
amino acid sequence of EmNHR1 DBD [145] applying the WinBlast software, version 0.2.0. With this 
procedure a certain set of putative DBD sequences was retrieved. To ensure a comprehensive 
identification of E. multilocularis NHRs also S. mansoni NHRs [105] along with the identified set of 
NHRs from the iterative tBLASTN were taken for further BLAST searches. Subsequently, the zinc-
finger structures of the identified DBDs were evaluated and a BLASTX analysis using boundaries of 
2 kb downstream and 5 kb upstream of the respective sequences was run for all identified genes 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
For phylogenitic tree reconstruction, respective sequences that were previously aligned with the help 
of CLUSTAL W, were allocated to MEGA 4.0. The Neighbour-Joining complete deletion method with a 
bootsrap value of 1000 was used. 
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4.13. Ethics Statement 
All experiments were carried out in accordance with the European and German regulations on the 
protection of animals (Tierschutzgesetz, Section 6). Ethical approval of the study was obtained by the 
local ethics committee of the government of Lower Franconia (621-2531.01-2/05). 
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5. Results 
5.1. FGFR signaling - EmFR 
In this work the role and function of EmFR, originally described by Schäfer [94], was analyzed in 
detail. Thus far, EmFR (562 amino acids, 63 kDa) was described as a single FGFR in the parasitic 
helminth E. multilocularis. EmFR harbors the typical structure common for FGFRs: a characteristical 
tyrosinekinase domain (sequence alignment; see 3.3.2), a transmembrane domain, an extracellular 
LBD and a signal peptide (for domain structure, see 3.3.2). Interestingly and conversely to all other 
known FGFRs, the LBD of E. multilocularis is composed of one single IG-domain instead of normally 
two or three IG-domains. This characteristic was meanwhile confirmed by the available genome data. 
Furthermore, it was found that after exogenous addition of either aFGF or bFGF to in vitro cultivated 
metacestode vesicles, a specific phosphorylation of the Erk-like MAP-kinase EmMPK1 occured [94]. 
Here, the expression pattern of EmFR was analyzed in different larval stages of E. multilocularis. The 
effect of host FGFs, heparin and specific FGFR inhibitors was analyzed in vitro (including metacestode 
vesicles, primary cells, dormant, and activated protoscoleces) in more detail and also on molecular 
level (proliferation studies, and signaling analysis). 
5.1.1. EmFR expression analysis in Echinococcus larval stages 
FGFRs are highly conserved throughout metazoan evolution [64]. They form a complex family of 
signaling molecules which are widely expressed in embryonic and adult tissue. Moreover, FGFRs play 
an important role in cellular differentiation and tissue-injury. First the expression of Emfr in 
Echinococcus larval stages was investigated by semi-quantitative RT-PCR. 
 
 
 
Fig. 8: Expression profile of Emfr in E multilocularis larval stages. Total RNA was isolated from in vitro 
cultivated metacestode vesicles (Mc), dormant (Pd), low-pH/pepsin activated protoscoleces (Pa), and in vitro 
cultivated primary cells (Pc). Total RNA was reverse transcribed and the resulting cDNA was then used as a 
template for semi-quantitative PCR using primers specific for Emfr and the constitutively expressed control 
gene Emact [160]. PCR products were run on a 2 % agarose gel and stained with ethidium bromide. The sizes of 
the marker bands (middle lane) are indicated left. 
 
Emfr transcripts were clearly detected in regenerating primary cells, in metacestode vesicles and in 
protoscoleces prior to (dormant) and after (activated) treatment with pepsin/low pH, although 
higher expression was observed in the metacestode and the activated protoscolex (Fig. 8). In parallel 
to genome sequencing, next generation transcriptome profiling is currently carried out at the Sanger 
Institute on all the larval stages mentioned above. Analyses of the respective dataset show 
expression of Emfr in all larval stages with about two to three times higher expression in 
metacestode vesicles and activated protoscoleces (data not shown). Thus the results obtained by 
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semi-quantitative RT-PCR were confirmed. Hence, Emfr is expressed in all larval stages that are 
involved in the infection of the intermediate host. 
5.1.2. Protein-protein-interactions studies of the intracellular domain of EmFR 
FGFs bind to FGFRs and induce their dimerization and the phosphorylation of specific cytoplasmic 
tyrosine residues. FRS2 is associated with the receptor and the phosphorylation of FGFRs and FRS2 
triggers the activation of cytoplasmic signal transduction pathways such as the Ras-MAP kinase 
pathway [69]. Therefore I tested whether the intracellular domain of EmFR (EmFRin) possibly 
interacts with the already described components of the E. multilocularis MAPK cascade. 
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Fig. 9.: Protein-protein-interaction of EmFRin. Translation fusions were generated for the Gal4-DNA binding 
domain (BD; vector pGBKT7) and the Gal4-activation domain (AD; vector pGADT7) with the intracellular domain 
of EmFR (EmFRin). These were transformed into yeast strain AH109 together with empty vectors (pGADT7, 
pGBKT7) or with different fusions for EmRas, EmRal, EmRap1, EmRap2, Em14-3-3, EmMKK1, EmMKK1, 
EmRaf [52,54,55,57,161] and EmElpN, EmElpC, EmPDZ [37,153]. Positive control (pGADT7-T x pGBK-53) and 
negative control (pGADT7-T x pGBK-Lam) were performed as described in the MATCHMAKER-manual 
(Clontech). Growth of colonies was assessed according to the MATCHMAKER-manual (Clontech). No growth 
could be detected (indicated by “-“) All experiments were repeated three to five times independently. 
 
First a translational fusion of EmFRin in pGADT7 and pGBKT7 was constructed. Then in a yeast-two 
hybrid approach these constructs were tested for interaction with EmRas, EmRal, EmRap1, EmRap2, 
Em14-3-3, EmMKKA, EmMKKB, and EmRaf [52,54,55,57,161]. Moreover, the interaction of EmElpN, 
EmElpC, and EmPDZ [37,153] with EmFRin was assessed (Fig. 9). EmElp, is an Ezrin-Radixin-Moesin-
like protein and most likely involved in cell-cell adhesion which is described for its mammalian 
counterparts [162,163]. EmPDZ interacts with EmElp and might represent an orthologue of 
mammalian ERM interaction partner EBP50 [37]. It is also known that bFGF signaling depends on 
heparan sulfate syndecan-4 to transduce an intracellular signal through its receptors (FGFRs). 
Interestingly the PDZ domain containing protein syntenin binds the C2 domain of the syndecans 
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[164,165]. Syntenin functions as a rate limiting factor for syndecan plasma membrane recycling and 
most likely for the recycling of heparin sulfate associated cargo like FGF/FGFR [166]. In the 
experiment, no interaction between EmFRin and any of the tested proteins (Fig. 9) was observed. 
Thus, neither components of the E. multilocularis MAPK cascade nor proteins related to FGF-FGFR-
recycling did interact with EmFRin. 
5.1.3. Host derived FGFs stimulate de novo DNA Synthesis in Echinococcus larvae 
in vitro 
Incorporation of bromodeoxyuridine (BrdU) into DNA as a measurement of cell proliferation has 
previously been used to demonstrate that FGFs stimulate the proliferation of various cell types, for 
example bone marrow derived stem cells [167]. In this experiment, metacestode vesicles and 
primary cells from the E. multilocularis isolate H95 were treated with either 10 nM and 100 nM aFGF 
or 10 nM and 100 nM bFGF in the presence of 1 mM BrdU for 48 h. De novo DNA synthesis as 
detectable by BrdU-incorporation was analysed in an ELISA using equal amounts of isolated 
chromosomal DNA. For detection of incorporated BrdU an anti-BrDU peroxidase-coupled antibody 
was used. 
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Fig. 10: Effect of FGFs on the proliferation of metacestode vesicles and primary cells of E. multilocularis. (A) 
Axenic metacestode vesicles (eight per well; H95) were starved for 48 h in 2 ml DMEM and (B) freshly isolated 
primary cells (H95) were grown for 48 h in 2 ml cDMEM-1. Then BrdU (1 mM) and FGFs (aFGF and bFGF: 10 or 
100 nM) were supplemented and cells were incubated for another 48 h. Cells were harvested, washed with PBS 
before lysis and DNA isolation. De novo DNA synthesis as detectable by BrdU-incorporation was analysed in an 
ELISA. For that, equal amounts of DNA (1 - 5 µg) were coated over night on a 96-well plate. Detection of 
incorporated BrdU was performed with an anti-BrDU peroxidase-coupled antibody using the substrate TMB. 
Colorimetric analysis was performed after 30 – 60 min with a spectrometer at 450 nm after stopping the 
reaction with 200 mM sulfuric acid. The bars represent the percentage of BrdU incorporation with the cDMEM-
1 control set to 100 %. The statistical evaluation of four independent experiments (n=4) which were conducted 
in duplicates is shown (error bars are indicated). Student’s t-test (two-tailed): *p < 0.05. 
 
Both, aFGF (at 10 nM: 122.2 % and at 100 nM: 137.3 %) and 100 nM bFGF (154 %) significantly 
stimulated the proliferation of metacestode vesicles when compared to the untreated control which 
was set to 100 % (Fig. 10 A). The same significant effect was detectable for primary cells of 
E. multilocularis: 100 nM aFGF (115 %) and 100nM bFGF (122.1) significantly stimulated the 
control aFGF 100 nM bFGF 100 nMl
0
50
100
150
200
*
*
115.2
122.1
100.0
P
ro
li
fe
ra
ti
o
n
 o
f
p
ri
m
a
ry
c
e
ll
s
(%
)
  Results 
 
51 
 
proliferation compared to the control sample (100 %) (Fig. 10 B). Thus, it is evident that both, aFGF 
and bFGF stimulated the proliferation of metacestode vesicles and primary cells of E. multilocularis. 
5.1.4. Growth and development of E. multilocularis is stimulated by host FGFs in 
vitro – primary cells 
FGFs have diverse biological activities including roles in mitogenesis and cellular differentiation [64]. 
In the above mentioned study by Schäfer [94] it was demonstrated that axenic metacestode vesicles 
cultured in cDMEM-1 in the presence of 100 nM aFGF or 10 nM bFGF grew twice the volume 
(0.28 ml) compared to the untreated control (0.14 ml) (Fig. 11 A). Also, after 4 weeks of incubation 
the effect was clearly visible. The FGF stimulated vesicles had approximately a 2.2 times larger 
volume (aFGF treated vesicles: 4.1 ml and bFGF treated vesicles: 4.3 ml) than the unstimulated 
control vesicles (1.9 ml) (Fig. 11 A; adapted from [94]). 
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Fig. 11: Effect of FGFs on E. multilocularis metacestode vesicles and primary cells. (A) Single axenic 
metacestode vesicles of the isolate H95 were in vitro cultivated in cDMEM-1 for four weeks in the presence of 
10 nM acidic and 5 nM basic FGF. The complete medium (1 ml) was changed every other day as well as the 
growth factors were supplemented. Control vesicles were kept in cDMEM-1. Growth (in ml) of vesicles was 
monitored. In each of the three independent experiments (n=3) four vesicles were examined for every single 
condition. The mean was calculated and the standard error of the mean (SEM) is indicated. (B-D) The 
regeneration process of axenically cultivated H95 primary cells was monitored for 21 days. Cells were cultured 
in cDMEM-1 (control), with the addition of 100 nM aFGF or 100 nM bFGF in either the presence or absence of 
10 µg/ml heparin. Half of the medium volume was renewed every other day and growth factors were 
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supplemented at concentrations calculated to the entire cultured volume. The number of newly formed 
metacestode vesicles at day 21 was analyzed. The bars represent the percentage of formed vesicles compared 
to the cDMEM-1 control without heparin (B) and (D) or with heparin (C). The statistical evaluation of three 
independent experiments (n=3) which were conducted in duplicates is shown (error bars are indicated). 
Student’s t-test (two-tailed): *p < 0.05. 
 
Since FGFs are key players in differentiation processes, the regeneration of axenically cultivated H95 
primary cells was also monitored for 21 days. Cells were cultured in cDMEM-1, with the addition of 
100 nM aFGF or 100 nM bFGF in either the presence or absence of 10 µg/ml heparin. After 21 days 
the formation of newly built metacestode vesicles was assessed as a measure of parasite 
development. When primary cells were stimulated with either aFGF or bFGF (Fig. 11 B) clearly more 
vesicles formed after 21 days compared to the untreated control. In the presence of aFGF and bFGF 
about 167 % and 153% more vesicles were formed, respectively. Interestingly, when heparin was 
introduced to the system, generally more vesicles appeared after 21 days, also in the non-FGF 
treated samples (Fig. 11 C). When taking the heparin stimulated cells as control, compared with the 
simultaneously treated aFGF/heparin or bFGF/heparin cells, the FGF effect is still clearly detectable 
and significant. Whereas the vesicles regenerating from heparin treated primary cells were set to 
100%, 155% and 138% vesicles were counted in the aFGF and bFGF treated samples, respectively. 
Moreover, the effect of heparin on the system of regeneration metacestode vesicles from primary 
cells was also examined (Fig. 11 D). The normal untreated control was set to 100 %. It is obvious, that 
in the presence of heparin approximately five times the amount of vesicles was formed after 21 days 
(470 %; Fig. 11D). If FGFs were added to the system even more vesicles were countable after the 
incubation period; 862 % for aFGF and 663 % for bFGF (Fig. 11D). Taken together, it becomes clear, 
that not only aFGF and bFGF stimulate the regeneration process of developing primary cells, but also 
heparin positively influences the process while still the FGFs can elicit their potential. 
5.1.5. Targeting the FGF signaling pathway of E. multilocularis: BIBF1120– effects 
on metacestode vesicles and primary cells 
BIBF1120 [Vargatef; (Z)-methyl3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl) amino) 
(phenyl)methylene)-2-oxoindoline-6-carboxylate]is triple-tyrosine kinase inhibitor. It inhibits human 
VEGFR-1, -2, and -3, FGFR-1, -2, and -3, and PDGFR α and β by binding to the ATP-binding site in the 
cleft of the kinase hinge region. It shows also activity against members of the Src family of kinases 
but displays a lower efficiency with a two- to three-fold higher IC50 compared to the above 
mentioned targets [21]. Since E. multilocularis only harbors one FGFR homologue but none for PDGF 
or VEGF the inhibitor might mainly block FGF-EmFR signaling. Therefore, BIBF1120 was chosen in this 
study. 
To test the effect of the FGFR inhibitor BIBF1120 on the viability and differentiation process in 
E. multilocularis in vitro, axenically cultivated metacestode vesicles and freshly isolated primary cells 
were incubated with DMSO (0.1%) or BIBF1120 at different concentrations (1 µM, 5 µM and 10µM) 
for several weeks (Fig. 12A). A dose-dependent effect was observed in both E. multilocularis cultures. 
Metacestode vesicles lost integrity over time (Fig. 12A-C). Whereas more than 90 % of the vesicles 
which were treated with DMSO survived after 18 days, only 8.75 % of the 1 µM, 2.5 % of the 5 µM 
and none of the 10 µM BIBF1120 treated vesicles survived. The first effect of the inhibitor was 
detectable after three days of incubation with 5 µM and 10 µM BIBF1120 causing about 7.5 % and 
19.6 % vesicle destruction, respectively. Statistically, 50 % of the vesicles were dead after 8, 10 and 
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13 days when treated with 1 µM, 5 µM or 10 µM of BIBF1120, respectively. As expected, the inhibitor 
also caused changes in the regeneration process of primary cells (Fig. 12D). After one day the 
samples did not show any differences, the primary cells started to form small aggregates. However, 
in the presence of 5 µM and 10 µM the primary cells failed to develop further; After 21 days, only 
1.8 % and 0 % newly formed vesicles were detected, respectively. Despite the tremendous effect of 
5 µM and 10 µM, the treatment with 1 µM BIBF1120 did not cause any morphological changes (Fig. 
12D-F) or alterations in regeneration. After 21 days control cultures and 1 µM BIBF1120 treated cells, 
reached the same numbers of newly formed vesicles. 
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Fig. 12: Treatment of E. multilocularis metacestode vesicles and primary cells with BIBF1120. (A) Axenically 
cultivated metacestode vesicles and freshly isolated primary cells of the isolate H95 were incubated with DMSO 
(0.1 %) and BIBF1120 at different concentrations (1 µM, 5 µM and 10µM) for several weeks. Metacestode 
vesicles were cultured in cDMEM-1 on a 12-well plate in 2 ml volume with 6- 8 vesicles per well. The survival of 
vesicles is depicted in percentages as the mean value and error bars indicate the SEM. The experiment was 
repeated three times in duplicates. (B) Intact, viable metacestode vesicle from in vitro culture treated with 
DMSO (0.1 %). (C) Metacestode vesicle after treatment with BIBF1120 for seven days. (D) Primary cells were 
cultured in cDMEM-1 on a 12-well plate in 2 ml volume supplemented with (E) DMSO control (0.1 %) and 
BIBF1120 at different concentrations 1 µM, 5 µM and (F) 10 µM. Magnification 25x. After 21 days the numbers 
of newly formed metacestode vesicles were counted. The DMSO control for each of the three experiments was 
set to 100 %. The horizontal line marks the mean value of all experiments. 
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In another experiment metacestode vesicles were either treated with DMSO or 5 µM BIBF1120 for 
five days. In both conditions, more than 90 % of all metacestode vesicles survived. Subsequently, 
primary cells were isolated according to the established protocol [49] and seeded on 12-well plates. 
Then, the cells were cultivated in the presence of DMSO (Fig. 13 A) and under various conditions: 
1 µM BIBF1120, 10 µg/ml heparin or a mixture of heparin (10 µg/ml) together with aFGF and bFGF 
(each 100 nM) with DMSO as solvent at 0.1 % (Fig. 13 A-C). 
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Fig. 13: The effect on the regeneration of primary cells isolated from metacestode vesicle pre-treated with 
BIBF1120. (A) Axenically cultivated metacestode vesicles were incubated in the presence of 0.1 % DMSO with 
or without 5 µM BIBF1120 for five days, after which more than 90 % of the vesicles survived in all conditions. 
Subsequent to isolation, primary cells from treated vesicles were seeded in 12-well plates as duplicates and 
were all cultivated in the presence of DMSO (DMSO control, open box) and under various conditions: 1 µM 
BIBF1120 (black box), 10 µg/ml heparin (large pixel box) and heparin (10 µg/ml) together with aFGF and bFGF 
(each 100 nM; small pixel box). The bars represent the calculated percentage of formed metacestode vesicles 
compared to the total number of vesicles in the DMSO control. (B) Microscopic pictures from heparin-treated 
primary cells, isolated from (B) DMSO or (C) 5 µM BIBF1120 pre-treated metacestode vesicles (day 21). 
Magnification 25x. In all cases, the error bars indicate the SEM from the five independent measurements which 
were performed in duplicates. Student’s t-test (two-tailed): *p < 0.05. 
 
Although more than 90 % of the 5 µM BIBF1120 treated vesicles did not show any sign of disintegrity 
after five days, primary cells from these vesicles only marginally regenerated after 21 days (Fig. 13 A); 
7 % (DMSO post-treatment) and 0 % (1 µM BIBF1120 post-treatment). Only when stimuli like heparin 
or heparin with the addition of aFGF and bFGF were supplemented a nominal development of new 
vesicles was detected; 46.5 % and 38.5 % respectively setting the DMSO pre-treated, DMSO post-
treated culture as 100 %. Thus, it can clearly be stated, that although the integrity of metacestode 
vesicles might not be affected, BIBF1120 had a clear effect on the cells within the metacestode 
vesicles, preventing the formation of new vesicles when used for the isolation of primary cells. 
Taken together, the above experiments demonstrated that BIBF1120 effectively inactivated in vitro 
cultivated metacestode vesicles and prevented regeneration of primary cells at 5 µM and 10 µM. 
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5.1.6. The effect of host FGFs and BIBF1120 on in vitro cultivated protoscoleces 
In addition to metacestode vesicles and primary cells of E. multilocularis, also protoscoleces as the 
infective larval stage of the final host were under investigation. Therefore, FGFs were applied to in 
vitro cultivated, activated protoscoleces from the isolate GH09. In detail, the protoscoleces were 
cultivated in cDMEM-1 for 21 days in the presence of either aFGF, bFGF (both 100 nM) or heparin 
(10 µg/ml). The medium was routinely exchanged every second or third day. In parallel the culture 
was monitored by light microscopy. After 21 days the culture was assessed for different phenotypes 
of protoscolex structures (Fig. 14 A and Fig. 15). 
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Fig. 14: Effect of FGFs and BIBF1120 on E. multilocularis in vitro activated protoscoleces. (A) In vitro activated 
protoscoleces of the isolate GH09 were in vitro cultivated in cDMEM-1 for 21 days in the presence of either 
FGFs (aFGF, bFGF: 100 nM), heparin (10 µg/ml) alone or in combination. (B and C) In vitro activated 
protoscoleces of the isolate GH09 were in vitro cultivated in cDMEM-1 for 21 days in the presence of either 
DMSO (0.1 %) or BIBF1120 (1 µM, 5 µM or 10 µM). Half the medium (1 ml) was changed every second or third 
day as well as the supplements calculated to the total volume of 2 ml. Control protoscoleces were kept in 
cDMEM-1. In each of the two independent experiments (n=2) duplicates of approximately 100-200 
protoscoleces were examined. The mean was calculated and the standard error of the mean is indicated. 
Student’s t-test (two-tailed): *p < 0.05. 
 
At the beginning of the experiment, all protoscoleces appeared evaginated and were motile (Fig. 
15A-C). In the course of treatment with host FGFs or heparin, there was no difference in the 
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phenotypic development of the in vitro cultivated and by low-pH pepsin treatment activated 
protoscoleces (Fig. 15 D - I). After three weeks of incubation most of protoscoleces presented the 
strobilar form, but yet changes in morphology occurred: Non-moving, also in shape and structure 
degraded protoscoleces were accounted as “dead”. Also fully globular structures which were floating 
in the media were observed, and were considered as “vesicle like structures”. In contrast, a small 
proportion of the protoscoleces rounded up over time, resulting in vesicle-like structures, but the 
suckers still were clearly detectable. Thus these structures were called “rounded protoscoleces”. 
After 21 days, the number of apparently dead protoscoleces was below 10 % in all cultures. The same 
holds true when analyzing the percentage of globular “rounded” protoscoleces (Fig. 14 A). 
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Fig. 15: Effect of host FGFs on in vitro cultivated, activated protoscoleces. In vitro activated protoscoleces of 
the isolate GH09 were in vitro cultivated in cDMEM-1 for 21 days in the presence of either FGFs (aFGF, bFGF: 
100 nM), heparin (10 µg/ml) alone or in combination. Micrograph of control (A) 25x (B) 50x and (C) 100 x 
magnification on day of isolation and activation by low pH-pepsin treatment. Micrograph of control (D), aFGF 
(E), bFGF (F), heparin (G), aFGF/heparin (H) and bFGF/heparin (I) treated protscoleces on day 14 at 100x 
magnification. Half the medium (1 ml) was changed every second or third day as well as the supplements 
calculated to the total volume of 2 ml. Control vesicles were kept in cDMEM-1. In each of the 2 independent 
experiments (n=2) duplicates of approximately 100 - 200 protoscoleces were examined. 
 
In another experiment the effect of BIBF1120 on in vitro cultivated and by low pH / pepsin treatment 
activated protoscoleces was assessed. For that, in vitro activated protoscoleces of the isolate GH09 
were further in vitro cultivated in cDMEM-1 for 21 days in the presence of either DMSO (0.1 %) or 
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BIBF1120 (1 µM, 5 µM, or 10 µM). Half the medium (1 ml) was changed every second or third day as 
well as the supplements calculated to the total volume of 2 ml. Control protoscoleces were kept in 
cDMEM-1. Again, the culture was analyzed in respect to different phenotypes (Fig. 14 B, C and Fig. 
16). At the beginning of the experiment, all protoscoleces appeared evaginated and were motile (Fig. 
16 A). After three weeks of incubation most of control and DMSO-treated protoscoleces kept the 
strobilar form, were still moving and less than 10 % seemed dead or rounded (Fig. 14 B). Yet, the 
body form with tegument and structures like rostellum and suckers were clearly defined throughout 
incubation. However, when incubated with BIBF1120 in various concentrations, changes in 
morphology and viability occurred (Fig. 14 B, C and Fig. 16). A clear tendency was recognized, that in 
a concentration dependent manner, more protoscoleces appeared dead. In DMSO treated control 
cultures 2.1 % protoscoleces were dead compared to 4 %, 12.4 % and 14.6 % in 1 µM, 5 µM, and 
10 µM BIBF1120 treated samples, respectively. In respect to the normal strobilar morphology, again 
a dose-dependent effect was present. The more inhibitor was present in the system the more 
globular and round the protoscoleces appeared. In DMSO treated control cultures 5.8 % 
protoscoleces were rounded to 13.9 %, 30.2 % and 35.5 % in 1 µM, 5 µM, and 10 µM BIBF1120 
treated samples, respectively (Fig. 14 B). The well-defined structure was lost and the neck was not 
identifiable anymore. Also, the appearance was lighter and less granular than in the DMSO control 
group. With respect to the appearance of vesicle-like structures not harboring any indications of 
structures like suckers it was obvious that the number of these structures decreased with increasing 
concentrations of BIBF1120 (Fig. 14 C). These experiments suggest that in regard to morphology and 
agility host FGFs do not alter the protoscoleces in in vitro culture. However, BIBF1120 seems to affect 
the morphology of in vitro cultivated protoscoleces resulting in globular structures and a higher 
percentage of dead protoscoleces over time. 
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E BIBF1120 5 µM 
 
F BIBF1120 5 µM 
 
G BIBF1120 10 µM 
 
H BIBF1120 10 µM 
 
Fig. 16: Effect of BIBF1120 on in vitro cultivated, activated protoscoleces. In vitro activated protoscoleces of 
the isolate GH09 were in vitro cultivated in cDMEM-1 for 21 days in the presence of either DMSO (0.1 %) or 
BIBF1120 (1 µM, 5 µM, or 10 µM). Half the medium (1 ml) was changed every second or third day as well as 
the supplements calculated to the total volume of 2 ml. In each of the two independent experiments (n=2) 
duplicates of approximately 100-200 protoscoleces were examined. A, B Micrograph of control samples C, D 
Micrograph of 1 µM BIBF1120 E,F Micrograph of 5 µM BIBF1120 and G,H Micrograph of 10 µM BIBF1120 
treated protoscoleces after 21 days of culture. Black arrows indicate defined structures as rostellum and 
suckers. White arrows indicate vesicle-like structures and grey arrows indicate at debris or dead 
protoscoleces. 
5.1.7. Targeting the FGF signaling pathway of E. multilocularis: SU5042– effects on 
metacestode vesicles and primary cells  
A second inhibitor, SU5402 (3-[(3-(2-carboxyethyl)-4-methylpyrrol-2-yl)methylene]-2-indolinone), 
which was described to specifically block FGFR kinase activity and also possibly VEGFR activity, was 
used for in vitro experiments. The inhibitor is like BIBF1120 part of the indolinone family. Its 
inhibitory effect is due to direct interactions of the inhibitor with the catalytic domain of human 
FGFR1. Both inhibitors binds to FGFR1 in the ATP binding cleft [28]. Binding of BIBF1120 to the 
human VEGFR-2 is mediated by binding to Cys919 and Glu917 [21]. However, the interacting residues 
of human FGFR1 with BIBF1120 have not been described so far. For SU5402 it is known that the 
hydrogen bond between the side chain amide of FGFR Asn568 in the hinge region and the 
carboxyethyl group of SU5402 confers to the specificity of the inhibitor. The respective Asn is 
conserved between FGFR1 and EmFR (Asn458). 
To test the effect of the FGFR inhibitor SU5042 on the viability and differentiation process in 
E. multilocularis in vitro, axenically cultivated metacestode vesicles and freshly isolated primary cells 
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were incubated with DMSO (0.1 %) or SU5042 at different concentrations (100 nM, 500 nM, 1 µM, 
5 µM, 10 µM, and 50 µM) (Fig. 17). When metacestode vesicles were treated with the inhibitor no 
change in viability or morphology was observed in comparison to the DMSO control samples. The 
highest concentration tested was 10 µM and did not harm the metacestode vesicles (Fig. 17 C). The 
growth of these differently treated vesicles has not been analysed in this study. Interestingly, when 
SU5042 was applied to regenerating primary cells, a dose-dependent effect was observed. The more 
inhibitor was present, the more vesicles developed after 18 days. In Fig. 17 A – C it becomes clear, 
that in the presence of SU5042 more vesicles regenerated, indicated by the white arrows. However, 
in these two independent experiments the total numbers of newly formed vesicles was not 
determined. 
 
A 25x B 25x C 25x 
   
D 50x E 50x F 50x 
   
Fig. 17: Treatment of E. multilocularis metacestode vesicles and primary cells with SU5042. (A-C) Axenically 
cultivated metacestode vesicles and freshly isolated primary cells of the isolate H95 were incubated with 0.1% 
DMSO (A) and SU5042 at 5 µM (B) and 10 µM (C) for two weeks. Metacestode vesicles were cultured in 
DMEM / 10 % FBS on a 24-well plate in 1 ml volume with 5 vesicles per well. The experiment was conducted in 
duplicates. (D-F) Primary cells were isolated from axenic metacestode vesicles (isolate H95) and cultured in 
cDMEM-1 on a 12-well plate in 2 ml volume supplemented with (D) DMSO control (0,1%) and SU5402 at 
different concentrations (E) 5 µM and (F) 10 µM for three weeks. Light microscopic pictures were taken on day 
18. The experiment was conducted twice in duplicates Magnification as indicated. White arrows indicate 
regenerating vesicle-like structures. 
 
In another experiment metacestode vesicles were either treated with 0.1 % DMSO or 10 µM SU5042 
for five days. Under both conditions, more than 95 % of all metacestode vesicles survived. 
Subsequently, primary cells were isolated according to the established protocol [49] and seeded on 
12-well plates. Then, the cells were cultivated in the presence of 0.1% DMSO (Fig. 18 A, D), 10 µM 
SU5042 (Fig. 18 B, E) or with host aFGF/bFGF (each 100 nM) (Fig. 18 C, F) for two weeks. It seemed 
that the pre-incubation of metacestode vesicles with 10 µM SU5042 might have a positive effect on 
regeneration. When comparing the DMSO control samples of either DMSO pre-treated or 10 µM 
SU5042 pre-treated vesicles, the regenerating vesicles from primary cells seemed more packed. Also, 
it seemed that more vesicles had developed after two weeks (Fig. 18 A, D). 
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Interestingly, SU5402 did not cause the same effect as BIBF1120 on E. multilocularis larval stages. 
There are several reasons to explain the observed effects of SU5402. First, although the respective 
Asn residue is conserved between FGFR1 and EmFR additional residues of the hinge region differ 
between FGFR1 (Tyr-Ala-Ser-Lys-Gly-Asn) and EmFR (Tyr-Arg-Met-Lys-Gly-Asn). This might cause 
conformational differences resulting that SU5402 is not able to bind to the specific site and therefore 
is not able block EmFR signaling. One could address this question with the help of the Xenopus 
oocytes model system. If SU5402 does not block EmFR signaling induced by aFGF or bFGF, GVBD will 
still be observed. Second, due to above speculated conformational differences SU5402 might be able 
to activate EmFR which again could be addressed in GVBD assays. An activation of EmFR could 
explain why metacestode vesicles withstand SU5402 treatment (the influence on growth was not 
assessed in the study) and why primary cells regenerated comparable as if they had been stimulated 
with FGFs. 
 
A B C 
   
D E F 
   
Fig. 18: The effect on the regeneration of primary cells isolated from metacestode vesicle pre-treated with 
SU5042. Axenically cultivated metacestode vesicles were incubated in the presence of 0.1 % DMSO (A–C) or in 
the presence of 10 µM SU5042 (D-F) for 5 days, after which more than 95% of the vesicles survived in all 
conditions. Subsequent to isolation, primary cells from treated vesicles were seeded in 12-well plates as 
duplicates and were all cultivated in the presence of 0.1 % DMSO (A, D), 10 µM SU5042 (B, E), or with host 
aFGF/bFGF (each 100 nM) (C, F). Microscopic pictures were taken after two weeks. Magnification 50 x. The 
experiment was in duplicates. White arrows indicate regenerating vesicle-like structures. 
 
The effect was even more pronounced when primary cells from either DMSO or 10 µM SU5042 pre-
treated vesicles were incubated in the presence of 10 µM SU5042 (Fig. 18 B, E). Compared to the 
respective control, the regenerating primary cells appeared more condensed and seemed to produce 
more vesicle-like structures, as indicated with the white arrows in the micrographs. The addition of 
host FGFs seemed to have a similar effect as the treatment with 10 µM SU5042 (Fig. 18 C, F). 
In summary, SU5042 did not result in morphological changes of metacestode vesicles over a period 
of two weeks, whereas primary cells tended to regenerate better under increasing concentrations of 
the inhibitor. When metacestode vesicles were pre-treated with inhibitor prior to primary cell 
isolation, this seemed also to positively affect the regeneration process. In future experiments, the 
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effect of SU5042 in combination with host FGFs should be analysed to validate the data obtained in 
this study. 
5.1.8. siRNA knock-down of EmFR – preliminary data 
To unravel the function of EmFR in more detail a first experiment was conducted in order to knock-
down EmFR with the use of a siRNA technique. It was published that E. multilocularis primary cells 
have been successfully exploited in siRNA knock-down experiments with promising results in 
achieving a knock-down on mRNA and protein level for EmElp and Em14-3-3 [147]. 
 
Therefore, an experiment according to the published protocol has been performed. Subsequent to 
isolation, primary cells were seeded in a 6-well plate, allowed to form mini-aggregates and were 
afterward subjected to electroporation with electroporation buffer, control siRNA Mm/Hs_MAPK1, 
Emelp siRNA and EmFR siRNA. The cells were seeded in fresh DMEM / 10 % FBS medium 
supplemented with BAT in the presence of RH- feeder cells. Half the medium was changed every 3 -4 
days and development of the cells was analysed light microscopically. The experiment was 
performed in quadruplicates in order to collect RNA and protein samples at two different time 
points. However, RNA and protein isolation failed in this experiment. Thus only light microscopic 
morphological assessment of the experiment could be performed. After six days, in all samples some 
aggregates had developed with an orange inclusion in the middle which is indicated by black arrows 
(Fig. 19). It seemed that in the siRNA-EmFR sample slightly more aggregates had appeared. In a 
second approach the primary cells were cultured in cDMEM-1 after electropoation. Compared to 
control siRNA (GFP siRNA) the primary cells treated with EmFR siRNA appeared not as dense and 
compact. However, both experiments were stopped after two weeks because apparently too much 
material was lost while media was changed. Until now, the effect of siRNA knock-down of EmFR is 
still elusive and further experimentation is needed. 
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Fig. 19: siRNA knock-down of EmFR in Echinococcus primary cells – preliminary data. Subsequent to isolation 
according to [147], primary cells were seeded in a 6-well plate, allowed to form mini-aggregates and were 
subsequently subjected to electroporation with (A) electroporation buffer (B) control Mm/Hs_MAPK1 siRNA (C) 
EmElp siRNA and (D) EmFR siRNA. (E) In a second approach GFP-siRNA was used as control in comparison to (F) 
EmFR siRNA. Half the medium was changed every 3 -4 days. Microscopic pictures were taken after 6 days (A-D) 
and after three days (E, F). Magnification 25 x. Black arrows indicate regenerating aggregate structures  
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5.1.9. EmFR is activated by aFGF and bFGF, leading to MAP-kinase signaling in 
Xenopus laevis oocytes 
In order to analyse the functional activity of EmFR, EmFR and the mutant EmFR TkD- were first 
expressed in HEK293T cells (Fig. 20). FGFRs are activated by FGFs as can be measured by 
phosphorylation which triggers the activation of cytoplasmic signal transduction pathways [64]. 
Interestingly, EmFR was phosphorylated without stimulation through FGF in this system (Fig. 20 A). 
The phosphorylation of EmFR was effectively blocked by calf intestinal phosphatase (CIP) treatment. 
Also, the dead-box kinase EmFR TkD- did not show any phosphorylation activity, neither in the 
absence nor in the presence of FGFs. For detection of transfection efficiency an anti-c-myc antibody 
was used. Phosphorylation was analysed with an anti-phopsho-FGF receptor (Tyr653/654; anti-pp-
tyr) antibody. Nevertheless, the heterologous expression of EmFR in HEK293T cells was not 
appropriate to analyse the effect of FGFs on EmFR because the receptor itself apparently was 
constitutively active in the system, also in the absence of the FGF stimuli. 
 
A 
control CIP - CIP + CIP - CIP +
anti-pp-tyr
anti-c-myc
EmFR TkD-EmFR wt
 
 
B 
EmFR TkD-EmFR wtcontrol
anti-p-tyr
anti-c-myc
 
 
Fig. 20: Western blot analyses of heterologously expressed EmFR and EmFR TkD- in HEK293T cells and 
Xenopus oocytes. Depicted are Western blot experiments of HEK293T cell lysates and Xenopuss oocytes 
expressing EmFR and EmFR TkD- using the anti-c-myc and either the anti-phopsho-FGF receptor (Tyr653/654; 
anti-pp-tyr) or an anti-phospho tyrosine (anti-p-tyr) antibodies detecting the overall amount of EmFR and 
EmFR-TkD- and the phosphorylated EmFR, respectively. (A) HEK293T cells were transfected using the standard 
procedure and prior to lysis parts of the sample was subjected to 30 min treatment with calf intestinal 
phosphatase (CIP). Cells were tranfected with empty vector psecHygroA for control. (B) Xenopus oocytes were 
allowed to express EmFR or EmFR TkD- for 48 h, then 10 nM aFGF or bFGF were added and cells were 
submitted to lysis after 24 h. As control a mock injection was chosen. 
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Therefore, EmFR and the mutant dead box kinase EmFR TkD- were expressed in stage VI Xenopus 
oocytes and checked on the one hand the phosphorylation (Fig. 20 B) status and on the other hand 
for germinal vesicle breakdown (GVBD) in the presence and absence of aFGF or bFGF (Fig. 21). 
Functional analyses of receptor tyrosine kinases using heterologous protein expression in stage VI 
Xenopus oocytes has been reported before [156,168,169] and in the case of pleurodele FGFR1 it was 
demonstrated that after stimulation with aFGF, GVBD of Xenopus oocytes as a measure of receptor 
activity and active signaling occurs [156]. EmFR did not induce GVBD in the absence of the FGF 
stimuli (Fig. 21 A). However, upon the addition of either aFGF or bFGF a dose dependent induction of 
GVBD was observed (Fig. 21 A) with aFGF being more potent than bFGF. 
Then the Xenopus oocyte membrane fractions were analysed in western blot analyses using an anti-
c-myc and an anti-phospho tyrosine antibodies detecting the overall amount of EmFR and EmFR-TkD- 
and the phosphorylated EmFR, respectively. Without the addition of FGFs the wild type EmFR does 
not show any phosphorylation, suggesting that in this system EmFR is not constitutively active. With 
the stimulation of either aFGF or bFGF a clear receptor phosphorylation was detected (Fig. 20 B). In 
the case of the dead-box kinase EmFR TkD- phosphorylation of the receptor was not detect at any 
condition. This lead to the assumption that also for EmFR the DFG motif is essential for tyrosine 
kinase activity. 
 
In addition to the experiments outlined above, BIBF1120 was tested in the Xenopus system (Fig. 
21 B). BIBF1120 can efficiently block the effect of aFGF and bFGF on EmFR at 10 µM and 20 µM, 
whereas with 1 µM still 90 % GVBD with aFGF and 50 % GVBD with bFGF were observed. GVBD 
induced by pleurodele FGFR1 stimulated with 10 nM aFGF [156] was also successfully blocked. The 
inhibition was even more pronounced because 1 µM BIBF1120 led to less GVBD (30 %) suggesting 
that BIBF1120 more effectively binds to FGFR1. Moreover, as expected BIBF1120 treatment did not 
alter the outcome of samples which expressed EmFR TkD-. EmFR TkD- is a dead box kinase unable of 
signal transduction and never led to GVBD in the presence of stimuli. 
In summary, with the use of the Xenopus expression system, it was demonstrated that EmFR is an 
active tyrosine kinase when activated by either aFGF or bFGF and thus causing GVBD. The effect was 
reversed when BIBF1120 was applied which successfully blocked EmFR signaling. 
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A   aFGF  PG 
Oocytes expressing  none 1 nM 5 nM 10 nM  10 µM 
EmFR  0% 0% 90% 100%  100% 
Pleurodele amphibian FGFR  0% n.d. 100% n.d.  100% 
   bFGF   
Oocytes expressing  none 1 nM 5 nM 10 nM   
EmFR  0% 0% 0% 90%   
Pleurodele amphibian FGFR  0% n.d. 90% n.d.   
 
B  BIBF1120 
Oocytes expressing  none 1 µM 10 µM 20 µM 
EmFR  0% 0% 0% 0% 
EmFR + aFGF [10 nM]  100% 90% 0% 0% 
EmFR + bFGF [10 nM]  90% 50% 0% 0% 
EmFR TkD-  0% 0% 0% 0% 
EmFR TkD- + aFGF [10 nM]  0% 0% 0% 0% 
EmFR TkD- + bFGF [10 nM]  0% 0% 0% 0% 
HsFGFR1  0% 0% 0% 0% 
HsFGFR1 + aFGF [10 nM]  100% 40% 0% 0% 
 
Fig. 21: The induction of GVBD in Xenopus oocytes expressing EmFR and EmFR TkD-. (A) Oocytes were 
allowed to express EmFR or pleurodele FGFR1 for 48 h, and then aFGF or bFGF ligands were added with 
different concentrations (1 nM, 5 nM, and 10 nM). (B) Wild type EmFR, mutant EmFR TkD- and pleurodele 
FGFR1 were expressed in Xenopus oocytes for 48 h, an then 10 nM aFGF or bFGF were added in the presence 
or absence of various concentrations of BIBF1120 (1 nM, 10 nM and 20 µM). Native oocytes treated with or 
without progesterone (10 µM) served as positive and negative controls, respectively. In all experiments GVBD 
was observed after 24 h of stimulation. Percentages of GVBD as indication for receptor activity in each group 
are shown. Each experiment was performed using a set of 20-30 oocytes and was repeated two times. 
5.1.10. Phosphorylation status of EmMPK1 in metacestodes and primary cells 
Since FGFs displayed a clear growth-stimulating and proliferative effect on E. multilocularis 
metacestode vesicles and primary cells, the underlying molecular signaling mechanisms of these 
phenomena were analysed. In mammalian systems, it is known that FGFs signal via FGFRs and induce 
an activation of the MAP-kinase cascade. Interestingly, EmMPK1 was simulated in E. multilocularis 
metacestode vesicles upon exogenous addition of aFGF or bFGF [94] This was detected by means of 
Western blots using the anti-Erk1/2 and the anti-phopsho-Erk antibodies to measure the overall 
EmMPK1 and phosphorylated EmMPK1, respectively [55]. However, it was not clear, whether host 
FGFs can induce the phosphorylation of EmMPK1 in Echinococcus primary cells. In a previous 
preliminary study [170] in which 1 nM of either aFGF or bFGF were used for stimulation of primary 
cells there was no change in phosphorylation of EmMPK1 compared to control samples. However, in 
this study, primary cells were incubated for two days in DMEM with 0.2% FBS and were subsequently 
stimulated with 10 nM or 100 nM aFGF or bFGF for two days. Using these conditions with elevated 
FGF concentrations an increase of phosphorylation of EmMPK1 was detected in the stimulated 
samples. Most clearly when 10 nM aFGF and 100 nM bFGF were applied (Fig. 22). 
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anti-p-Erk
anti-Erk 1/2
 
 
Fig. 22: The effect of FGFs on the EmMPK1 of primary cells. Depicted are Western blot experiments of primary 
cell lysates using the anti-Erk1/2 and the anti-phopsho-Erk antibodies detecting the overall EmMPK1 and 
phosphorylated EmMPK1, respectively after separation on a 12% PAA gel. Intact primary cells were kept in 
cDMEM-1 (control), starved in DMEM with 0.2% FBS for two days (unstimulated) or after starvation have been 
treated with 10 nM or 100 nM aFGF or bFGF for two days. 
 
Moreover, this study investigated the effect of BIBF1120 on the phosphorylation of EmMPK1. As the 
inhibitor caused a dose-dependent damage of the metacestode vesicles, a block in regeneration of 
primary cells and is known to act on FGFRs, one could speculate that the MAP-kinase cascade is 
blocked. For that, axenic metacestode vesicles were starved in DMEM without FBS for 4 days and 
then treated with either 5 µM or 10 µM BIBF1120 for 30 min. Indeed a slight reduction of the 
phosphorylated EmMPK1 was detectable (Fig. 23 A). The effect was more pronounced for 10 µM 
BIBF1120. Experiments, in which BIBF1120 was applied to primary cells, gave similar results. In detail, 
freshly isolated primary cells were directly subjected to cDMEM-1 supplemented with either 5 µM or 
10 µM BIBIF1120 for 4 h. Control samples were treated with 0.1 % DMSO. With both inhibitor 
concentrations testet, the phosphorylation of EmMPK1 was diminished compared to control DMSO 
treated primary cells (Fig. 23 B). 
A B 
anti-p-Erk
anti-Erk 1/2
anti-Elp EmElp
P~EmMPK1
EmMPK1
 anti-p-Erk
anti-Erk 1/2
anti-Elp EmElp
P~EmMPK1
EmMPK1
 
 
Fig. 23: The effect of BIBF1120 on the EmMPK1 phosphorylation of metacestode vesicles and primary cells. 
Depicted are Western blot experiments of (A) metacestode vesicle lysates and (B) primary cell lysates using 
the anti-Erk1/2 and the anti-phopsho-Erk antibodies detecting the overall EmMPK1 and phosphorylated 
EmMPK1, respectively after separation on a 12% PAA gel. Axenic metacestode vesicles were starved in 
DMEM without FBS for 4 days and then treated with either 5 µM or 10 µM BIBF1120 for 30 min. Freshly 
isolated primary cells were directly subjected to cDMEM-1 supplemented with either 5 µM or 10 µM 
BIBIF1120 for 4 h. Control samples were treated with 0.1 % DMSO. Subsequently to treatment protein 
lysates were prepared immediately. Internal control for protein content of the lysates, the constitutively 
expressed protein EmElp was detected with an anti-EmElp antibody. 
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All together, these data demonstrate that aFGF and bFGF stimulate EmMPK1 phosphorylation in 
metacestode vesicles and primary cells. Furthermore, BIBF1120 caused a dephosphorylation of 
EmMPK1 in metacestode vesicles and primary cells suggesting that FGF-FGFR signaling in 
E. multilocularis involves the MAP-kinase signaling cascade. 
5.1.11. Phosphorylation status of EmAkt in metacestode vesicles and primary cells 
It is known that FGFs signal via FGFRs and induce an activation of the MAP-kinase cascade. 
Moreover, in mammals the PI3 kinase/AKT pathway is activated and implicated in cell survival and 
cell fate determination [171,172]. EmAkt has been identified in a previous study [173]. Therefore, the 
effect of host FGFS and BIBF1120 on EmAkt signaling was investigated and the phosphorylation of 
EmAkt was analysed using anti-phospho-Akt antibody in protein lysates of primary cells. 
 
                A           B 
anti-p-Akt
anti-Elp
 
 
Fig. 24: The effect FGFs on the EmAkt phosphorylation of primary cells Depicted are Western blot 
experiments of primary cell lysates using the anti-phospho-Akt and the anti-EmElp antibodies after separation 
on a 12% PAA gel. (A) Freshly isolated primary cells were starved in DMEM 0.2 %FBS for two days and then 
treated with either 100 nM aFGF or 100 nM bFGF for 3 h. (B) Freshly isolated primary cells were directly 
subjected to cDMEM-1 supplemented with either 5 µM or 10 µM BIBIF1120 for 4 h. Control samples were 
treated with 0.1 % DMSO. Subsequently to treatment protein lysates were prepared immediately. 
 
 
In detail, freshly isolated primary cells were starved in DMEM 0.2 %FBS for two days and then treated 
with either 100 nM aFGF or 100 nM bFGF for 3 h. Compared to untreated primary cells, there was no 
difference in phosphorylation of EmAkt in the aFGF or bFGF treated samples (Fig. 24A). Moreover, 
the influence of BIBF1120 was investigated. For that, freshly isolated primary cells were directly 
subjected to cDMEM-1 supplemented with either 5 µM or 10 µM BIBIF1120 for 4 h. Control samples 
were treated with 0.1 % DMSO. In untreated and BIBF1120 treated samples a clear phosphorylation 
was detected (Fig. 24B). However, there was no difference in intensity between DMSO control cells 
and BIBF1120 treated cells. Thus far, the phosphorylation of EmAkt has not been analysed in 
metacestode vesicles or protoscoleces. Altogether, in primary cells, the activation of EmAkt is not 
influenced by FGFs or BIBF1120. In treated and untreated samples a comparable, but clear 
phosphorylation was present. 
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5.1.12. The E. multilocularis genome does not encode for own canonical FGFs 
A variety of at least 23 FGFs have been identified in several organisms ranging from nematode and 
Drosophila to humans. Although, FGFs vary in size they usually share a conserved core region of 120 
amino acids [67]. FGFs act in concert with heparin or heparan sulfate proteoglycan to activate FGFRs 
and to induce the pleiotropic responses which lead to the range of cellular responses. Thus, one 
could assume if E. multilocularis encodes a FGFR, also FGFs might be present in this particular 
cestode organism. However, when searching with either human or C. elegans egl-17 and let-756 FGFs 
against the E. multilocularis genome and transcriptome data, no significant BLAST hit was obtained, 
suggesting that no canonical FGF is present in the E. multilocularis. In detail, it is reported that FGFs 
are sometimes linked to certain genes on the genome of for example humans. For instance, FGF1 is 
located on chromosome 5q in proximity to FGFR4 [63,64]. When analysing the genomic surrounding 
of Emfr on contig 1713 (Fig. 25) with BLAST searches based on transcriptome data, downstream 
within 10 kb just a homolog to the integrator complex subunit 7 and upstream within 10 kb a 
homolog to sideroflexin was identified. There was no evidence for any FGF homologue. Then, the 
surrounding of the putative E. multilocularis nou-darake (Emndk; sequence see supplementary 
material) was analysed. Nou-darake was first described in Dugesia japonica and is involved in 
planarian brain development [84]. It is a putative actor of the FGF signaling pathway present in all 
major metazoan phyla [72]. EmNDK exhibits a high homology to the planarian NDK including the 
extracellular domain consisting of three IG domains, a transmembrane domain and as expected the 
intracellular TkD typically for FGFRs is absent. In humans, the homologous gene is described as FGFR-
like 1 (FGFRL1), but in this case it was named the E. multilocularis gene Emndk, as the homology to 
the planarian gene is more pronounced. In the literature, it is reported, that nou-darake and some 
FGFs are co-expressed. Conversely, no FGF homologue could be identified in the genome data, in the 
proximity to Emndk situated on contig 3410 of the latest genome assembly. Upstream within 30 kb 
of Emndk, a ribose-phosphate pyrophosphokinase 1,2 homolog and a GTP-binding Ras-like homolog 
was identified. Downstream within a range of 50 kb of Emndk, two transcriptional units were 
identified. However, in a BLAST search either no significant (n.s.) hit was retrieved, suggesting the 
presence an E. multilocularis specific transcript or just a hypothetical non characterized (n.c) protein 
was identified. Thus, with the in silico data analyses conducted in this study, it is most likely that 
E. multilocularis does not possess any canonical FGFs. 
 
Fig. 25: Gene locus maps for Emfr and Emndk genes on assembled E. multilocularis genome contigs. 
Schematically displayed are the Emfr and Emndk loci present on contigs 1713 and 3410, respectively, of the 
latest E. multilocularis genome assembly version as well as the 5’ and 3’ flanking reading frames. Black arrows 
indicate the reading direction of the respective open reading frame. diras: GTP-binding Ras-like; fr: fibroblast 
growth factor receptor; ints: integrator complex subunit 7; n.c.: no characterized, but hypothetical protein in 
BLAST analysis; ndk: nou-darake; n.s.: no significant hit in the BLAST analysis; rppk12: ribose-phosphate 
pyrophosphokinase 1,2; sfxn: sideroflexin. 
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5.2. NHR signaling – EmNHR1 
5.2.1. Expression analysis of Emnhr1 in Echinococcus larval stages 
The expression of Emnhr1 (sequence see 7.1) in larval stages was analyzed by semi-quantitative RT-
PCR [145]. Emnhr1 transcripts are present in all analysed stages: metacestode vesicles, in 
protoscoleces before (dormant protoscoleces) and after activation through pepsin/low-pH treatment 
protoscoleces (activated protoscoleces) as well as in in vitro cultivated primary cells (Fig. 26). It 
seems, that Emnhr1 is to some extent higher expressed in the dormant protoscolex and is least 
expressed in activated protoscoleces. Data from the transcriptome profile (kindly provided by the 
Sanger Institute, Hinxton, UK) of Emnhr1 support these findings, with the relative expression level of 
Emnhr1 highest in dormant protoscoleces which was set to 100 % (Fig. 26B). Least expression was 
detected in in vitro cultivated metacestode vesicles (28.9 %) and activated protoscoleces (35.2 %)  
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Fig. 26: Expression analysis of Emnhr1. (A) After isolation of total RNA from in vitro cultivated metacestode 
vesicles (Mc), dormant (Pd) and activated protoscoleces (Pa) as well as in vitro cultivated primary cells (Pc) the 
RNA was reverse transcribed. Subsequently, the cDNA was subjected to PCR with oligonucleotides specific for 
Emnhr1. As control the constitutively expressed gene Emelp [44] was used. The resulting PCR amplicons were 
separated on a 1 % agarose gel and stained with ethidium bromide. DNA size marker bands are indicated to the 
left. Figure taken from [145] (B) Expression of Emnhr1 from transcriptome profiling analysis. Normalized 
relative gene expression is given, with the highest expression set to 100 %. 
 
Taken together, these data indicate that Emnhr1 is constitutively expressed in important larval stages 
of the parasite’s lifecycle, namely of the intermediate host and on its way to the system of the 
definitive host. 
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5.2.2. Recombinantly expressed EmNHR1 – an attempt to raise a specific antibody 
For the analysis of protein expression levels of EmNHR1 in different E. multilocularis larval stages a 
specific antibody for detection is a useful tool. Therefore, the deduced amino acid of EmNHR1 was 
subjected to in silico analysis using a tool for predicting antigenic peptides within a protein sequence 
(http://immunax.dfci.harvard.edu/Tools/antigenic.html). Hence, a partial sequence of EmNHR1 
(EmNHR1-ab, residue 170 – 408) was chosen and cloned into the pBAD/Thio-® vector for 
recombinant expression in E. coli. After the induction with 0.2% arabinose for 4 h in E.coli BL21, the 
fusion protein EmNHR1-ab was purified under native conditions via the 6xHis – tag. The quality of the 
protein purifications was validated by both Coomassie staining and Western blotting (Fig. 27) with 
anti-V5 antibody. Apparently, the recombinant protein was expressed as detected by Western blot 
(Fig. 27 B), but the purity of the recombinant protein was not very high. Another attempt to express 
EmNHR1 in the vector pRSET and to purify the respective fusion protein failed. For the production of 
a polyclonal antibody against EmNHR1 rabbits were intravenously immunized at immunoGlobe® 
Antikörpertechnik GmbH. The recombinantly expressed EmNHR1 was used for this and was dialysed 
against 1xPBS before immunization. Rabbits were reboosted three times before the final bleeding. 
However, with each final serum, the EmNHR1-ab fusion protein which had been used to immunize 
the rabbit could not be detected in Western blot assays (data not shown). Thus, the attempt to 
generate a polyclonal antibody specific against EmNHR1 was not successful. 
 
A                                                                                             B 
eluate
62
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62
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Fig. 27: Recombinant expression of EmNHR-ab in E. coli using the pBAD-thio vector. The expression of the 
fusion protein EmNHR1ab/Thio was induced with 0.2 % arabinose for 4 h in E. coli BL21 using the pBAD/Thio-
Topo® vector (Invitrogen) and was subsequently purified via the 6xHis-tag under denaturing conditions as 
described. The induction and purification was analyzed on a 12 % PAA –gel followed by Coomassie staining 
and Western blotting with anti-V5 antibody (Invitrogen) according to the manufacturer’s recommendations. 
The samples separated on the PAA-gel were: E. coli lysate prior (- arabinose) and after (+ 0.2 % arabinose) 
induction; the lysinB residual, the protein fraction, which did not bind to the Ni2+ column (supernatant) and 
the washed out unspecific bound proteins (washing buffer); the eluted protein fractions. The arrow marks the 
corresponding fusion protein, while the smaller fragments detected with the anti – V5 antibody were most 
likely degradation products. 
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5.2.3. Protein-protein interaction studies of EmNHR1 and its domains: LBD and 
DBD 
It has been repeatedly reported that NHR receptors are modulated by NHR co-regulators, namely 
coactivators or corepressors, also through direct protein-protein interaction [174,175].  
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pGADT7 - - - - 
EmNHR1-FL - (+)- n.d. n.d. 
EmNHR1-DBD - n.d. (+)- n.d. 
EmNHR1-LBD - n.d. n.d. (+)- 
EmSkip - - - - 
EmSmadA - - - - 
EmSmadB - - - - 
EmSmadC - + ++ - 
EmSmadD - - - - 
EmSmadE - - - - 
EmSmadE* - - - - 
EmSmadA* - - - - 
EmSmadB* - - - - 
EmSmadC* - + ++ - 
EmAlien - - - - 
EmGt198 - - - - 
      
B  Fusion with Gal4-activation domain 
  pGADT7-TY** EmNHR1-FL EmNHR1-DBD EmNHR1-LBD 
 pGBKT7-EmJab1 (+)- - + + 
 
Fig. 28: EmNHR1 protein interaction studies with E. multilocularis NHR co-regulators, EmSmads and EmJab1. 
(A) Translation fusions were generated for the Gal4-DNA binding domain (BD; vector pGBKT7) and (B) the Gal4-
activation domain (AD; vector pGADT7) with the full-length EmNHR1 (EmNHR1-FL), EmNHR1-LBD and EmNHR1-
DBD. These were transformed into yeast strain AH109 together with empty vectors (pGADT7, pGBKT7) or with 
different fusions for EmSkip [61] and EmSmadA, EmSmadB [60] as well as EmSmadC, EmSmadD [58]. An 
asterisk marks the constitutively active forms of EmSmadA, EmSmadB, EmSmadC [58,60] and EmSmadE [176]. 
Positive control (pGADT7-T x pGBK-53) and negative control (pGADT7-T x pGBK-Lam) were performed as 
described in the MATCHMAKER-manual (Clontech). Growth of colonies was assessed according to the 
MATCHMAKER-manual (Clontech). The characters “-“, “+”, and “++” indicate no growth or growth under 
medium and high stringency conditions. Slight growth under medium stringency conditions, which is blocked 
under 7.5 mM 3-AT treatmentis indicated by “(+)-“. Instead of empty pGADT7 control, pGADT7-TY was used as 
described [177] and indicated by “**”. Not defined (n.d.) shows that no double-transformants for this plasmid 
combination were generated. Figure and legends adapted from [145]. Several independent experiments (n= 3-
5) were performed. 
 
In a yeast-two hybrid approach it was therefore tested, whether EmNHR1 interacts with EmSkip [61], 
EmAlien [62], or EmGt198 [178]. To this end a translational fusion of full length EmNHR1-FL, 
EmNHR1-DBD and EmNHR1-LBD in pGADT7 and pGBKT7 was constructed. In the experiments, no 
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interaction between any of the EmNHR1 domains and EmSkip, EmAlien or EmGt198 (Fig. 28 A) was 
observed, suggesting that other parasite specific co-regulators of NHR could be present. Moreover, 
the interaction of EmJab1 with EmNHR1-FL and EmNHR1-DBD was assessed (Fig. 28 B). EmJab1 is a 
homolog to the H. sapiens Jab1 which is part of the signalosome complex and involved in hormone-
dependent activation of steroid-hormone-receptors [179]. Jab1 also acts as a modulator of 
intracellular signaling (reviewed in [180,181]). It was described earlier [177], that EmNHR1-LBD 
(construct by [62]) positively interacts with EmJab1. In this study, a positive interaction between 
EmJab1 and EmNHR1-LBD, EmNHR1-LBDtrunc and EmNHR1-DBD was detected, whereas no 
interaction was observed with EmNHR1-FL (Fig. 28). In addition it has been reported that members of 
the Smad family, intra-cellular transcription factors of the TGF β/BMP-signaling pathway interact 
with NHR [114,182]. Noteworthy, it was found that the translational fusion of EmSmadC and its 
constitutively activated form EmSmadC* expressed in the pGBK positively interact with the empty 
pGADT7 [58]. Therefore both, the translational fusions of all EmNHR1 constructs in pGADT7 and 
pGBKT7 were tested in order to exlude false positive results. Whereas EmSmad A, constitutively 
activated EmSmadA (EmSmadA*), EmSmadB, constitutively EmSmadB (EmSmadB*) [60], EmSmaD 
[58], EmSmadE and constitutively activated EmSmadE (EmSmadE*) [176] did not interact with either 
EmNHR1-FL, EmNHR-DBD or EmNHR-LBD, a clear protein-protein interaction was detected between 
EmSmadC and EmNHR1-FL and EmNHR1-DBD. Also, EmSmadC* interacted with EmNHR1 and 
EmNHR1-DBD (Fig. 28A). Hence, EmNHR1 might act in concert with TGF-β/BMP-signaling in the 
parasite. 
5.2.4. EmNHR1-LBD dimerization studies 
NHR like VDR usually form homo- or heterodimers upon ligand binding [183]. Therefore, it was 
investigated if the EmNHR1-LBD and its C-terminally truncated form (EmNHR1-truncLBD) can form 
homodimers (Fig. 29 A). As method of choice a modified yeast-two-hybrid was used in which the LBD 
of NHRs is fused to the Gal4-DBD or to the Gal4-LBD and double transformants are incubated in the 
presence of potential ligands [145]. In the presence of non-cognate compounds, no interaction is 
detected, whereas in the presence of cognate ligand, the NHR LBDs form dimers that result in 
positive readout [1,17-20]. 
Translational fusions of EmNHR1-LBD (cloned with oligonucleotides: EmNHR1-LHQ-NcoI-fwd, 
EmNHR1-FIE-XmaI-rev) as well as EmNHR1-truncLBD (cloned with oligonucleotides: EmNHR1-LHQ-
NcoI-fwd, EmNHR1-ALT-XmaI-rev) in pGBKT7 and EmNHR1-LBD in pGADT7 were transformed into 
Y187 yeast strain and grown in selective medium. First, no homodimerization was detected when the 
yeast was grown in selective unsupplemented medium (Fig. 29 A). Once 5 % human or bovine serum 
was added to the yeast cultures a clear positive signal in the liquid β-galactosidase assay was seen as 
a measure of homodimerization of EmNHR1-LBD. The effect was also detectable with 10 % (data not 
shown) and 20 % (Fig. 29 B) serum. A dimerization of EmNHR1-LBD has also been detected when 
transformed yeast were grown in the presence of 20 % E. multilocularis hydatid fluid (Fig. 29 A; HF). 
However, no dimerization was observed, when BD-EmNHR-truncLBD was tested with AD-EmNHR-
LBD. Thus, the ability of EmNHR1-LBD to form homodimers is dependent on the C-terminus of the 
LBD. In Fig. 29 B the reaction of EmNHR1 LBD to fractionated FBS is depicted. Briefly, a putative 
ligand is present in FBS fractions between 10–30 kDa of molecular mass, because a positive signal 
was detected in the FBS fraction smaller than 30 kDa (FBS < 30 kDa) but larger than 10 kDa (FBS > 
10 kDa). 
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Fig. 29: Comparative β-Galactosidase liquid assays to determine EmNHR1- LBD dimerization. Yeast cells 
(strain Y187) were transformed with the pGADT7-EmNHR1-LBD and pGBKT7-EmNHR1-LBD or a C-terminal 
truncated pGBKT7-EmNHR1-LBD. (A) The cells were then cultured over night in selective SD-Leu/-Trp medium 
either without supplement (w/o suppl.) or in the presence of 5 % FBS, 5 % human serum (5 % hS) or 20 % 
E. multilocularis hydatid fluid (20 % HF). Figure adapted from [145]. (B-E) The assay was performed with 
pGADT7-EmNHR1-LBD and pGBKT7-EmNHR1-LBD transformed yeast. Selective SD-Leu/-Trp medium was 
supplemented with: 20 % FBS, FBS < 30 kDa, FBS > 30 kDa, FBS < 10 kDa, FBS > 10 kDa, heat inactivated FBS 
(FBS HI), non heat inactivated FBS (FBS NHI), NHI or HI dextran-coated charcoal treated FBS (FBS DCC NHI or 
HI), Panserin (Pan), conditioned Panserin (cPan), Panserin devoid of either lipids (Pan w/o L), 
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Lipids/Cholesterol (w/o L/Ch) or Lipids/Cholesterol/Vitamins (w/o L/Ch/V), DMEM, DMEM/FBS or cDMEM-1. 
pGAD-ElpN/pGBK-ElpC as positive control [37] (pos. control) and pGADT7-T/pGBK-Lam as negative control 
(neg. control). The statistical evaluation of 3-5 independent measurements of β-Galactosidase activity is 
shown including the standard error of the mean (SEM), *p < 0.05. 
 
Moreover, the signal resulting from the FBS could not be eliminated by treatment with either 
400 µg/ml Proteinase K for 90 min at 56 °C or dextran-coated charcoal regardless whether it has 
been heat inactivated twice for 45 min at 56 °C (Fig. 29 C). 
In additional experiments different culture media for E. multilocularis cultivation were subjected to 
the modified Y2H assay (Fig. 29 D). PanserinTM401 (Pan) and conditioned PanserinTM401 (cPan) both 
lead to a positive signal, indicating that the putative ligand for EmNHR1 is present in these media. 
DMEM without FBS on the other hand did not result in a positive signal supporting the idea that the 
ligand is present in the FBS. Conditioned DMEM (cDMEM-1) resulted in a slight positive reaction 
which might be due to the fact that some components of the FBS are used by the RH- cells. In an 
additional experiment PanserinTM401 either without lipids, without lipids/cholesterol or without 
lipids/cholesterol/vitamins was analysed. These components are usually supplemented in the 
medium. Interestingly, in the absence of the vitamins no homodimerization of EmNHR1-LBD could be 
detected whereas the absence of lipids or cholesterol did not alter homodimerization. However, no 
specific vitamin could be identified in this study. Vitamin B12 (0.013 mg/l) and Biotin (0.013 mg/l) 
were tested alone and in combination, but neither could induce a homodimerization of EmNHR1-LBD 
(Fig. 29 F). Taken together, these results indicated that host serum contains at least one ligand that 
can be recognized by EmNHR1. When a truncated version of the EmNHR1 LBD was used (lacking 
parts of the C-terminal LBD region), no elevated β-Galactosidase units were measured, indicating 
that the complete LBD was necessary for ligand-dependent dimerization of EmNHR1 [145]. 
5.2.5. Effect of bile salts and conjugated bile salts on axenically cultivated 
metacestode vesicles 
To examine the effect of bile salts and related substances (conjugated bile salts) as well as 
progesterone and aldosterone H95 metacestode vesicles from 3 months in vitro co-culture were 
transferred to axenic conditions in the presence of these substances. The growth was monitored 
over a time period of 6 weeks. Substances to be tested were applied at physiological concentrations 
present in the portal vein blood of humans as indicated (Fig. 30 A and B). Control vesicles were 
cultured with the respective solvent: water, ethanol, methanol or chloroform. The medium (cDMEM-
1; 2 ml) of each 15 ml tube was replaced every second or third days in every 15 ml tube and 
incubated at 37 °C under nitrogen atmosphere. For each group ten replicates were prepared. 
Compared to the respective control metacestode vesicles, those that were grown in the presence of 
bile salts (BS), cholic acid (CA), desoxycholic acid (DCA) as well as lithocholic acid (LCA) were 
significantly bigger after six weeks (Fig. 30 A and B). The influence of 2 µM LCA (Fig. 30 A) seemed to 
be more pronounced (3.1 fold increase in diameter), than the positive effect of 0.02 µM LCA (2.6 fold 
increase in diameter) and 0.02 µM DCA (2.5 fold increase in diameter). Upon stimulation with 
0.02 µM BS a 1.7 fold increase in vesicle diameter was observed. Also the presence of CA resulted in 
a 1.9 fold increase in diameter. Moreover, chenodesoxy acid (CDA) resulted in a better growth of the 
vesicles: 1.8 fold and 2.3 fold at 2 µM and 0.02 µM CDA, respectively (Fig. 30 A). However the effect 
was not statistically significant. Furthermore, the influence of progesterone and aldosterone as 
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members of the steroid hormone family was tested. Both substances did not alter the growth rate of 
the vesicles over time. The metacestode vesicles reached a diameter between 7 mm and 13 mm, 
comparable to the control vesicles (7 – 11 mm). The effect of all mentionend substances has not 
been tested on E. multilocularis primary cells yet. 
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Fig. 30: Influence of bile salts, conjugated-bile salts, progesterone and aldosterone on axenic metacestode 
vesicles. Metacestode vesicles were grown in 15 ml tubes over a time period of six weeks. Medium was 
changed every 2-3 days supplemented with (A) chenodesoxy acid (CDA), desoxycholic acid (DCA) and 
lithocholic acid (LCA) at indicated concentrations or (B) bile salts (BS), cholic acid (CA), progesterone (Pro) and 
aldosterone (Ald) at indicated concentrations. Control vesicles were cultured with the respective solvent: 
water, ethanol, methanol or chloroform. For each group ten replicates were prepared. The mean was 
calculated and the standard error of the mean (SEM) is indicated, respectively. For estimation of significance a 
Student’s t-test (two-tailed) was performed with a significance level of *p < 0.05. 
 
Taken together the presence of various bile salts and conjugated bile salts resulted in an increase of 
metacestode vesicles over time compared to the respective controls. The stimulation with either 
progesterone or aldosterone did not result in a better growth. 
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5.3. NHR signaling – other putative EmNHRs 
5.3.1. In silico analysis and identification of putative E. multilocularis NHRs 
With the E. multilocularis genome at hand the question whether additional putative NHR are present 
in the parasite genome was addressed by in silico analysis. To this end various BLAST analyses on the 
available genome information were carried out. First, the EmNHR1 Znf-C4 zinc finger motif as well as 
the respective motifs from S. mansoni NHRs [105] were used for the identification of related 
sequences in the E. multilocularis genome. To identify the entire set of NHRs that is present in 
E. multilocularis an iterative TBLASTN search was conducted using as query the deduced amino acid 
sequence of EmNHR1 DBD (contig 3395) [145]. All together, 17 additional sequences which showed 
similarities to the respective DBD domains were identified. The subsequent SMART analysis detected 
in 16 out of these 18 sequences ZnF_C4 motifs (Table 1). An alignment of the EmNHR1 DBD 
(contig 3395) and the other putative NHR-DBD of E. multilocularis indicates a high conservation of 
the DBDs harbouring the ZnF_C4 motif including conserved cysteine residues (Fig. 31 A). Furthermore 
a phylogenetic tree in which the DBDs of the E. multilocularis NHRs are compared to those of 
S. mansoni was reconstructed (Fig. 31 B) and shows that most of the Echinococcus NHRs do have 
close orthologs in the trematode [145]. In the next step all 18 sequences including 2 kb down-stream 
and 5 kb up-stream of the putative DBD coding sequence were submitted to BLASTX analyses 
(against database nr) and scanned for homologies (Table 1, [145]). The best hit judged by the lowest 
E-value and the homologues found in the trematode S. mansoni were listed (Table 1). The sequence 
of contig 1756 did not produce a significant hit suggesting either a false positive prediction or a 
possible species specific NHR. Among the other sequences it is obvious that the putative NHR of 
E. multilocularis show homologies to S. mansoni NHRs: SmTR4 (contig 1644), SmTRb (contig 1680), 
SmHNF4 (contig 1702), SmE78 (contig 2122), SmHR96a (contig 3309), SmNR4A5 (contig 3425), and 
SmFTZ-F1a (contig 3442) (Table 1; nomenclature of the schistosome NHRs, [105]). Moreover, the 
structural unusual NHR containing two DBDs have been identified (contig 1779, 1872, and 2681; Fig. 
31), homologous to nuclear receptor 2DBD-γ and 2DBD-α, respectively [140,141]. Furthermore, for 
the putative Echinococcus NHR, encoded on contig 1798, clear homologies to SmTLL were observed 
in the DBD but not in the LBD (Table 1). 
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Fig. 31: In silico identification of putative NHR in E. multilocularis. (A) Amino acid sequence comparison of 
the DBDs of 17 E. multilocularis NHRs. The contig numbers of the current E. multilocularis genome assembly 
that encode the NHRs are indicated to the left. In the case of members of the 2DBD family, the ZnF_C4 motifs 
are marked by “a” (most N-terminal motif) and “b” (most C-terminal motif). Residues that match the 
consensus are printed in white on black background, residues with similar function are marked in grey. 
Conserved DBD structures such as the P-, DR-, and D-boxes are indicated above the alignment and conserved 
cysteine residues as asterisk below the alignment. (B) Phylogenetic tree depicting DBD homologies between 
the 17 E. multilocularis NHRs and 21 NHRs identified in S. mansoni [105]. The E. multilocularis NHRs are 
indicated by the contig number of the present genome assembly. Figure and legends adapted from [145]. 
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The NHR, encoded on contig 3440, exhibited homologies within the LBD to SmRXR2 but is 
characterized by an untypical P-box (CDSCRA; Fig. 31) which cannot be found in any of the 
schistosome receptors. Although the NHR encoded on contig 2878 displayed homology to SmRAR-
like in the DBD, no other true orthologs for both schistosome RXR receptors as well as SmDSF, 
SmPNR or SmRAR-like were not found in the E. multilocularis genome [145].However, unlike 
S. mansoni, the genome of E. multilocularis contained an additional member of the CESCKA family, 
EmNHR1, besides the Echinococcus ortholog encoded on contig 3309 (Fig. 31; Table 1). Moreover, 
similar sequence analyses were performed on the E. granulosus genome [145]. The same set of NHRs 
was identified as in E. multilocularis (data not shown). This demonstrates, that cestodes of the genus 
Echinococcus contain less NHRs than schistosomes. The main difference between the NHR subsets of 
the analysed cestodes compared to the trematode is the absence of true RXR orthologs and the 
presence of only one member of group 2E NHRs which, in schistosomes, is made up of the receptors 
SmTLL, SmPNR and SmDSF [105]. Conversely, Echinococcus has more receptors with DBD and LBD 
similarities to the HR-96 group, including EmNHR1. 
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Table 1: In silico identification of 17 members of the NHR family in E. multilocularis 
Contig 
#a 
TBLASTN SMART BLASTX  Homology to 
Position ZnF_C4b E-value Positionb E-value Best hit - homologiesc S. mansoni 
1644 481637 - 481467 2.63E-30 483637 - 476467 3.00E-29 >ref|XP_002581285.1| Tr4/Tr2 (homologue) [Schistosoma 
mansoni] emb|CAZ37524.1| Tr4/Tr2 (homologue) [Schistosoma 
mansoni]  
SmTR4 
1680 186953 - 187156 2.88E-27 184956 - 192156 2.00E-46 >ref|XP_002573733.1| thyroid hormone receptor [Schistosoma 
mansoni] emb|CAZ29965.1| thyroid hormone receptor, putative 
[Schistosoma mansoni] 
SmTRb 
1702 102326 – 102150 2.67E-31 104329 - 97150 1.00E-35 >gb|ACD77184.1| putative hepatocyte nuclear factor 4 nuclear 
hormone receptor [Callosobruchus maculatus] 
SmHNF4 
1756d 6913 - 8633 n.d. 8913 - 1833 > 0.1 n.d. – No NHR -  - 
1779 88954 – 86636 
85722 – 83572  
1.65E-22 
2.4E-29 
90954 - 81636 2.00E-17 >ref|XP_002573082.1| nuclear hormone receptor [Schistosoma 
mansoni] emb|CAZ29314.1| nuclear hormone receptor, putative 
[Schistosoma mansoni] 
Sm2DBDγ 
1798 6287 – 6364 6.09E-26 4287 - 11364 4.00E-14 >gb|ADG26734.1| tailless protein [Platynereis dumerilii] SmTLL (DBD) 
1872 361173 – 366071 
365772 – 366071 
1.24E-26 
1.4E-29 
359176 - 371071 5.00E-32 >ref|XP_002582074.1| nuclear receptor 2DBD-gamma 
[Schistosoma mansoni] emb|CAZ39174.1| nuclear receptor 
2DBD-gamma [Schistosoma mansoni] 
Sm2DBDγ 
2122 200727 - 203164 6.67E-32 198730 - 208164 1.00E-28 
 
>ref|XP_002410392.1| nuclear receptor, putative [Ixodes 
scapularis] gb|EEC12905.1| nuclear receptor, putative [Ixodes 
scapularis] 
SmE78 
2681 142976 – 143859  
144838 – 145255 
7.8E-10 
5.9E-33 
140985 - 150258 5.00E-13 >ref|XP_002578901.1| nuclear hormone receptor [Schistosoma 
mansoni] emb|CAZ35139.1| nuclear hormone receptor, putative 
[Schistosoma mansoni] 
Sm2DBDβ 
2822 79036 - 79239 2.31E-26 77036 - 84239 6.00E-30 
 
>ref|XP_001994574.1| GH17319 [Drosophila grimshawi] 
gb|EDV91203.1| GH17319 [Drosophila grimshawi] 
- 
2878 337761 - 335686 8.03E-26 339761 - 330692 4.00E-08 >ref|XP_002575396.1| RAR-like nuclear receptor [Schistosoma SmRAR-like 
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mansoni] emb|CAZ31629.1| RAR like nuclear receptor 
[Schistosoma mansoni] 
NR (DBD) 
2891d 140405 - 144600 n.d. 138405 - 145485 3.00E-13 >ref|XP_002575730.1| nuclear hormone receptor [Schistosoma 
mansoni] emb|CAZ31964.1| nuclear hormone receptor, putative 
[Schistosoma mansoni] 
- 
3309 400163 - 399395 2.63E-21 402163 - 395080 3.00E-19 
 
>ref|XP_002575014.1| nuclear receptor nhr-48 [Schistosoma 
mansoni] gb|AAV80235.1| CAR [Schistosoma mansoni] 
emb|CAZ31247.1| nuclear receptor nhr-48, putative 
[Schistosoma mansoni] 
SmHR96α 
3395 9827 - 9726 1.91E-18 11830 - 4726 9.00E-31 >emb|CBM40944.1| nuclear hormone receptor 1 [Echinococcus 
multilocularis] 
SmHR96α 
3400 259948 259748 1.29E-24 261948 - 254751 3.00E-29 >ref|XP_002572951.1| steroid hormone receptor ad4bp 
[Schistosoma mansoni] emb|CAZ29183.1| steroidogenic factor 1 
(stf-1) (sf-1) (adrenal 4 binding protein) (steroid hormone 
receptor ad4bp) (fushi tarazu factor homolog 1), putative 
[Schistosoma mansoni] 
SmFTZ-F1-α 
3425 163477 - 164189 5.95E-29 161477 - 169189 3.00E-16 >ref|XP_002569614.1| nuclear hormone receptor nor-1/nor-2 
[Schistosoma mansoni] 
SmNR4A5 
3440 155860 - 156036 6.11E-08 153866 - 161036 3.00E-08 >ref|XP_001660403.1| Nuclear hormone receptor (HR78) [Aedes 
aegypti] gb|EAT47063.1| Nuclear hormone receptor (HR78) 
[Aedes aegypti] 
SmRXR2 
(LBD) 
3442 72501 - 72713 4.51E-20 70504 - 77713 1.00E-79 >emb|CAX73127.1| nuclear receptor subfamily 5, group A, 
member 2 [Schistosoma mansoni] 
SmFTZ-F1 
 
a,b: Position of the DBD and the 2 kb down-stream- 5 kb up-stream sequence of the putative DBD on the respective contig. In 2DBD members, both ZnF_C4 motifs are 
indicated. 
c: Highest LBD homologies (% identical/% similar residues) to NHRs of S. mansoni (above) or to proteins present in the nr-aa database (http://www.genome.jp). 
d: No LBD could be identified. 
Table adapted from [145]
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5.3.2. Expression of other EmNHRs in Echinococcus larval stages 
The expression profile of all identified E. multilocularis NHR was analyzed using the transcriptome 
dataset provided by the Sanger Institute (Hinxton, GB) for E. multilocularis larval stages. The majority 
of the identified NHR is expressed constitutively in the different larval stages: metacestode vesicles, 
dormant and activated protoscoleces and primary cells (Table 2; [145]). Interestingly, a clear 
differential expression pattern was observed for NHRs encoded on contigs 2822 (only expressed in 
metacestode), 2878 (absent in metacestode vesicles) and 3425 (only expressed in protoscoleces) 
[145]. No or very weak expression was detected in the larval stages for the NHR encoded on contigs 
1680 and 1798. Taken together, at least 17 different NHR are present in the E. multilocularis genome 
and are most likely transcribed throughout the various E. multilocularis developmental stages with 
the exception of the NHR encoded on contigs 1680 and 1798. 
 
Table 2: Expression data of E. multilocularis putative NHR derived from direct transcriptome sequencing on 
rRNA-depleted total RNAa. 
 
Contig metacestode vesicle dormant protoscoleces activated protoscoleces  primary cells 
1644 +b + + + 
1680 - - - - 
1702 +/- +/- +/- +/- 
1779 + + + + 
1798 - +/- - - 
1872 + + + + 
2122 +/- + +/- + 
2681 + + + + 
2822 + - - - 
2878 - + + + 
3309 +/- + + +/- 
3395 + + + + 
3400 - +/- +/- +/- 
3425 - + + - 
3440 +/- + + + 
3442 + + + + 
a: http://www.sanger.ac.uk/resources/downloads/helminths/echinococcusmultilocularis.html. 
b: “+” indicates clear expression, “+/-“ weak expression and “-“ no detectable expression. 
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5.4. NHR signaling – EmHNF4 
5.4.1. Isolation and characterization of the Emhnf4 cDNA and the genomic locus 
As described before the in silico analysis of the E. multilocularis genome identified 17 putative NHR 
(5.3.1), among them a hepatocyte nuclear factor 4-like receptor (EmHNF4). Human HNF4 plays an 
important role in liver development and is a key player in metabolic pathways [128,184]. Since 
E. multilocularis primarily manifests its growth in the human liver, EmHNF4 was characterized in 
more detail. 
Two different transcripts for this gene were identified by RACE experiments: Emhnf4a and Emhnf4b. 
More specifically, the full cDNA sequence of Emhnf4a was amplified from a cDNA library [185] and 
Emhnf4b from cDNA of E. multilocularis J31 activated protoscoleces (see supplement). The full length 
cDNA measured 2299 bp and 1711 bp for Emhnf4a and Emhnf4b, respectively, with the identical 
5’UTR of 39 bp, the identical 3’UTR of 181 bp and an alternate putative polyadanylation signal 
(TATGAA, [186]) 15 bp upstream of the polyA tail. For both isoformes two putative start codons were 
identified (position 19 and 40 of the cDNA sequence). The second start codon displayed a good 
quality Kozak sequence (GxxATGG; [187,188]). Thus the putative coding sequence was selected from 
the second ATG. The resulting open reading frame was 2079 bp for emhnf4a and 1491 bp for 
Emhnf4b which encoded for putative proteins of 692 aa and 496 aa with a theoretical molecular 
mass of 76 kDa and 55 kDa, respectively. Due to limitations in time no further studies have been 
conducted if other putative isoforms of Emhnf4 are present. However, there were first hints, that 
other putative isoforms could be present in metacestode vesicles and primary cells. 
 
 
Fig. 32: Domain structure of EmHNF4a, EmHNF4b and the human HNF4A protein. The in silico analysis using 
SMART predicted a DNA binding domain containing a Zn-finger (ZnF_C4) for all analyzed protein sequences. For 
HsHNF4A (P41235.3) and EmHNF4a also a LBD which is typical for NHR was present. In all three sequences an 
activation motif 2 AF-2 (black arrow) was identified. Lengths of the proteins are indicated on the right. 
 
Domain analysis using SMART (http://smart.embl-heidelberg.de/; [95,96]) displayed the following 
results for the two isoforms EmHNF4a and EmHNF4b (Fig. 32). Both putative proteins reveal the 
presence of a typical C4 zinc finger (ZnF_C4) DBD between residues 221 and 292 which is typical for 
NHRs. However, only EmHNF4a displayed a hormone receptor LBD between residues 355 and 542 
whereas EmHNF4b harbors a truncated LBD, below threshold. Therefore, it was not detectable in 
SMART. This is explained by the fact that the LBD is encoded by exons V – VIII, of which exons VI-VIII 
are absent in EmHNF4b. Moreover, an AF-2 motif (LLGDILL) was identified between residues 585 and 
590 for EmHNF4a and between residues 389 and 394 for EmHNF4b. This AF-2 motif follows the rule 
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ΦΦXaΦΦa/L [189]. However, instead of the acidic glutamic acid it contains the acidic aspartic acid at 
the fourth position within the AF-2 motif, when comparing the E. multilocularis HNF4 isoforms with 
the human HNF4A or sequences from D. melanogaster HNF4 or C. elegans NHR64. 
Several homolog proteins from various species have been identified when the nucleotide sequence 
was subjected to BLASTX [157,158] search against SWISSPROT. The overall identity of EmHNF4a and 
EmHNF4b was 23 %/16 % to the human HNF4A and, 19 %/13 % to D. melanogaster HNF4 and 
17 %/11 % to C. elegans NHR64 (Table 3), respectively. When analysing the DBD of both 
E. multilocularis HNF4 isoforms and the other HNF4 proteins the identity was remarkably high. For 
example, EmHNF4a and EmHNF4b DBD displayed 76.9 %/62.8 % identity to the DBD of HsHNF4A 
(Table 3). The identities within the LBD are overall lower between 9.2 % (LBD EmHNF4b/LBD 
CeNHR64) and 28.2 % (LBD EmHNF4a/LBD HsHNF4A; Table 3). The multiple alignment of the DBD 
and the LBD region of the above analyzed proteins is depicted in Fig. 33 and was obtained from 
MUSCLE for the alignment. In an additional analysis using PSORTII two nuclear localisation signals 
pat4 (RRKH at position 253) and pat7 (PRSRCRR at position 171) have been identified for both 
E. multilocularis HNF4 isoforms. However, no bipartite motif was identified. Furthermore, there were 
no hints for RNA-binding motifs, N-myristoylation patterns, or prenylation motifs. 
 
Table 3: Identity matrix of the two putative EmHNF4 isoforms and other HNF4 proteinsa. 
 
Full coding sequence 
 EmHNF4a EmHNF4b CeNHR64 HsHNF4A DmHNF4 
EmHNF4a ID     
EmHNF4b 70.6 ID    
CeNHR64 17.0 10.8 ID   
HsHNF4A 23.3 15.9 31.1 ID  
DmHNF4 19.2 12.9 20.9 37.0 ID 
DBDb      
 EmHNF4a EmHNF4b CeNHR64 HsHNF4A DmHNF4 
EmHNF4a ID     
EmHNF4b 80.7 ID    
CeNHR64 64.1 51.2 ID   
HsHNF4A 76.9 62.8 71.7 ID  
DmHNF4 73.0 60.2 70.5 92.3 ID 
LBDc      
 EmHNF4a EmHNF4b CeNHR64 HsHNF4A DmHNF4 
EmHNF4a ID     
EmHNF4b 30.2 ID    
CeNHR64 21.7 9.3 ID   
HsHNF4A 28.2 14.7 34.8 ID  
DmHNF4 24.6 10.3 32.7 65.6 ID 
 
a: full length sequence of the different HNF4 proteins (C. elegans NHR64: CeNHR64, O44960.2; D. melanogaster 
HNF4: DmHNF4, P49866.2 and human HNF4A: HsHNF4A, P41235.3); 
b: DNA binding domain of the different HNF4 proteins; 
c: Ligand binding domain of the different HNF4 proteins 
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Fig. 33: Amino acid sequence alignment of EmHNF4a/EmHNF4b DBD and other HNF4 proteins. Shown are 
sequences of EmHNF4a (residues 210 – 549), EmHNF4b (residues 210 – 353), C. elegans NHR64 (CeNHR64; 
O44960.2; residues: 27 - 330), D. melanogaster HNF4 (DmHNF4; P49866.2; residues: 104 - 410), and human 
HNF4A (HsHNF4A, P41235.3; residues: 60 - 355). The threshold for identical amino acid residues, which are 
highlighted in white on black background, is set to 75 %. Similar residues are shaded in grey. The DNA binding 
domain and the LBD domain are indicated by a dotted and black line below the alignment, respectively. The 
conserved C residues of the ZnF-C4 motif are marked by stars. 
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The genomic Emhnf4 locus was analyzed by pairwise alignment of the E. multilocularis genome 
(E_multilocularis_contigs_070110.fa) and the Emhnf4a transcript. The locus spans a region of 10.5 
kb. Within the coding region, 8 introns (length between 43 bp and 4049 bp) with canonical gt-ag 
splice sites were identified and separated 9 exons between 94 bp to 322 bp. Exons VI, VII and VII are 
absent in transcript Emhnf4b. The gene emhnf4 is localized on contig 1702 of the E. multilocularis 
genome assembly (E_multilocularis_contigs_070110.fa). In an earlier assembly 
(M_locularis_contigs_230108) the gene was situated on contigs 3313 and 3314. 
 
A 
 
 
 
B 
 
Exon length (bp) splice donor splice acceptor intron length (bp) amino acid 
    5’UTR (39)  
I 94 ACGgtgagt aagACT 4049 D32 
II 309 AGAgtaagca cagAGA 140 K135 
III 294 CGGgtgggtt tagGCA 2337 G233 
IV 180 CAGgtgag tagCGG 86 A293 
V* 119 GCGgtagatt tagACA 43 A332 
VI* 150 CAGgtattgt tagCTG 75 Q382 
VII* 322 CGGgtaatttt aagGTC 1064 G490 
VIII 309 CAGgtgatt cagGTC 209 G593 
IX 299   3’UTR (181)  
Fig. 34: Chromosomal organisation of the E. multilocularis hnf4 locus. A) The chromosomal region as 
determined in this study is depicted as a grey line. Exons (I–IX) are shown as black boxes with the size of each 
exon (in bp) given above. The dark grey shaded exons are absent in the Emhnf4b transcript. The locations of 
coding regions for DBD and the LBD are indicated by black lines. The bar below represents the scale bar in bp. 
B) Gene structure of Emhnf4. The gene Emhnf4 is localized on contig 1702 of the genome assembly file 
E_multilocularis_contigs_070110.fa. All exon/intron boundaries display canonical gt-ag motifs. Asteriks indicate 
that exons V, VI and VII are alternatively spliced in the Emhnf4b isoform, whereas Emhnf4a contains all IX 
exons. 
 
Taken together, these analyses showed that EmHNF4a is a typical NHR and related to the NR2A1 
family [115]. In mammals HNF4 controls embryogenesis and has a central role in hepatocyte 
differentiation and function [128,190]. The role and function of the E. multilocularis HNF4 proteins 
has to be analyzed in additional studies especially in regard to the AF-2 motif. 
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5.4.2. Expression analysis Emhnf4a and Emhnf4b in Echinococcus larval stages 
The expression of Emhnf4a and Emhnf4b in larval stages was analyzed by semi-quantitative RT-PCR 
[145].Fig. 35 A demonstrates, that Emhnf4a and Emhnf4b transcripts are present in all analysed 
stages: metacestode vesicles, in protoscoleces before (dormant protoscoleces) and after activation 
through pepsin/low-pH treatment protoscoleces (activated protoscoleces) as well as in in vitro 
cultivated primary cells. Emhnf4a is to some extent higher expressed in metacestode vesicles and 
Emhnf4a is least expressed in dormant protoscoleces. Data from the transcriptome profile of Emhnf4 
support these findings, being expressed in all analyzed stages. 
 
 
Fig. 35: Expression analysis of Emhnf4a and Emhnf4b. After isolation of total RNA from in vitro cultivated 
metacestode vesicles (Mc), dormant (Pd) and activated protoscoleces (Pa) as well as in vitro cultivated primary 
cells (Pc) the mRNA was reverse transcribed. Subsequently, the cDNA was subjected to semi-quantitative PCR 
with oligonucleotides specific for Emhnf4a and Emhnf4b. As control the constitutively expressed gene Emelp 
[44] was used. The resulting PCR amplicons were separated on a 1 % agarose gel and stained with ethidium 
bromide. DNA size marker bands are indicated to the left and the right.  
5.4.3. Protein-protein interaction studies of EmHNF4 
NHR receptors are modulated by NHR coactivators or corepressors and also through direct protein-
protein interaction [174,175]. In a first experiment I it was tested whether the DBD of either 
EmHNF4a (EmHNFa-DBD) or EmHNF4b (EmHNF4b-DBD) interact with EmSkip [61] and EmAlien [62]. 
For that translational fusions of EmHNF4a-DBD and EmHNF4b-DBD (Fig. 36) in pGADT7 and pGBKT7 
were constructed. 
 
 
 
Fig. 36: Amino acid comparison of EmHNF4a-DBD and EmHNF4b-DBD. Identical amino acid residues are 
highlighted in white on black background. Variant residues are in black on white background. Amino acid 
residues are given in 1-letter code. 
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In the experiments, no interactions between EmHNF4a-DBD and EmHNF4b-DBD with EmSkip (Fig. 37) 
were observed. Whereas EmHNF4a-DBD did not interact with EmAlien, there was an intermediate 
interaction between EmHNF4b-DBD and EmAlien. Yet other parasite specific co-regulators of NHR 
could be present and need to be identified. 
Moreover, it has been described that members of the Smad family interact with NHR [114,182]. Since 
the translational fusion of EmSmadC and its constitutively activated form EmSmadC* expressed in 
the pGBK positively interact with the empty pGADT7 [58] the translational fusions of all EmHNFa/b-
DBD-constructs in pGADT7 and pGBKT7 were tested in order to exlude false positive results. 
EmHNFa-DBD did not interact with any of the EmSmad proteins (Fig. 37). EmSmadA, EmSmadA*, 
EmSmadB, EmSmadB* [60], EmSmadC [58] and EmSmadC* [58] did not interact with EmHNF4b-DBD 
(Fig. 37). An intermediate protein-protein interaction was detected between EmHNF4b-DBD and 
EmSmadD as well as EmSmadE [176] and also constitutively activated EmSmadE (EmSmadE*) [176] 
(Fig. 37). Again, an E. multilocularis NHR might act together with TGF-β/BMP-signaling in the parasite. 
 
  Fusion with Gal4-DNA binding domain 
  pGBKT7 EmHNF4b-DBD EmHNF4a-DBD 
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pGADT7 - - - 
EmHNF4a-DBD - - - 
EmHNF4b-DBD - - - 
EmNHR1-FL - - - 
EmNHR1-DBD - - - 
EmNHR1-LBD - - - 
EmSkip - - - 
EmAlien - + - 
EmSmadA - - - 
EmSmadB - - - 
EmSmadC - - - 
EmSmadD - + - 
EmSmadE - + - 
EmSmadA* - - - 
EmSmadB* - - - 
EmSmadC* - - - 
EmSmadE* - + - 
     
Fig. 37: EmHNF4a-DBD and EmHNF4b-DBD protein interaction studies with E. multilocularis NHR co-
regulators and EmSmads. Translation fusions were generated for the Gal4-DNA binding domain (BD; vector 
pGBKT7) and the Gal4-activation domain (AD; vector pGADT7) with the EmHNF4a-DBD and EmHNF4b-DBD. 
These were transformed into yeast strain AH109 together with empty vectors (pGADT7, pGBKT7) or with 
different fusions for EmSkip [61], EmAlien [62], EmSmadA, EmSmadB [60] as well as EmSmadC, EmSmadD [58] 
and EmSmadE [176]. An asterisk marks the constitutively active forms of EmSmadA, EmSmadB, EmSmadC 
[58,60] and EmSmadE [176]. Positive control (pGADT7-T x pGBK-53) and negative control (pGADT7-T x pGBK-
Lam) were performed as described in the MATCHMAKER-manual (Clontech). Growth of colonies was assessed 
according to the MATCHMAKER-manual (Clontech). - and + indicate no growth or growth under medium 
stringency. Several independent experiments (n= 3) were performed. 
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5.5. Serum-free cultivation of E. multilocularis 
The standard in vitro cultivation system for E. multilocularis uses hepatoma cell lines as feeder cells 
because these cells secrete host factors which help the parasite to proliferate and to differentiate in 
vitro [47,161]. To exclude direct effects of the feeder cells an axenic cultivation system devoid of 
these feeder cells was established [48]. Noteworthy, the vesicles were grown in medium which was 
preconditioned by RH- and allowed growth for several months. Yet, in this system one cannot study 
the exclusive effect of hormones or other substances and notably serum is still absolutely necessary 
to support larval growth. Therefore, I aimed to develop a defined minimal, serum-free medium for 
the cultivation of E. multilocularis in vitro either in the presence or absence of RH- feeder cells.  
5.5.1. Adaptation of RH- to serum free conditions 
PanserinTM401 is a commercially available serum-free medium and was chosen in these experiments 
in order to establish a defined minimal, serum-free cultivation system for E. multilocularis. First, the 
growth of RH- in PanserinTM401 was analysed. Direct transfer from normal culture medium 
containing 10 % FBS to PanserinTM401 was not satisfying because RH- cells did not attach as firmly to 
the cell culture flask’s bottom as cells which were kept under serum conditions (Fig. 38A-E). Also, the 
formation of cell aggregates (“clumps”) was observed (Fig. 38D, E). Therefore, a second approach 
was chosen: RH- cells were slowly adapted to grow under serum-free conditions with continuously 
reducing the amount of FBS every passage (Fig. 38F-M). In detail, cells from normal medium (DMEM 
10 % FBS) were transferred to PanserinTM401 supplemented with 10 % FBS at 1x106 cells in 50 ml 
volume. After one week cells were transferred to PanserinTM401 containing 5 % FBS (Fig. 38F). 
Subsequently the concentration of FBS was reduced to 1 % followed by 0.5 %. RH- cells grew 
comparable to control cells which were kept in DMEM/10 % FBS (Fig. 38G, H). When FBS was omitted 
(Fig. 38I) RH- still firmly attached on the flask bottom, but grew slower as the control cells (Fig. 38B). 
However, morphology and adherence to the plastic surface were comparable to the control cells. 
After successive passages, RH- cells adapted to the serum-free medium (Fig. 38L) and resumed 
normal growth rate at approximately passage ten (Fig. 38M). 
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A DMEM 10 % FBS, d2 B DMEM 10 % FBS, d3 C DMEM 10 % FBS, d5 
   
D Pan 0 % FBS, d4 E Pan 0%FBS, d7 F Pan 5 % FBS, d3 
   
G Pan 1 % FBS, d2 H Pan 0.5 % FBS, d3 I Pan 0 % FBS, p0, d3 
   
K Pan 0 % FBS, p1, d5 L Pan 0 % FBS, p7, d5 M Pan 0 % FBS, p12, d5 
   
Fig. 38: Adaption of RH- cell line to serum-free PanserinTM401. (A-C) RH- cells were cultured in DMEM/10 % 
FBS as control. (D-E) Direct transfer of 1x106 RH- cells from normal medium to 50 ml serum-free 
PanserinTM401 at day four (D) and day seven (E). (F-M) Successive decrease of serum concentration from 5 % 
FBS (F), 1 % FBS (G), 0.5 % FBS (H) to PanserinTM401 without supplemented serum (I). (L, M) Cells were 
continuously kept in serum-free PanserinTM401. (L) RH- cells adapted to PanserinTM401 after seven weeks 
(passage seven) and after 12 weeks (I). d: day, p: passage, Pan: PanserinTM401. Magnification 10x. 
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5.5.2. Co-cultivation of E. multilocularis under serum-free conditions and in vivo 
passage 
With RH- adapted to serum-free PanserinTM401 I tested whether the usual co-cultivation system for 
E. multilocularis metacestode vesicles [47,161] was to be directly transferred to a new serum-free co-
cultivation system with PanserinTM401 (passage p1). For that, E. multilocularis H95 material was 
isolated from a jird and subjected to in vitro co-cultivation under serum-free conditions. In detail, 
PanserinTM401 and RH- cells which have previously been adapted to serum-free PanserinTM401 have 
been applied with the same parameters as the regular serum-supplemented cell culture (1 ml 
parasite material in 50 ml PanserinTM401 with 1x106 RH- cells). As control the material was grown in 
DMEM/10 % FBS with RH- cells from standard culture (Fig. 39A). Over time, both culture conditions 
successfully proved to support the formation of metacestode vesicles (Fig. 39A-K). However, it was 
obvious that under serum-free conditions the quantity of developing metacestode vesicles was 
reduced and also the volume of these vesicles was smaller (Fig. 39 B, F) compared to the standard co-
cultivation procedure (Fig. 39A, E, I). Nonetheless, material from both cultivation systems has been 
successfully cultured up three months. After this time period still less metacestode vesicles were 
obtained from the serum-free co-culture system. In order to overcome this phenomenon 
metacestode vesicle from serum-free culture were subjected to axenic conditions (see section: 
Axenic cultivation of metacestode vesicles and cultivation of primary cells under serum-free 
conditions) and thereafter were injected into the peritoneum of jirds. Subsequently, after two 
months the animals were sacrificed, E. multilocularis material was isolated and subjected to serum-
free PanserinTM401 RH- co-culture. The developing metacestode vesicles (passage p2; Fig. 39C, G) 
presumably adapted to PanserinTM401 and grew better than the material from the first experiment 
(Fig. 39B). The volume and the quantity of the metacestode vesicles were higher, still less as the 
control co-culture supplemented with serum (Fig. 39A, E). Again, the procedure was repeated and a 
second and third in vivo passage was conducted. Metacestode vesicles from the third (passage p3; 
Fig. 39H) and fourth round (passage p4; Fig. 39K) of co-cultivation in PanserinTM401 reached the same 
volume but never reached the same quantity of vesicles. Nevertheless, a noticeable adaption to 
serum-free co-culture was reached by the means of intercalating multiple in vivo passages. 
Noteworthy is the fact that E. multilocularis material was also grown in PanserinTM401 without any 
feeder cells. However, no formation of metacestode vesicles has been observed (data not shown). 
Moreover, the introduction of insulin (860 nM) to the system did not alter the outcome. This 
suggests that PanserinTM401 does not contain all necessary growth or differentiation factors needed 
for proliferation and differentiation of E. multilocularis metacestodes vesicles and insulin cannot 
compensate the situation. 
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A DMEM 10 % FBS, d8 B Pan, p1, d8 C Pan, p2, d8 
   
D Pan, p3, d8 E DMEM 10 % FBS, d27 F Pan, p1, d27 
   
G Pan, p2, d27 H Pan p3, d27 I DMEM 10 %FBS, d106 
   
K Pan, p4, d106   
 
  
Fig. 39: Co-cultivation of E. multilocularis metacestode vesicles with RH- cells under serum-free conditions. 
E. multilocularis material isolated from a jird was either cultured in DMEM/10 % FBS in the presence of feeder 
cells (A, E, I) or in serum-free PanserinTM401 in the presence of RH- cells (B, F). Images were taken after eight 
days (A, B), 27 days (E,F) and 106 days(I) of cultivation. Following axenic cultivation, the material was 
subjected to in vivo passage. Thereafter, the E. multilocularis material was isolated from a jird and either 
cultured in DMEM/10 % FBS in the presence of feeder cells (A, E) or in serum-free PanserinTM401 in the 
presence of RH- cells (C, G). This procedure was repeated twice (D, H, K). d: day, p: passage of co-cultivation, 
Pan: PanserinTM401. Magnification 2.5x 
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5.5.3. Axenic cultivation of metacestode vesicles and cultivation of primary cells 
under serum-free conditions 
After the serum-free co-culture system had been developed the next step was to establish an axenic 
serum-free cultivation system for E. multilocularis. For that conditioned PanserinTM401 (cPan) was 
produced by RH- seeded at 1x106 cells in 50 ml PanserinTM401 and cultivated for seven days. Axenic 
cultivation was performed as described for the standard method [49]. The pre-conditioned medium 
was supplemented with the reducing agents (BAT, β-mercaptoethanol, L-Cys) under nitrogen 
atmosphere and was replaced with new medium every other day. Two observations which differ 
from the standard axenic culture have been made in this experimental setup. First, residual RH- 
seemed to stick on the metacestode surface. Therefore, it took a longer cultivation period to 
eliminate the feeder cells. The best time point was not determined. Second, the metacestode 
vesicles appeared less turbid and were less robust compared to the standard axenic metacestode 
vesicles (data not shown). These two facts made it difficult to obtain enough material for the 
isolation of primary cells. 
Consequently, the first three attempts to regenerate metacestode vesicles from isolated primary 
cells from axenic, serum-free metacestode vesicles failed (data not shown). The isolated primary cells 
were either cultured in conditioned PanserinTM401 or hydatid fluid from axenic serum-free 
metacestode vesicles under reducing conditions in nitrogen atmosphere. Also the cultivation of the 
primary cells together with RH- feeder cells using PanserinTM401 as medium applying a trans-well 
system did not result in regenerating metacestode vesicles. In a final experiment the double amount 
of axenic metacestode vesicles had been used for primary cell isolation compared to the volume of 
the standard isolation procedure. Subsequent to isolation the primary cells were cultured in 
conditioned PanserinTM401 in the presence or absence of a cocktail of growth factors: 100 nM insulin, 
100 nM aFGF, 10 nM bFGF and 10 µg/ml heparin. The experiment was performed under reducing 
conditions in a nitrogen atmosphere. Half the medium was replaced every other day and new growth 
factors were supplemented. After three weeks of incubation metacestode vesicle-like structures had 
developed under both conditions. There was no difference in the number of formed metacestode 
vesicle-like structures (Fig. 40A, C). Compared to the regeneration of metacestode vesicles from 
primary cells kept under serum-conditions it was obvious that the cells in this experiment also 
attached to the bottom of the plate and formed mini-aggregates (Fig. 40C, D). This effect was more 
visible when the growth factors had been present (Fig. 40D). 
In summary, this is the first time where metacestode vesicle-like structures have formed under 
serum-free conditions. However, improvement of the experimental setup is needed to routinely 
obtain regenerating vesicles under serum-free conditions. 
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A cPan, p1, d21 B cPan, p1, d21  
  
C cPan + stimuli, p1, d21 D cPan + stimuli, p1, d21 
  
Fig. 40: Cultivation of E. multilocularis primary cells under serum-free conditions. Axenic metacestode 
vesicles from serum-free culture were used for primary cell isolation. Subsequent to isolation the primary cells 
were cultured in conditioned PanserinTM401 in the absence (A, B) or presence (C, D) of the growth factors: 
100 nM insulin, 100 nM aFGF, 10 nM bFGF and 10 µg/ml heparin for 21 days. White arrows indicate newly 
formed metacestode vesicle-like structures. Black arrows indicate mini-aggregate formation attached to the 
bottom of the plate. Images were taken after three weeks of incubation. cPan: pre-conditioned 
PanserinTM401, d: day, p: serum-free passage. Magnification 5x 
 
5.5.4. Influence of insulin and serotonin on axenic metacestode vesicles cultured 
in PanserinTM401 
Although a serum-free co-cultivation and an axenic cultivation system was established it was still not 
possible to investigate potential direct effects of selected substances on the growth, proliferation 
and differentiation of E. multilocularis larval stages. In the co-cultivation system the feeder cells 
directly or indirectly influence these processes by the secretion of substances or by cell-cell contact. 
With the usage of the axenic model the secreted host factors from RH- cells possibly change the 
development of E. multilocularis and might alter the response to selected substances. Therefore, 
another set of experiments was performed. Briefly, E. multilocularis material was isolated from 
infected jirds and subjected to standard co-cultivation using DMEM/10 % FBS with RH- feeder cells. 
Once the metacestode vesicles had developed to a diameter of 2-3 mm, the vesicles were 
transferred to axenic conditions in order to eliminate host feeder cells. Subsequently single axenic 
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metacestode vesicles were incubated in a nitrogen atmosphere in 15 ml tubes under various 
conditions. Most importantly PanserinTM401 was chosen for cultivation in comparison to pre-
conditioned PanserinTM401. With this setting I was able to investigate whether host factors from RH- 
cells possibly change the response to selected substances for the first time without the influence of 
serum. 
Initially, the effect of insulin on metacestode growth was analysed. It was described that insulin 
(86 nM) promotes the growth of H95 metacestode vesicles cultured in DMEM/10 % FBS [161,191]. 
However, when grown in cDMEM-1 medium this positive effect was not observed. The volume of the 
metacestode vesicles was less (0.8 ml) than the control metacestode vesicles (1.05 ml) which were 
kept in cDMEM-1 medium [161]. These results have been reproduced in this study (Fig. 41A, B). Here, 
GH09 metacestode vesicles cultured in DMEM/10 % FBS reached a diameter of 4 mm whereas 
vesicles stimulated with insulin (100 nM) had an average diameter of 5 mm after an incubation 
period of five weeks. When the metacestode vesicles were subjected to cDMEM-1 medium in the 
presence or absence of insulin, the positive effect was absent. Under both conditions the vesicles 
had a diameter of 7 mm after five weeks of incubation (Fig. 41A, B). A similar observation was made 
using PanserinTM401 and pre-conditioned PanserinTM401 for cultivation (Fig. 41C-E). On the one hand 
a dose dependent insulin effect on metacestode vesicles cultured in PanserinTM401 was detected. 
The presence of 100 nM insulin (isolate H95) caused only a slight increase in diameter after five 
weeks of incubation (Fig. 41C). However, the presence of 860 nM insulin (isolate GH09) lead to a 
clear increase of vesicle diameter from 6 mm to 8 mm compared to the respective control (Fig. 41D). 
On the other hand, the study revealed that insulin exhibits the opposite effect when the 
metacestode vesicles were grown in pre-conditioned PanserinTM401 (Fig. 41E). As mentioned above 
the same holds true when pre-conditioned cDMEM-1 medium was applied (Fig. 41B, F). Interestingly, 
both PanserinTM401 and pre-conditioned PanserinTM401 lead to a comparable growth; after five 
weeks of incubations the vesicles had a diameter of about 6 mm. In contrast, vesicles cultured in 
DMEM/10 % FBS did not reach the same diameter compared to cDMEM-1; after five weeks of 
incubations the vesicles had a diameter of about 4 mm and 7 mm, respectively.  
Moreover the survival rate of the analysed metacestode vesicles after five weeks of incubation 
reached between 90–100 % when cultured either in pre-conditioned cDMEM-1 (100 %, 100 %) or 
PanserinTM401 (100 %, 90 %) media in the presence or absence of insulin, respectively. In contrast, 
survival rates of metacestode vesicles were reduced (50–80 %) under the regimen of DMEM/10 %FBS 
(50 %; 80 %) or PanserinTM401 (80 %, 70 %) in the presence or absence of insulin, respectively. These 
data are in concordance with previous observations [161]. 
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Fig. 41: Influence of insulin on axenic metacestode vesicles cultured in different media. Single axenic 
metacestode vesicles of the isolate GH09 (A – D) or H95 (E, F) were in vitro cultivated in different media for six 
weeks in the presence of 100 nM(A-C, E) or 860 nM (D, F) insulin. The complete medium (1 ml) was changed 
every other day as well as the growth factors were supplemented. Control vesicles were kept the respective 
medium without insulin. Increase of vesicles diameter was monitored over time. In this experiments (n=1) 10 
vesicles were examined for every particular condition. The mean was calculated and the standard error of the 
mean is indicated. 
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Furthermore the process of brood capsule formation as an important differentiation step towards 
the protoscolex larval stage was examined in this study (Fig. 42). There was a striking difference in 
the percentage of brood capsule formation when comparing none pre-conditioned media 
(DMEM/10 % FBS or PanserinTM401) to pre-conditioned media (cDMEM-1 or cPan). After five weeks 
of incubation 25 % percent of the vesicles which were kept in DMEM/10 %FBS developed brood 
capsules compared to 90 % of the vesicles cultured in cDMEM-1. The difference between 
PanserinTM401 and cPan was even more pronounced: 14.4 % to 90 % (Fig. 42). The presence of insulin 
did not change the outcome. After five weeks of incubation 90 or 100 % of all metacestode vesicles 
developed brood capsules when cultured in cDMEM-1 or cPan, respectively. However, only 40 % or 
none of the metacestode vesicles had developed brood capsules after cultivation in DMEM/ 10 %FBS 
or PanserinTM401, respectively. Interestingly, it seems that the process of building up brood capsule is 
faster in cDMEM-1 conditions compared to cPan irrespective of insulin (Fig. 42 B). Whereas 90 % of 
the metacestode vesicles cultured in cDMEM-1 developed brood capsules only 10 % of the vesicles 
cultured in cPan built up brood capsules after two weeks. 
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Fig. 42: The influence of insulin on the formation of brood capsules in different culture media. Single axenic 
metacestode vesicles of the isolate GH09 were in vitro cultivated in the presence of 100 nM insulin using 
different media for six weeks. In (A) none pre-cultured media: DMEM/ 10 % FBS and PanserinTM401 (Pan) were 
examined whereas in (B) pre-conditioned media cDMEM-1 and PanserinTM401 (cPan) were analyzed. The 
complete medium (1 ml) was changed every other day as well as the growth factors were supplemented. 
Control vesicles were kept the respective medium without insulin. The formation of brood capsules was 
monitored over time. In this experiments (n=1) ten vesicles were examined for every particular condition and 
the percentage of vesicles showing brood capsules is plotted. 
 
The influence of serotonin on the growth of metacestode vesicles was also analysed (Fig. 43). 
Serotonin might play a role in liver regeneration and liver cirrhosis [192-194]. In this experiment 
serotonin negatively influenced the growth of metacestode vesicles under all conditions tested. 
Metacestode vesicles were cultured either in cDMEM-1 or PanserinTM401 in the presence or absence 
of 50 ng/ml serotonin. After six week of incubation control vesicles reached a diameter of 7 mm in 
PanserinTM401 or 9 mm in cDMEM-1 compared to 7 mm and 4 mm under serotonin treatment, 
respectively. 
Unfortunately, the experiment could not be performed with DMEM/10 % FBS or conditioned 
PanserinTM401 due to limited sources of metacestode vesicles. 
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Fig. 43: Influence of serotonin on axenic metacestode vesicle growth cultured in different media. Single 
axenic metacestode vesicles of the isolate H95 were in vitro cultivated in cDMEM-1 (A) or PanserinTM401 (B) 
for six weeks in the presence of 50 ng/ml serotonin. The complete medium (1 ml) was changed every other 
day as well as the growth factors were supplemented. Control vesicles were kept the respective medium 
without serotonin. Increase of vesicles diameter was monitored over time. In this experiments (n=1) Ten 
vesicles were examined for every particular condition. The mean was calculated and the standard error of the 
mean is indicated. 
 
5.5.5. Cultivation of primary cells in serum-free PanserinTM401 
A Pan B Pan + 100 nM insulin 
  
Fig. 44: Serum-free cultivation of primary cells derived from metacestode vesicles cultured in cDMEM-1. The 
regeneration process of axenically cultivated H95 primary cells was monitored for 21 days. Primary cells were 
isolated from metacestode vesicles kept in cDMEM-1. After isolation cells were cultured in PanserinTM401 (A) 
(Pan) or with the addition of 100 nM insulin (B). Half of the medium volume was renewed every other day and 
growth factors were supplemented at concentrations calculated to the entire cultured volume. Developing 
metacestode-like structures are indicated by black arrows. White arrow point at calcium bodies. 
 
As mentioned in the last section, there is a need to analyze the effects of substances on the growth 
and differentiation of E. multilocularis larval stages without the influence of either host cells or 
serum, as both conditions might influence the outcome of the development and differentiation. 
Therefore, I tested if PanserinTM401 alone supports growth of freshly isolated primary cells derived 
from standard axenic culture in serum and host factor-containing cDMEM-1. In detail, freshly isolated 
primary cells of the isolate H95 were incubated for three weeks in PanserinTM401 in the absence or 
presence of 100 nM insulin (Fig. 44) under reducing atmosphere. Compared to the standard protocol 
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for the cultivation of axenic primary cells using cDMEM-1, it was obvious, that the morphology of the 
vesicle-like structures that developed after three weeks was very different. No clear laminar layer 
was formed and it seemed that these structures were rather “dense aggregates” of primary cells, 
than a vesicle composed of an outer laminated and an inner germinal layer with hydatid fluid within 
(Fig. 44). There was no difference in outcome between none stimulated samples (Fig. 44A) compared 
to insulin stimulated samples (Fig. 44B). In this experiment the influence of aFGF, bFGF and serotonin 
was also examined. No clear result was obtained for these substances. There was the impression that 
aFGF and bFGF promoted the development of vesicle-like structures (data not shown). Serotonin 
seemed to have no influence on the regeneration when compared to the control. However, the 
numbers of regenerating vesicle-like structure was not quantified in this experiment. Yet it remains 
unclear if these aggregates were true metacestode vesicles. Because of the atypical morphology this 
experimental setup was not followed up. Noteworthy, due to time constraints the experiments in 
which pre-conditioned PanserinTM401 was used for cultivation of primary cells derived from axenic 
cDMEM-1 metacestode vesicles have not been conducted. 
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5.5.6. Mass spectrometry and Western blot analyses of pre-conditioned 
PanserinTM401 
In a previous study it was reported that RH- cells secrete insulin during in vitro cultivation into the 
medium [195]. The insulin transcript was detected by RT-PCR of isolated mRNA from RH-. With the 
development of the serum-free axenic cultivation system for E. multilocularis the question whether 
RH- secrete certain substances into the medium was re-addressed. In this study I decided to detect 
potentially secreted substances on protein level by means of SDS-PAGE/Western blot analyses. 
According to the manufacturer PanserinTM401 does not contain any insulin. I analysed PanserinTM401 
medium in comparison to pre-conditioned PanserinTM401. First, equal amount of the two different 
media were subjected to SDS-PAGE and proteins were visualized by silver staining (Fig. 45). 
Interestingly a protein band of approximately 55 kDa was present in pre-conditioned PanserinTM401 
but was absent in the PanserinTM401 medium. This protein band was most clearly observed in the 
sample of pre-conditioned PanserinTM401 which was diluted in water (1:10) before. Moreover, a 
protein band of approximately 12 kDa was detected in pre-conditioned PanserinTM401 only. As 
control also DMEM/10 % FBS and cDMEM-1 were analyzed. There was no obvious difference in the 
protein pattern between these two media (Fig. 45). Very prominent in all samples appeared a protein 
band of approximately 60–65 kDa, which supposedly was albumin. 
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Fig. 45: Silver-stained PAA-gel of different media used for the culture of E. multilocularis. Equal amounts of 
none diluted or a 1:10 dilution of PanserinTM401 (Pan), pre-conditioned PanserinTM401 (cPan), DMEM/10 % FBS 
(DMEM/FBS) or pre-conditioned DMEM/10% FBS (cDMEM-1) were applied onto a 12 % PAA-gel. The samples 
were separated by SDS-PAGE followed by silver staining. The white and black arrow mark protein bands of 
approximately 55 kDa and 12 kDa which are present in cPan, respectively. 
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In order to identify the two protein bands a mass spectrometry analyses was conducted in 
cooperation with J. Clos (Bernard-Nocht-Institute). However, the protein of 12 kDa could not be 
excised from the PAA-gel. Thus it could not be analyzed by mass spectrometry. The analyses of the 
55 kDa protein band resulted in one significant hit when the identified peptides where subjected to 
the Mascot platform. The protein of interest was identified as Bos taurus albumin which is according 
to the manufacturer present in PanserinTM401 medium. 
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Fig. 46: Western blot analyses of PanserinTM401 medium and RH- conditioned PanserinTM401. Equal amounts 
a 1:10 dilution of PanserinTM401 (Pan) and pre-conditioned PanserinTM401 (cPan) were applied onto a 12 % 
PAA-gel. The samples were separated by SDS-PAGE followed by western blot analyses using the anti-insulin and 
the anti-Igf antibodies after separation. 
 
Moreover, a western blot analyses was conducted. For that equal volumes of PanserinTM401 and pre-
conditioned PanserinTM401 were separated by SDS-PAGE and blotted onto a nitrocellulose 
membrane. I was interested whether insulin or insulin-like growth factor (Igf) were detectable in 
these two different media. Insulin promotes growth of E. multilocularis. Also insulin-like growth 
factor (Igf) was chosen for analyses. Igf is closely related, but did not promote growth and survival of 
E. multilocularis metacestode vesicles under axenic conditions in vitro [161]. 
All proteins of interest, insulin and Igf were detected by specific antibodies in this analysis in pre-
conditioned PanserinTM401, but unexpectedly also in PanserinTM401. However, these proteins were 
not detected at the expected molecular weight of insulin 12 kDa and Igf 6 kDa. Instead both proteins 
were detected as proteins of approximately 82 kDa molecular weight. This hints that the proteins are 
in complex with albumin. Interestingly, insulin was detected at a higher level in pre-conditioned 
PanserinTM401, suggesting that in vitro cultivated RH- indeed secrete insulin into the medium. 
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5.6. EmMPK3 – a serum-responsive MAPK 
5.6.1. Phosphorylation of EmMPK3 is not induced by serum in metacestode 
vesicles, dormant and activated protoscoleces 
EmMPK3 has been recently described as a third MAPK of E. multilocularis [196]. EmMPK3 is a 
homologue to the Erk7/Erk8 protein family. It was reported that EmMPK3 is serum-responsive [170]. 
This observation was made when freshly isolated primary cells of E. multilocularis were cultured in 
the absence of serum for one day and thereafter stimulated with 10 % serum for 3 h (Fig. 47A; taken 
from [170]). In Western blot analyses a band of approximately 70 kDa was unexpectedly detected 
with a phospho-specific antibody for Erk MAPK. This antibody recognizes the pT-E-pY motif [197], 
which is not only present in EmMPK1, but also in EmMPK3. With this information at hand, I 
performed three other sets of experiments, testing whether EmMPK3 is also serum responsive in 
metacestode vesicles, dormant and activated protoscoleces. 
 
In detail, axenic metacestode vesicles of H95 were kept in DMEM without serum for four days before 
being treated with 10 % FBS for three hours. Protoscoleces of J31 were isolated and either non-
activated or pespsin/low-pH activated according to the standard procedure in the presence or 
absence of 10 % serum. Western blot analyses of these samples were performed after separating 
equal amounts of total protein on acrylamid gel using the anti-Erk1/2 and the anti-phospho- Erk 
antibodies (Fig. 47B). In this experimental setting no signal representing a protein of approximately 
70 kDa was detectable upon stimulation with serum using the phospho-specific antibody for Erk 
MAPK. This suggests that EmMPK3 is not serum-responsive in these analyzed larval stages in contrast 
to the finding that EmMPK3 was serum-responsive in E. multilocularis primary cells [170]. About the 
activation of EmMPK1 it is known that EmMPK1 is phosphorylated in standard in vitro cultured 
metacestode vesicles as well as in dormant and pepsin/low-pH activated protoscoleces [161]. 
Standard in vitro culture medium contains serum. In this study a clear activation of EmMPK1 after 
serum stimulation was detectable with the phospho-specific antibody Erk (Fig. 47B). The activation of 
EmMPK1 under serum stimulation in activated protoscoleces was not as pronounced as in 
metacestode vesicles or dormant protoscoleces (Fig. 47B). This might be explained by the fact that 
the overall protein amount of EmMPK1 is less in activated protoscoles compared to metacestode 
vesicles or dormant protscoleces [161]. Nonetheless a faint protein band using the phospho-specific 
antibody was detectable in the samples of activated protoscoleces (Fig. 47B). Most importantly, with 
this study I demonstrated that EmMPK1 is activated by serum stimulation in metacestode vesicles, 
dormant and activated protoscoleces whereas this observation has not been made in primary cells 
([170];Fig. 47A). 
Taken together, EmMPK3 is serum-responsive in primary cells, but not in metacestode vesicles or 
dormant and activated protoscoleces. However, EmMPK1 activation seems to have to the inverse 
pattern compared to EmMPK3 activation. 
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Fig. 47: Stimulation of Echinococcus primary cells, metacestode vesicles, dormant and activated 
protoscoleces with serum. (A) Freshly isolated primary cells were incubated in medium without serum for 24 h 
and afterwards stimulated with 10 % FBS for 3 h. A Western blot analysis of these cells was realized after 
sample separation on acrylamid gel using the anti-Erk1/2, anti-phospho-Erk and the anti-Em10 antibodies as 
indicated to the left. Figure and figure legends are taken from [170]. (B) Metacestode vesicles (Mc) of H95 were 
kept in DMEM without serum for four days before being treated with 10 % FBS. Protoscoleces of J31 were 
isolated and either non-activated (Pd) or pepsin/low-pH activated (Pa) following the standard procedure in the 
presence or absence of serum. A Western blot analysis of these samples was performed after separating equal 
amounts of total protein on acrylamid gel using the anti-Erk1/2 and the anti-phospho-Erk antibodies as 
indicated on the bottom. 
5.6.2. Expression analysis of Emmpk3 
The expression of Emmpk3 in larval stages with and without serum stimulation was analyzed by 
semi-quantitative RT-PCR [145] (Fig. 48A). Emmpk3 is higher expressed in the activated protoscoleces 
and least expressed in dormant protoscoleces and metacestode vesicles under both conditions. 
When comparing serum-treated and non-treated samples, the expression of Emmpk3 is clearly 
enhanced in primary cells in the presence of serum. Metacestode vesicles and activated 
protoscoleces do not show differences in expression level compared to the non-stimulated samples. 
But it seems that the expression is slightly down-regulated when dormant protoscoleces are serum-
treated. Data from the transcriptome profile of Emmpk3 showed that the relative expression level of 
Emmpk3 was the highest in activated protoscoleces which was set to 100 % (Fig. 48B) followed by 
primary cells with 90 % expression. Least expression was detected in in vitro cultivated metacestode 
vesicles (4.7 %). The dataset was generated from material kept under serum conditions. Thus, one 
must compare transcriptome analysis with the expression of Emmpk3 under serum stimulation. Yet, 
the material was not treated exactly alike, as the samples of the semi-quantitiviv RT-PCR analysis 
have been starved before serum stimulation and samples from the transcriptome analysis have not. 
Nevertheless, expression of Emmpk3 in serum-treated samples was the highest in activated 
protoscoleces and primary cells. This is in accordance with the transcriptome dataset. 
In summary, Emmpk3 is highest expressed in activated protoscoleces, but expression of Emmpk3 is 
up-regulated in primary cells upon serum-stimulation. 
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Fig. 48: Expression analysis of Emmpk3 in the presence and absence of 10 % serum in Echinococcus. (A) 
Axenic metacestode vesicles were cultured in DMEM without FBS for four days and then stimulated with 10 % 
FBS for 3 h. Protoscoleces were isolated with the standard method in the presence and absence of 10 % FBS in 
the medium. Dormant protoscoleces were activated (by low pH/pepsin treatment) either in the presence or 
absence of 10 % serum. Freshly isolated primary cells were subjected to DMEM without FBS for 24 h and 
thereafter stimulated with 10 % FBS for 3 h. Subsequently, RNA was isolated and reverse transcribed. Serial 
dilutions of cDNA were subjected to PCR with oligonucleotides specific for Emmpk3. As control the 
constitutively expressed gene Emelp [44] was used. The resulting PCR amplicons were separated on a 1 % 
agarose gel and stained with ethidium bromide. DNA size marker bands are indicated to the left. (B) 
Expression of Emmpk3 from transcriptome profiling analysis. Normalized relative gene expression is given, 
with the highest expression set to 100 %. Mc: metacestode vesicles, Pd: dormant protoscoleces, Pa: activated 
protoscoleces, Pc: primary cells. 
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6. Discussion 
 
Parasitic helminths share a large degree of common genetic heritage with their various vertebrate or 
non-vertebrate hosts. This includes basic cellular functions, proteins and also conserved cell-cell-
communication mechanisms which involve small peptide cytokines and lipophilic/steroid hormones. 
In vitro studies have proven that serum as a supplement is crucial for the development of 
E. multilocularis larvae, most probably because it contains signals that are essential for the 
development and the survival of the parasite [20,46,47]. In the present work the role of FGF signaling 
via the transmembrane receptor EmFR and the function of lipophilic/steroid hormones signaling via 
EmNHRs for the development of E. multilocularis were the major points of interest. Understanding 
these conserved signaling mechanisms is important to develop new strategies in order to combat 
helminth diseases. Such studies might also be facilitated if a serum-free in vitro cultivation system for 
E. multilocularis was available to exclude effects from substances present in the serum. Therefore, I 
also investigated the feasibility of a defined minimal medium for E. multilocularis. 
6.1. FGFR signaling - EmFR 
In metazoans, signaling via transmembrane receptor kinases is an evolutionary conserved 
mechanism. For E. multilocularis interactions between parasite receptor kinases and corresponding 
host cytokines have been identified for various pathways. For example, molecular mechanisms 
involved include the EGF, the insulin, and the TGF-β/BMP pathways [20,55,56,170,176,195]. In the 
present work, I studied the FGF-FGFR pathway of E. multilocularis and whether this pathway is 
important for the development of the parasite. FGFs and their specific receptors build up a complex 
family of signaling molecules and contribute to angiogenesis, cellular differentiation and tissue-injury 
repair [65]. Previous work on E. multilocularis larvae indicated that the FGF signaling pathway might 
be involved in proliferative processes since host FGF stimulated metacestode growth when 
exogenously added to in vitro cultivated vesicles. Furthermore, an E. multilocularis FGFR ortholog, 
EmFR, was characterized at the molecular genetic level and was shown to encode a tyrosine kinase 
with a single extracellular Ig-like domain, instead of two or three Ig domains as it is usually the case 
for vertebrate and invertebrate FGFRs. This particular domain is critical for sensing and binding the 
specific FGF ligands [63,64]. 
Due to the availability of the first draft of the E. multilocularis genome sequencing project [198,199], 
the situation of FGF signaling in this parasite could, in this work, be approached from a genomic 
perspective. These analyses first confirmed the unusual structure of the E. multilocularis FGFR since 
upstream of the so far characterized, single Ig-domain (determined according to cDNA 5’ RACE data, 
[94]), no further Ig-domain encoding sequences were found. Furthermore, apart from EmFR no other 
FGFR-like tyrosine kinase is encoded by the E. multilocularis genome. Hence, despite its 
biochemically unusual structure in the extracellular domain, EmFR was indeed the likeliest candidate 
to mediate effects of host FGF on the parasite and thus chosen for further analyses. 
Next, I was interested whether EmFR, despite the unusual extracellular structure, is principally able 
to sense host FGFs. To this end, EmFR was first functionally expressed in HEK293T cells. However, in 
this system the receptor was constitutively active, indicated by phosphorylation of the double 
tyrosine motif corresponding to the human FGFR1 pYpY653/654 residues, even in the absence of 
exogenously added FGF. HEK293 cells might express and secrete intrinsic FGFs [200] which could 
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activate the cestode receptor causing the phosphorylation. Thus, additional functional analyses were 
carried out using the model system of Xenopus oocytes in which EmFR and the dead-box kinase, 
EmFR TkD-, were expressed. In this system GVBD is used as read out and it only occurs if active 
signaling via the MAPK cascade takes place mediated by heterologously expressed kinase receptors 
[201]. In these experiments, both exogenously added human aFGF and bFGF induced GVBD in a 
dose-dependent manner when wild-type EmFR was heterologously expressed, but no GVBD was 
observed upon expression of a kinase-dead EmFR mutant. Furthermore, EmFR, but not the dead-box 
kinase mutant, was phosphorylated at a conserved motif in the presence of human FGFs. These 
results clearly indicated that EmFR, despite its unusual extracellular domain, is capable of sensing 
human FGFs and that it undergoes autophosphorylation in a manner typical for FGFRs. Furthermore, 
these results also indicated that at least in this heterologous system, activated EmFR is able to 
transmit signals to the Erk-like MAPK cascade module since GVBD in Xenopus oocytes strongly 
depends on the activation of this module [156,169].  
Having had established that EmFR is a functional kinase capable of sensing human aFGF and bFGF, 
the study was extended to in vitro analyses using different E. multilocularis larval stages. I wanted to 
examine the effect of human FGFs on E. multilocularis parasites in vitro mainly focusing on growth 
and differentiation processes. First, E. multilocularis metacestode vesicles and primary cells were 
cultured in the presence of BrdU and stimulated with either aFGF or bFGF. By measuring BrdU 
incorporation into the DNA it was demonstrated that the host cytokines, aFGF and bFGF, promoted 
proliferation. A higher de novo DNA synthesis rate was detected for metacestode vesicles as well as 
for regenerating primary cells upon FGF stimulation. These findings support earlier observations that 
stimulation with either aFGF or bFGF result in increased metacestode vesicle volume over time [94]. 
Another line of evidence supporting the proliferative effect of FGFs comes from experiments in 
which regenerating primary cells were cultured with FGFs. Compared to control samples significantly 
higher numbers of metacestode vesicles developing from primary cells have been detected in the 
presence of aFGF and bFGF. This finding was even more pronounced when heparin was introduced 
to the system. It is known that heparin or heparan sulfate proteoglycans interact with FGFs and are 
needed to activate FGFRs effectively [69,202]. Taken together, these data clearly indicated that host-
derived FGFs are able to promote parasite proliferation and development in vitro. 
The only cell type of free-living and parasitic flatworms that is able to undergo mitosis are neoblasts 
(totipotent stem cells that are also called germinal cells or germinative cells; [150]) and previous 
investigations already showed that Echinococcus primary cell cultures are strongly enriched in this 
type of cells [49]. Since exogenously added FGFs significantly induced BrdU incorporation in primary 
cell cultures (as well as metacestode vesicles) it is reasonable to assume that this is due to a direct 
stimulation of neoblast proliferation by host cytokines. Interestingly, previous investigations on the 
regeneration capacity of planarians already indicated that in these organisms the FGFRs are 
expressed in neoblasts and control stem cell differentiation and growth [82]. Hence, similar to the 
situation in the free-living ancestors of cestodes, EmFR might be expressed in the Echinococcus stem 
cell population and activate the parasite’s Erk-like MAPK cascade module, leading to enhanced 
proliferation and subsequent differentiation. This hypothesis is further supported by findings of this 
and a previous study [94] which indicate that the Echinococcus Erk-like MAPK module is stimulated in 
metacestode vesicles upon exogenous addition of host FGF, leading to phosphorylation and thereby 
activation of the Erk-like MAPK EmMPK1 [55]. This study now could show that the same holds true 
for primary cells. Upon stimulation with exogenous host FGF the Erk-like MAPK EmMPK1 is activated. 
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This process is very likely mediated through EmFR, because EmNDK, the other FGFR-like molecule 
identified in this study, does not possess a tyrosine kinase domain. It is also unclear whether NDK-like 
proteins bind canonical FGFs. Therefore, EmNDK most likely will not be able to transduce signals to 
downstream MAPK modules. 
To further investigate the role of EmFR in Echinococcus development and to assess whether FGF 
signaling pathways might be promising for the development of novel chemotherapeutics against AE, 
studies using the tyrosine kinase inhibitor BIBF 1120 (VargatefTM) were performed. BIBF 1120 is a 
small molecule compound originally designed to bind to human FGFRs [203]. It has been shown to 
effectively inhibit human FGFR1-3 as well as the FGFR-related receptors VEGFR1-3 and PDGFR  and 
 by binding to the ATP-binding site in the cleft of the kinase hinge region [204]. It shows also activity 
against members of the Src family of kinases but displays a lower efficiency with a two- to three-fold 
higher IC50 compared to the above mentioned targets [204]. The compound is well tolerated by 
human cancer patients and shows low cross-reactivity in the human kinome [203,204]. Since the 
E. multilocularis genome only harbors the gene for one FGFR homologue, EmFR, but no genes for 
PDGF- or VEGF-like receptors the inhibitor might mainly block FGF-EmFR signaling. Therefore, 
BIBF1120 was chosen in this study. 
In a first set of experiments, the effect of BIBF 1120 on the activity of EmFR in the Xenopus GVBD 
assay system was studied. Although slightly less active than against the human FGFR, BIBF 1120 could 
effectively inhibit GVBD in EmFR-transgene oocytes upon stimulation with aFGF and bFGF. Hence, 
BIBF 1120 should not only be of use to study the role of EmFR in Echinococcus development, but can 
also act as a lead substance for the identification of drugs that display higher activity against EmFR 
and lower affinities against human FGFRs and related kinases. When tested in in vitro cultivation 
systems for Echinococcus larvae, BIBF1120 displayed remarkable activity against metacestode 
vesicles and effectively inhibited the regeneration process of primary cells. These results sustain the 
assumption that FGF-EmFR signaling contributes to E. multilocularis development as the block of the 
signaling cascade has significant impact on these two larval stages. 
Especially stem cells of the parasite seem to be influenced by these signaling mechanisms because 
the regeneration processes was also blocked when primary cells were taken from E. multilocularis 
metacestode vesicles pre-treated with sub-lethal dosages of BIBF1120. Mechanistically BIBF1120 first 
seems to affect proliferating stem cells, probably killing them, before the complex structure of the 
metacestode vesicle breaks down. Primary cells isolated from such vesicles might contain lower 
numbers of functional stem cells, leading to a significantly reduced regeneration capacity. 
Interestingly, FGFs or heparin significantly increased numbers of vesicles developed from these pre-
treated cells. This implies that by triggering the FGF-EmFR signaling pathway, residual stem cells are 
stimulated to proliferate and subsequently differentiate toward metacestode vesicles.  
Next, I wanted to assess whether the negative effect of BIBF1120 on metacestode vesicles and 
primary cells can be correlated with a block of phosphorylation of EmMPK1 upon FGF stimulation. 
This would suggest that the inhibitor indeed interferes with the Erk-MAP-kinase module of the 
parasite. Indeed, in metacestode vesicles and primary cells, the activation of EmMPK1 was clearly 
blocked although the phosphorylation of EmMPK1 was not completely abolished. This might be due 
to several other stimuli present in the serum which might lead to the activation of this particular 
signaling pathway [55]. 
In humans FGF-FGFR signaling triggers not only the RAS-MAP kinase pathway, but also the PIP3K/AKT 
pathway is induced. For example, FGF-2 signaling via FGFR2 activates the AKT pathway protecting 
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human embryonic stem cells from stress-induced cell death [205]. Therefore, I investigated, if the 
putative PIP3K/AKT-like pathway of E. multilocularis might be affected by BIBF1120 treatment. 
However, there was no difference in AKT phosphorylation between BIBF1120 treated and un-treated 
primary cells. Also, host FGFs failed to induce AKT activation in primary cells of E. multilocularis. This 
suggests that in contrast to the human system, FGF-FGFR signaling in E. multilocularis primary cells 
occurs mainly through the MAPK cascade module, but not via PIP3K/AKT signaling. 
 
Until now, the role of FGF-EmFR signaling was only examined in metacestode vesicles and primary 
cells because these stages are relevant for the human cause of disease. Primary cells mimic the early 
phase of infection whereas metacestode vesicles represent later stages of infection [150]. To 
broaden the picture of potential functions of this particular signaling pathway I examined whether 
FGFs and also BIBF1120 might influence the maintenance of activated E. multilocularis protoscoleces, 
particularly.  
Protoscoleces of E. granulosus show the unique capacity of being able to mature into strobilar adult 
stages when ingested by a definitive canid host, but also of ‘dedifferentiating’ into fully developed 
cysts when released into the intermediate host body cavity upon cyst rupture [206]. This capacity 
appears to be also shared by protoscoleces of E. multilocularis [13], which could also routinely be 
observed in in vitro systems where E. multilocularis protoscoleces were incubated with hepatocyte-
conditioned media for longer periods of time (my own observations). In the presence of FGFs there 
was no obvious alteration in morphology compared to un-stimulated control protoscoleces. The 
polarized body with suckers and hooks was clearly visible. However, although FGFs did not change 
the morphology and agility of activated protoscoleces, BIBF1120 did indeed have an impact on this 
larval stage. Under BIBF1120 treatment the distinct polarized body changed over time resulting in 
globular structures. Also, a higher percentage of dead or dying protoscoleces was detected. Thus the 
inhibitor interferes with developmental processes leading to a dedifferentiation. Hence, FGF-FGFR 
signaling possibly contributes to the maintenance of the protoscolex structure. This would support 
the result that FGFs did not change protoscolex morphology over time, but maintain its structural 
integrity. Of course, one can speculate that EmFR was not accessible for the FGFs but for the 
inhibitor. Thus, FGFs did not alter protoscolex morphology in contrast to the inhibitor, which affected 
this larval stage. However, FGFRs can also bind non-canonical ligands like cadherins or other cell 
adhesion molecules which control for example vascular integrity in humans, mesoderm layer 
formation in D. melanogaster or axon maintenance in C. elegans [207-209]. This would also explain 
why FGFs did not induce effects in in vitro cultivated protoscoleces. However BIBF1120 did affect 
protoscoleces as it blocks the signaling via the EmFR receptor regardless of which ligand induces the 
signaling process. The potential importance of FGF-EmFR signaling to maintain and stabilize the 
protoscolex larval structure, is further supported by the finding that the gene Emfr showed highest 
expression in activated protoscolecs, although the transcript is detectable in all intermediate larval 
stages that participate in the infection of the intermediate host. 
Taken together, BIBF1120 was shown to effectively kill metacestode vesicle, to prevent formation of 
vesicles form primary cells and led to the depolarization of protoscoleces. These findings are 
promising and make BIBF1120 and its derivatives interesting drugs on the way to improve AE 
treatment options. BIBF1120 is an indolinone derivative which is thought to bind to the ATP binding 
site in the kinase domain of the receptor, resulting in interference with receptor dimerization and 
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blockage of signaling [203,204]. Structural analysis of the catalytic domain of EmFR and comparison 
with human homologues could be helpful in order to identify EmFR-specific inhibitors. 
 
To complement the in vitro experiments I conducted bioinformatic analyses to identify further 
potential components of the FGF-EmFR signaling cascade of E. multilocularis. The Ras-Raf-MAPK 
pathway is well characterized in E. multilocularis [161]. However, molecules homolog to the 
fibroblast growth factor receptor substrate 2 (FRS2) which is usually associated with the human 
receptors and triggering the activation to the cytoplasmic signal transduction pathway could not be 
identified by means of these computational approaches. This might be due to the fact that putative 
Echinococcus FRS2 is not well conserved and therefore not detectable by homology searches. FRS 
adaptor proteins usually link vertebrate FGFRs to Grb2 and subsequently via SOS to Ras [70]. 
However, C. elegans FGFR signaling can also occur independently of the multi-substrate adaptor FRS2 
[210]. That is why I investigated whether EmFR possibly interacts directly with the down-stream 
MAPK cascade components, for example EmRas or EmRaf. However, no such direct interactions 
between EmFR and the ERK-MAPK components have been identified in the yeast-two hybrid 
experiments. Thus future studies are needed to examine the exact molecular mechanism of FGF-
EmFR signaling and its respective signaling components. 
Another highly interesting question in this context is whether E. multilocularis does not only express 
factors for the detection of host-derived FGF-ligands, but also FGF-like molecules itself. Along with 
FGFRs, such ligands are expressed by organisms of all major metazoan lineages from chordates to 
insects, nematodes and even cnidarians [64,211,212]. Sequence conservation between these factors, 
e.g. human FGF and FGF-ligands of cnidarians, are usually high enough to identify respective 
molecules by BLAST searches. When I used human, insect, nematode and cnidarians FGF-ligand 
sequences in searches on the Echinococcus genome sequence, however, no significant match was 
found. In contrast to the co-evolution of FGF-FGFRs which has lead to an increased ligand-receptor 
specificity in vertebrates [64] this might not apply to the parasite’s FGF-FGFR signaling system. One 
might speculate that Echinococcus and other flatworms (like Planarians) have lost their FGF encoding 
genes over time. But FGFRs might have been under positive selection because signaling via integrin 
or cadherin receptors occurred [207-209]. To this end the complex structure of the multiple Ig-
domains was no longer needed and lost. However, when Echinococcus and other flatworms 
encountered their mammalian hosts, FGFs ligands of host origin came in contact with the parasite’s 
FGFR molecules which were then capable to sense these peptides. For Echinococcus it is likely that 
host FGFs are available, especially in the early phase of infection. Echinococcus induces liver damage 
[213] and FGFs counteract this damage by orchestrating liver regeneration processes. [214,215]. 
Thus, the parasite might sense signals of the host which could regulate parasite development. This 
hypothesis could also apply to parasitic trematodes because the FGFR-like molecule of schistosomes 
also depicts a similar domain structure compared to the Echinococcus EmFR, and canonical FGF-like 
ligands have not been identified either (Brehm, personal communication). 
 
In conclusion, the presented data demonstrate that host-parasite hormonal cross-communication in 
the case of FGF-FGFR signaling take places and is an important mechanism for the development of 
the parasite. Thereby host FGFs influence proliferation and differentiation of the parasite in vitro. 
The parasite expresses one FGFR which is able to sense these host peptides. Stimulation with host 
FGFs activates the parasite’s Erk-like MAPK, very likely mediated by EmFR. In vivo, host and parasite 
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are in close contact, as metacestode tissue grows infiltratively inside the liver of the host and induces 
liver damage [213]. Thereby host FGFs are secreted to induce liver regeneraton and therefore should 
also be able to bind to the surface of the parasite’s FGFR. Thus, FGF-EmFR signaling should occur and 
most likely is important for the early phase of metacestode establishment, for the proliferation and 
maintenance of metacestode vesicles as well as for the survival of protoscoleces at a later time point 
of infection. Nevertheless, future studies are needed to identify all components of the FGF-EmFR 
signaling pathway. This together with additional siRNA screens [147] could help to understand the 
various functions of the pathway for E. multilocularis development. Moreover, this study clearly 
indicates that EmFR can be considered an interesting drug target since intervention with the small 
molecule inhibitor BIBF1120 caused parasite death. In the future EmFR-specific inhibitors should be 
developed to minimize side effects in individuals who are treated against AE. 
6.2. NHR signaling – EmNHR1, EmHNF4 and other putative EmNHRs 
Serum is essential for the development of E. multilocularis because it contains peptide hormones like 
insulin, EGF, or TGF-β. These substances provide essential signals for the development and the 
survival of the parasite [20,46,47]. Also lipophilic/steroid hormones are present in serum and fulfill 
important functions for differentiation and homeostasis [98,216,217]. Lipophilic/steroid hormones 
are usually sensed by NHRs which form a superfamily of phylogenetically related proteins. They are 
essential in development, differentiation and homeostasis [97]. While in the parasitic trematode 
S. mansoni 21 members of NHRs have been identified [104,105], little was known about the presence 
of NHRs and their potential role in developmental processes for the cestode E. multilocularis 
[62,178]. In theory, the E. multilocularis should also be capable to react to lipophilic host hormones 
and therefore I assessed the role of NHRs in parasite development. 
In a bioinformatic analysis based on the genome and the transcriptome data available for 
E. multilocularis I was able to identify a set of 17 E. multilocularis NHRs. These putative receptors 
partly cover the set of trematode S. mansoni and S. japonicum NHRs. For 11 Echinococcus NHRs high 
similarities within the DBD and the LBD to the respective orthologous factors in schistosomes were 
found. This indicates similar structure and function relationships of these receptors between the 
species. For the Echinococcus NHR which is encoded on contig 2891, no prediction of a LBD was 
possible. However, neither a LBD was predicted for the longest available EST sequence of the closest 
S. mansoni ortholog, SmHR96b, again indicating similar structure and function of NHRs. Yet 
prominent differences have been detected between the sets of NHRs of E. multilocularis and 
schistosomes. No clear SmRXR ortholog was predicted in the E. multilocularis genome. Instead, one 
Echinococcus gene with homologies to the SmRXR2 in the LBD but not in the DBD was identified. 
Whether this NHR is capable to undergo heterodimer-formation with other Echinococcus NHRs, as 
typical for this type of receptors, remains to be established. In addition only one ortholog in 
Echinococcus was identified to the closely related SmTLL, SmDSF and SmPNR receptors as well as for 
the SmTRa, SmTRb and SmRAR-like receptors, indicating again differences in NHR signaling between 
cestodes and trematodes. This is emphasized by the fact that E. multilocularis has at least two 
receptors showing no homology to the NHR set of schistosomes (contigs 2878 and 3395). One of 
them is EmNHR1 (contig 3395) the sequence of which has been identified previously by the analysis 
of a cDNA library of trans-spliced Echinococcus genes [62]. With the dataset of the putative NHRs at 
hand, the expression of the genes was investigated based on the transcriptome dataset. It seems 
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that most of the receptors are constitutively expressed in the larval stages which were included in 
the dataset. However, one receptor shows preferential expression in the protoscolex whereas 
another lacks expression in metacestode vesicles. Noteworthy, for two predicted receptors no 
significant expression was observed in the analyzed larval stages. This either could mean that these 
putative receptors are pseudogenes or they might be expressed in adult worms, for which no 
transcriptional data was available. Thus, on the one hand validation of the transcriptome data is 
needed either by my means of microarrays or quantitative real-time PCR and on the other hand 
there is strong need to obtain transcriptome data from all E. multilocularis developmental stages, like 
the adult worm or the oncosphere. 
Noteworthy, the identification of ‘estrogen receptors’ (a and b isoforms) and an ‘androgen receptor’, 
which are all members of the NHR family, in the cestode T. crassiceps has been claimed [143]. 
Recently, the same group also reported on the presence of a ‘progesterone receptor’ in T. solium 
that apparently displayed high homologies to vertebrate members of the progesterone receptor 
subfamily of NRs [218]. However, none of these studies presented the actual sequences of the 
cestode NHRs. Instead, primers specifically designed against the DBDs of murine estrogen, androgen 
and progesterone receptors were employed in PCR amplification from Taenia parasite material, and 
a positive amplicon was taken as evidence that the respective receptors also exist in these cestodes 
[143,218]. My study of the E. multilocularis genome did not discover the presence of such receptors 
[145], nor are NHRs with high homology to vertebrate steroid receptors present in the genomes of 
schistosomes [105] or planarians (Brehm, personal communication). There are two possible 
explanations for these discrepancies. On the one hand, cestodes of the genus Taenia could 
significantly differ from all other flatworms in their set of NHR encoding genes, being equipped with 
additional members that display considerable homologies to vertebrate sex steroid receptors 
(possibly acquired by horizontal gene transfer) [145]. On the other hand, the amplified PCR products 
could have resulted from host contamination that was present in the Taenia parasite material, which 
was directly taken out of mammalian hosts [143,218]. I consider the second explanation likelier, 
which does, of course, not exclude that mammalian sex steroids might interact with one of the 
‘flatworm-typical’ NHRs that were identified in E. multilocularis [145]. 
As already mentioned above, I identified at least two Echinococcus NHRs which do not show 
homologies to the NHRs of schistosomes, one of them EmNHR1. In this study a detailed structural 
analyses of EmNHR1 was conducted because on the one hand the receptor shows high homologies 
to the DAF-12/HR-96 subfamily of NHRs. This family is considered to be an evolutionarily conserved 
receptor group regulating cholesterol homeostasis and longevity in diverse metazoans [216,219,220]. 
Both C. elegans DAF-12 and D. melanogaster HR-96 operate as sentinels for low cholesterol 
concentration [219,220]. E. multilocularis, like all cestodes, is unable to synthesize de novo most of 
their own membrane lipids, including cholesterol, and has to take them up from the host during an 
infection [221,222]. Thus, EmNHR1 might play a role to sense cholesterol concentration thereby 
regulating the cholesterol uptake of E. multilocularis from the host. On the other hand, EmNHR1 is a 
very interesting study object as it is trans-spliced which indicates that the receptor might be involved 
in cell cycle control or growth of the parasite (Brehm, personal communication).  
Cognate ligands of DAF-12 are Δ4 and Δ7 dafachronic acids (Δ4 and Δ7 DA). DAF-12 binds these 
ligands and shifts from its ligand-bound form to a ligand-free form and controls the formation of the 
dauer larval stage once environmental conditions are unfavorable [223,224]. Under harsh 
environmental conditions, the biosynthesis of these ligands is drastically reduced and subsequent 
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signaling pathways lead to the formation of the dauer larval stage [225]. Likewise, HR-96 is described 
to bind cholesterol derivatives sensing cholesterol concentrations. HR-96 is activated when cellular 
cholesterol concentrations drop below a critical threshold in order to protect cells from severe 
cholesterol deprivation [219,226]. In mammals, the Liver X receptors LXRα and LXRβ are the NHRs 
with highest homologies to the DAF-12/HR-96 family and ligands are oxidized cholesterol molecules, 
so called oxysterols which serve as intermediary substrates in steroid hormone and bile-acid 
synthesis [216]. Based on the homologies of the EmNHR1 LBD to the LBDs of those NHRs, it is 
possible that the EmNHR1 ligand is also a cholesterol derivative. First hints of the cognate ligand of 
EmNHR1 come from yeast-two hybrid experiments in which human and bovine serum as well as the 
serum-free medium PanserinTM401, which contains defined lipid components like cholesterol, caused 
EmNHR1 LBD dimers, which NHRs in their active state typically form [109]. The cognate ligand of 
EmNHR1 might either be an Echinococcus-internal ligand that arises from cholesterol metabolism, or 
the actual ligand for this NHR could also be provided by the host. The latter is supported by the fact 
that sera led to the dimerisation of the EmNHR1-LBD. The fact that hydatid fluid also caused EmNHR1 
dimerisation in this yeast-two hybrid approach does not contradict the hypothesis of a host-derived 
ligand for EmNHR1 because the hydatid fluid contains a large number of host serum components 
that are transported into the hydatid fluid by still uncharacterized mechanisms [221,227]. Therefore, 
EmNHR1 could function as a sensor of cholesterol or cholesterol-like substances and thereby could 
regulate gene that are involved in the uptake of such compounds. Nevertheless, the cognate ligand 
of EmNHR1 was not elucidated in this study. Therefore, future are necessary and one could use 
highly sensitive, luciferase-based cellular assays or direct in vitro binding assays on the purified LBD 
of EmNHR1 to identify the cognate ligand of EmNHR1. Substances, like cholesterol, oxysterols, bile 
acids or other cholesterol-derived compounds should be considered as potential ligands and 
therefore should be analyzed. The yeast-two hybrid system applied in this studies has never been 
used to detect similar interactions for complex cholesterol derivatives and probably was not the 
optimal method [145]. Thus, whether EmNHR1 indeed fulfils a similar role in E. multilocularis as DAF-
12 in C. elegans or HR-96 in D. melanogaster still requires further experimentation [145]. Especially, 
with respect to the finding, that E. multilocularis genome also encodes two additional NHRs of which 
the LBDs display homologies to DAF-12/HR-96 and LXRs. The one receptor encoded on contig 2681 is 
a member of the invertebrate-specific 2DBD-NHR family. The other receptor is encoded on 
contig 3309 and harbors homology to the LBD of HR-96, and also, like EmHNR1, shares the CESCKA 
motif in the DBD, which is important for DNA-binding [103]. These two putative NHRs have clear 
homologs in S. mansoni, namely Sm2DBDba and SmHR96a. This highlights that EmNHR1 compared to 
S. mansoni is unique to the cestode E. multilocularis. Nevertheless, based on the homologies in the 
DBD and the LBD, EmNHR1 is a homolog of the DAF-12/HR-96 family. The receptor might have 
evolved by gene duplication, and might therefore fulfill distinct function in E. multilocularis, e.g. 
sensing host-derived ligand to sense environmental stress instead of intrinsic ligands from the 
parasite. 
Concerning the role of EmNHR1 for Echinococcus development, one might speculate about down-
stream target genes. Since EmNHR1 harbors a similar P-box within the DNA recognition helix 
compared to C. elegans DAF-12 and D. melanogaster HR-96 this could impliy that the receptor may 
recognize identical DNA binding half sites, most likely hexameric DR5 direct repeats separated by 
5 bp as it has been described for C. elegans DAF-12 and D. melanogaster HR-96 [123,228,229]. A 
preliminary bioinformatic approach identified similar DR5-like repeats in the promoter region of 
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genes that are encoding a Fyn-like kinase, a pou-domain-like transcription factor as well as for the 
ortholog of the Niemann-Pick disease Type C1 gene (data not shown). The latter is required for sterol 
absorption in the midgut epithelium under control of HR-96 [230]. This points towards the hypothetis 
that like in Drosophila the Echinococcus NPC1 could possibly be regulated by EmNHR1. 
Furthermore, also important for possible down-stream signaling mechanisms of EmNHR1 is the fact 
that this study showed a direct interaction between EmNHR1 DBD and the AR-Smad EmSmadC, 
which is part of the parasite’s TGF-β signaling pathway [58]. Until now no direct interactions between 
DAF-12 and components of the TGF-β signaling pathway have been demonstrated in C. elegans. 
However, it is well established that DAF-12 operates on the convergence of the insulin-like and TGF-
β-like signaling pathways in C. elegans. Particularly DAF-12 acts down-stream of the two respective 
pathways and shifts from its ligand-bound form to a ligand-free form and controls the formation of 
the dauer larval stage once environmental conditions are unfavorable [223,224]. Nevertheless, in 
mammals it has been described that NHRs like the vitamin-D-receptor (VDR) as well as the LXR form 
complexes with AR-Smads (Smad 2/3), however, using the NHR co-activator RAP250 as linking 
protein [231]. Thus cross-communication between NHRs and TGF-β signaling pathways might be 
another conserved mechanism. Although further investigations are needed to unravel the molecular 
details and differences because TGF-β signaling either induces the production of cognate NHR ligands 
or downstream Smad transcription factors, either directly or indirectly, interact with the NHR 
components [145]. Yet the finding that NHRs and TGF-β signaling possibly cross-communicate in 
E. multilocularis is sustained by the fact that the E. multilocularis co-repressor EmSkip also physically 
interacts with EmSmadA and EmSmadB [58,61]. In the human system, SKIP interacts in a ligand-
dependent manner with the heterodimer formed by the VDR and the retinoid-X-receptor (RXR) 
[232]. In my hands I did not find an interaction of EmNHR1 with EmSkip. In fact EmNHR1 is not a 
homolog of either VDR or RXR. Therefore, other co-regulators, not yet identified in E. multilocularis 
are potential candidates which might interact with EmNHR1. 
 
Among the 17 putative NHRs also a HNF4-like receptor was identified. Human HNF4 plays an 
important role in liver development and is a key player in metabolic pathways [128,184]. Endogenous 
bile acids, which are present in liver tissue, are thought to be the cognate ligands for human HNF4 
[233,234]. Also, in Drosophila the HNF4 homolog DmHNF4 possibly binds fatty acids and is activated, 
inducing enzymes that drive fatty acid oxidation for energy production [235]. Echinococcus is 
incapable of synthesizing most of its lipids de novo and fatty acids are known to be important for 
Echinococcus development [221,236]. EmHNF4 was characterized in more detail because it might 
fulfill similar functions as its human homolog. The cognate ligand should be available for the parasite 
because it manifests its growth in the liver of the host. 
I this study two isoforms of EmHNF4, EmHNF4a and EmHNFb, have been identified which possibly 
fulfill distinct functions in E. multilocularis. EmHNF4a shows remarkable homologies to the DBD and 
the LBD of other HNF4 proteins. Therefore, one might speculate that fatty acids might be the cognate 
ligands for EmHNF4a. This hypothesis is supported by the finding that the Arg 226 of the human 
HNF4 alpha which bind the carboxylic acid head group of the fatty acid ion is conserved in EmHNF4a 
(Arg 387) [233]. EmHNF4a is expressed throughout the larval stages which participate during the 
infection of the intermediate host. On the other hand, EmHNF4b does not harbor a complete LBD. 
Yet the DBD is highly conserved between all HNF4 homologs. Due to the structural difference in the 
LBD, one might speculate, that EmHNF4b cannot bind bile acids. EmHNF4b is expressed in all 
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analyzed larval stages, but upregulated in activated protoscoleces. Thus it might influence 
developmental processes of the protoscolex. Moreover, the two isoformes seem to differ in respect 
to their ability to interact with components of the TGF-β/BMP pathway. EmHNF4a does not interact 
with EmSmads, but EmHNF4b interacts with co-smad EmSmadD and the BR-smad EmSmadE. In the 
human cell line HepG2, HNF4 alpha expression is repressed by TGF-β [237]. The exact mechanism is 
not yet clear. There are indications that signaling is mediated via Smads, at least in the murine 
model. The repression of HNF4 by TGF-β was interfered by dominant negative Smad3 [238]. One can 
only speculate whether the same holds true for E. multilocularis or whether this mechanism might be 
one aspect of parasite-host-interaction mediated by host TGF-ß triggering EmHNF4 responses. This 
could be analyzed in further studies by stimulating metacestode vesicles with TGF-β and thereafter 
checking the expression levels of the EmHNF4 isoforms. In conclusion, it appears that there are 
specific regulatory mechanisms on the convergence of NHR signaling and TGF-β/BMP signaling 
pathways in E. multilocularis. On the one hand, EmNHR1 directly interacts with EmSmadC and on the 
other hand EmHNF4b interacts with EmSmadD and EmSmadE. The putative functions of the different 
EmHNF4 isoforms and also the role of NHR-TGF-β/BMP signaling cross-communication must be 
addressed in further studies. Once for example siRNA screens are established a stage dependent 
analysis could facilitate to unravel these aspects [147]. 
Taken together, the data obtained in this study indicate that EmHNF4a might act as classical HNF4 
homolog and thereby sensing bile acids, whereas EmHNF4b might regulate different functions 
mediated by other potential ligands which bind to other distinct parts of the receptor since the 
typical LBD is absent. At least for Xenopus it has been described that a yet unknown protein is able to 
bind to XHNF4 independently of the LBD. This protein is present in Xenopus embryos and inhibits 
HNF4 binding to the DNA [239]. Moreover, one should examine whether the EmHNF isoforms are 
involved in the regulation of lipid or cholesterol metabolism, as human HNF4 binds to a hormone-
response element in the proximal apolipoprotein M promoter and positively regulates the apoM 
gene expression adjacent to the HNF-1alpha-binding site [240]. Such a process could be highly 
relevant for parasite development and survival because it recruits host cholesterol via EmABP [221] 
and thus EmHNF4 could be crucial for the regulation. 
 
To conclude, this is the first comprehensive study on NHR signaling in any cestode. E. multilocularis 
expresses a set of 17 diverse NHRs which partly cover the NHRs of the trematodes S. mansoni and 
S. japonicum. However, the cestode also contains several NHRs encoding genes that are unique to 
the parasite suggesting distinct differences in regulatory mechanisms between the species. There is 
no evidence for an expansion of NHRs which is for example the case in the nematode C. elegans 
[241]. Among the set of Echinococcus NHRs, EmNHR1 is a member of the DAF-12/HR-96 family and 
might be involved in sensing cholesterol. The cognate ligand was present in host serum and induced 
LBD dimerisation. This indicates a putative parasite-host cross-communication mechanism, by which 
at least the parasite senses host hormones. Thereby its development is influenced by the host. 
Moreover, a HNF4 homolog was identified. EmHNF4a might bind fatty acids because the DBD and the 
LBD are highly conserved in comparison to the human homolog. Furthermore, EmNHR1 and 
EmHNF4b both interacted with components of the TGF-β/BMP signaling pathway suggesting a cross-
communication between the two different pathways within the parasite. Based on these findings 
investigations regarding the role of NHR signaling for E. multilocularis development will be greatly 
facilitated. 
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6.3. Serum-free cultivation of E. multilocularis 
In vitro cultivation systems for E. multilocularis larval stages have been developed and constantly 
improved over the past years [49,147-149,161]. Now, it is feasible to culture metacestode vesicles, 
protoscoleces and primary cells either in co-culture with feeder-cells or under axenic conditions in 
the absence of these feeder cells. Yet, for available cultivation systems it is essential to add serum 
which supports growth and survival of the parasite [150,191]. However, a serum-free cultivation 
system using a defined-minimal medium for E. multilocularis might contribute to unravel 
mechanisms of parasite development. It might facilitate studies on how either small peptide 
cytokines or lipophilic/steroid hormones influence the parasite development without side-effect 
caused by the various substances present in serum. 
In this study, a serum-free cultivation method using commercially available serum-free 
PanserinTM401 as medium has been developed. During the experimental procedures it was obvious 
that PanserinTM401 medium supported the development of the parasite but the resulting 
metacestode vesicles were rather fragile and small. The same was observed under serum-free axenic 
conditions. Obviously, sub-optimal growth conditions affect the proper formation of the inner 
cellular layer and the outer laminated layer of the vesicles causing alterations in the development of 
these vesicles. Interestingly, after in vivo passage of metacestode vesicles from PanserinTM401 co-
culture with subsequent axenic adaption, the appearance of metacestode vesicles changed. After 
several in vivo passages the material isolated from the jirds developed into metacestode vesicles 
which reached the same volume and turbidity as material from standard procedures. This noticeable 
adaption to serum-free co-culture suggests that possible mechanisms of selection are occurring. In 
detail, Echinococcus stem cells could be responsible for this observation. When jirds are infected with 
larval metacestode vesicles by intraperitoneal injection, it is believed that stem cells from the 
metacestode vesicles are causing the infection in the animal and subsequently developing into 
metacestode tissue. This mechanism is comparable when the intermediate host ingests infective 
eggs harboring the oncosphere and in this case the oncosphere’s stem cells are the only cells that 
contribute to the formation of the metacestode tissue [20]. Thus, I propose that by in vivo passage 
stem cells from vesicles, which in vitro grew better under serum-free conditions, were selected and 
expanded, which lead to an ameliorated generation and growth of metacestode vesicles in the 
subsequent in vitro passages. This hypothesis is supported by the finding that parasite material which 
was isolated from the liver of a jird and subjected to in vitro cultivation shows enhanced growth in 
the liver of a jird after intraperitoneal injection, compared to material that was isolated from the 
peritoneum of a jird (Hemer, personal communication). The underlying mechanisms such as 
potential genomic or proteomic adaptations still need to be identified in future experiments. 
Because of the difficulties of the above described serum-free cultivation of E. multilocularis, the 
serum-free cultivation system was modified as follows. Prior to the cultivation in PanserinTM401 the 
metacestode vesicles were cultured by means of the established co-culture and axenic culture. 
Thereafter, these vesicles were directly transferred to serum-free medium. This system allows 
analyzing substances that potentially influence the parasite’s development in a serum-free 
environment over a sufficient period of time. First, I investigated whether the mitogenic effect of 
insulin was detectable in this system. Insulin-signaling plays an important role in Echinococcus 
development and host-insulin serves as a mitogenic stimulus inducing proliferation [161,173,195]. 
Insulin exerted a growth promoting effect on metacestode vesicles which however was abolished 
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when the vesicles were kept in conditioned PanserinTM401. Thereby this study confirmed previously 
findings [161] when vesicles were cultured in DMEM supplemented with serum. From that I conclude 
that the effect of insulin is not altered by the presence or absence of serum. However, it is influenced 
by factors secreted from the feeder cells into the medium. One of these factors is insulin itself as 
indicated by Western blot analyses. Insulin, presumably bound to albumin, was detected in non-
conditioned PanserinTM401 but higher amounts of insulin were present in conditioned 
PanserinTM401. This is in contrast to the manufacturer’s statement that PanserinTM401 does not 
contain insulin. However, upon inquiry the company stated that the albumin which is supplemented 
to PanserinTM401 is not tested for purity and therefore could be a source of contamination. Thus, I 
think that insulin is present in PanserinTM401 and albumin serves as carrier for these substances. This 
carrier function of albumin is well known and is even used for therapeutic and diagnostic agents, 
primarily for diagnosing and treating diabetes, cancer and rheumatoid arthritis [242,243]. In contrast, 
to the growth promoting effect of insulin, which was not dependent on serum, the formation of 
brood capsules was strictly dependent on serum and independently of insulin. Thus, serum might 
influence the outcome of differentiation and possibly proliferation processes of E. multilocularis. I 
therefore, suggest implementing this newly developed axenic serum-free cultivation of metacestode 
vesicles as the method of choice, when investigating the role of specific substances for the 
development of E. multilocularis metacestode vesicles. 
6.4. EmMPK3 – a serum-responsive MAPK 
EmMPK3 is a homolog of the Erk7/Erk8 family which in humans plays a role in regulating stress 
responses [244-247]. It was previously shown that EmMPK3 is activated by serum in primary cells of 
E. multilocularis [196]. Since serum is a critical component for the in vitro cultivation of 
E. multilocularis, this study extended experiments to other E. multilocularis larval stages to address 
the question whether EmMPK3 is activated by serum in the larval stages that contribute to the 
infection of the intermediate host.  
To this end metacestode vesicles and protoscoleces, either non-activated or activated, were cultured 
in the presence or absence of serum. There was no evidence that serum induced the 
phosphorylation, hence the activation of EmMPK3 in metacestode vesicles or protoscoleces. Thus, 
the activation of EmMPK3 mediated through serum is confined to Echinococcus primary cells. This 
finding is supported by the Emmpk3 gene expression profile. Although the gene Emmpk3 is 
expressed throughout the different larval stages an upregulation upon stimulation with serum was 
only detected in primary cells. Thus, both on transcriptional as well as on translational levels 
EmMPK3 is induced under serum-conditions. Until now, it remains unclear which component of the 
serum is leading to the observed effects. Nevertheless, these findings indicate that EmMPK3 might 
be important for metabolic processes within regenerating primary cells. In the human system Erk8 is 
activated by serum and has been shown to be associated with Src-kinase activity [245], which is 
another pathway not yet characterized in E. multilocularis. Bioinformatic analysis suggests that 
homologs of Src-kinases are present in the parasite. Therefore, future studies should address the 
specific function of EmMPK3 in primary cells. Moreover, I was able to show that EmMPK1 activation 
by serum seems to be negatively correlated with EmMPK3 activation. There was no change in 
phosphorylation upon serum stimulation in primary cells, but in metacestode vesicles and 
protoscoleces, either dormant or activated. EmMPK1 is associated to support cell growth [170]. 
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These differences in MAPK signaling must be further investigated to clearly understand larval 
development and growth of E. multilocularis. Yet other pathways might influence these processes as 
it has been suggested that also the PIP3K/AKT-like pathway might contribute to the growth of 
primary cells [170]. Overall, these findings show that EmMPK1 and EmMPK3 fulfill distinct functions 
in regard to E. multilocularis development in a stage-dependent manner. 
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7. Supplement 
7.1. Full length cDNA sequence of Emnhr1 (isolate H95) 
>Emnhr1 
caccgttaatcggtccttaccttgcagttttgtatgATTCCTGGTTCATCAATCCTTGAATGACGTCa
CAAAAGCAAGCGCTTCATGCTCAGATGTCTAGTGTGATTCATGACGACCGGCAATGTTTCATGATTCC
ATCAAGTATTGATTGCAGCAGTTGTCCTCCTGGCACGAGTGCACGAAGAAGAGATGAAAAGAAATGTG
CTGTCTGTGGAGATCATGCTGTGGGCTTTAACTTTGGGGCCATTGCCTGCGAGTCATGCAAGGCGTTC
TTCCGTCGTAATGCACTCCGAGCCACCATGCCCCCATGCCTATTCAACGGTAGTTGCTTGATTCAGGT
GAAAACGCGCCGGTTCTGTTCGCCTTGTCGTCTTTCCAAGTGTTTTGCTGTGGGAATGCGCAAGTCTT
GCATCATGGATGAAAAAGCAAAACGAGAACGAAGGGAGAAGATTCAGCGTAATCGGGAGCGAAAAGTT
GCCTCAGGTCAAATTGCCGGCTCTGGTGGGGCAATTGCGCGCTCGAATTCCCCTCCACGGTGTTATCA
AGGCAACTCCTCTCCCAATCCCGACTATCACTCACACTCTCTAGCCCCAGATCCCTCGGCACCTCCGC
ACCATCATCAACAGACACCACCCTCCTACTATCCTTTGATCTCAGCATCTCACCCTGCCACGGCGACT
GAGGCGCTGCCCTCCACTGGCTGTCACAATGCTGTCAACGAGGATTCTGGAATGCGGAGTACTTGGCA
GATGCCTCAAAATCTTCATCAGGATCGCTTACCTACGGTCGAGAGTTCGATACATGCTTATTCTTCCC
ATCATCTACACCAGTCCCATTTGATGACTCCTCCGTCATCTTCCGGGCCTCATCCACCATCCTCGTTT
GGAGGCATGGAGTCCTATTCCCACCCAGCGCAGTCACTTCCTGAGGTACAAGGCGCCTCTGAGGCAAc
ACCCAATGAGGCCTGGTTACAATTGGTGACCTCGTCGAAGGCACTCGAGGAGAATTCCACCACACTAC
CCTATTTTGTTAAGAAGCCAGCAAAGACAGCTCTCACCACCTCTTCGAAATATCCACCCTCTCACGCG
AATGAAGACTCTAAGTCCGGTGTAAAAAATGTCCTTGATGGTCACGTTTGGACACTGGAACCGGAGGA
TCCATCAAACAAGGAGTGTATAGCGCTGTGTCCAGACTTTTTAAAATCGGGAATGGCCCGCCTCCTCT
CGAAGCATCAGTGGACGGCGCTGAACGACCTTCGCAGTGCCTACGAGACGTCCTTTCTCGATTGTGCC
TCCGATCACGCGCCGGAGAGCAGCTCAAATATTACTATAAGTAGTTTGGTGAATACTTCTGGTTTTTT
GGTACGGAAGTTTATAAAtTTCGCAAAGAAGTTGGCCGACTTCTCCGTCCTCGGTCAAGAGGGTCAAA
TTTGTCTACTCAAGGGGGTTGTCTTAAATGCCCTTTTTATCCGCTCCGCCAGTCATTATGATGTTATC
AAGGATGTGTGGGTCACTCCAAAGGGTGAAATACCCACCAGTATACTTAAAATTGCTACAGGAATGCA
AAATCTCTATGAGGAGCACGCCAAGTACTGCAGGAACTTTGCTGATGTTGTTAAAAGGGACTCCCATT
TGGTGGCTCTGATGCAGGTGTTGTGTCTCTTCGCTCCAGATCGTCCTCGCCTTTCCGATCGTCAATCG
GTATCCAATATCTACGACCGTTACATTCTACTGTTGAAGCACTATCTGGAAGCCCGCCACGGTTTCAC
TCGAGGTCGAACTTTATTGGCTGCCGTGTTGACTAATCTGGCGGAGTTACAGGCTCTGACCGACAACT
ATGGTCATATCCTTCTCCACGTCGATCCAAGCAAGGTGGATCCCCTGATCCTTGAAGTGTTCAATCTT
CCGGATCGTAAGAAGGCTAATAAGGATGTGGTGGAGGTGGGATCAGATTCAAGtCCTTTAATTACGGT
TGAGGCAAACACCTCCAATTCTAACATGACTAATTCCTCCTAAACCAGAGATTTCAAAGATGGCACAC
TTGAGAATGATACTCAGACGCACACATCCAACAATTCCACAGAGAATGAGACTATGTCCCAATTTTCC
AGCATAAATATGGTACATATGTTTATCGAGTGATGTCAGTGTCTATATCTTGCCGATTGTAAATAATC
GCTCCACATTTTTGTGTGTGTGTGTGCTTCAGTATTGCTGCGTGTGTCAACTCGCGTTTTGNGTCATC
ACTCACCACACATCCCCCCTTCCCCTCCTCGCTTTTTTAAATCACTGACTTTTGTCTTCTTTTTTGAG
GTGATTTTCTGTAAAGAATTGTGATATGTGTGACTATTCTTTCCTCCTCCTCCTACCCTGCTGCTTCT
AGGTTTACCTCCCGGCCCTCCCCTTTCCCACTTCCCCTTTATTTTTCTGTTTCACTCTGACGTCTACG
CATATTTTGCATTTTAAAGTTGAAGTAGATGTTTCGCTATGAAATAAATATTTTTGGTCCTCTGAAAA
AAAAAAAAAAAAAA 
 
_: Spliced Leader; ATG/TAA: start codon/stop codon; _: polyadenylation site 
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7.2. Full length cDNA sequences of Emhnf4a and Emhnf4b 
>Emhnf4a 
TGAGCCTCCAGAGTAGACATGAATCCACACAACTTTGAAATGGACCTCTACAATAGCAGCAGCGGTGG
CATCACCCAACCACGGCAACATGCACAACAATTCGTGAACACTTCAGGCGAGGAGTTCGAGGACGACT
CCTCCCTCCTCTTGCCAAGTCTCGTCGATACAAATTTTGTGGAGAGTGTTCCTGGAACCGCCTCCTAC
TACAATGGAACTCCCGCAACCAATCAGAATGGTGCATGGCTCACACCCCTCCCAACTTCATGTTCCAT
TGAACCGATACATTCAACCGACGTCTATAGACCCTATCTCCCAGATCAAACGCAGCTGCGATGGGAGA
CTCAGGTTGATCCAAATGTCGCCTACTATGCACCCGTTCTAGAGCCGATTGGATTCACCTGTGCGGAA
ACGTTAATTACCAACCACGAGGAGTATCGAAAGAAGATGAACTCAGAATCAGGAATCGCTGAAGGTGA
GATGCTGACAGCTATTGTCAATGGTGACACCACAGCCAGTGGGTACTCTCAAACCCCTGAGGTGACCT
CTACTCCAAGGTCGCGTTGCCGTCGGGGTTCACAGAATGCCGTAAAGGGAGAGGCCAGCCTGGGGGGA
AGGAATCCCCATCAGGAGGATTCCCTGATGGCCTCTTTTGAAGTCAAAATCGACGACCGACCTCCCTC
GGGTTCTGCCTCTCTATCCATCTCCAACTGTCTTATTTGTGGAGACAAAGCAACGGGCAAACACTACG
GCGCATATTCATGTGACGGGTGTAAgGGATTTTTCCGACGTTCTGTGCGTCGAAAACACACCTACAGT
TGTCGGTACaATCGAACTTGCACAATTGACAAAGACATGCGTAATCAATGCCGTTTTTGCCgGCTGAa
AAAGTGCTTCCGGGTGGGCATGAACCGCGCAGCGGTCCAAAACGAGcGCGATAAAATCAGCaATCGAA
gGCCGTTTTGCGACGCGTCGGgACTGaaTgGCACTctaATCGATATCAGCACTCTACTTAGAGCCGAG
GTTGAATCCAAGGCGACAGCCGAAGGGATTGAGACAAAGGATCTTTCCTCTACTGGACCACTAAGTCT
AGCTGAAATTTGTTCAGCCATGAAAATTCATCTTTTTCGTTTAATCAATTGGGCAAGACAGCTGGATT
GCTTTGTTAATCTGGATATGCAAGATCAGCTGACTTTGCTACGTGGGAACTCGGGGGAAATGCTCCTT
CTAAGCATGGTTTGGCAGGCCATTTGCACGTCATCTCAACAAATCGATGAGGCTGGGACATTTATCAA
CCTCTTTCATCGGTTAAATATCGCGTTTATGGAAGTAATCAAGGCCAGTGGCAGTGGTTGCAATGAAT
TTCCAGCCATGCCTTGTTGCGCTGATGACAGCAAGTTGGATGCTATTCTCAAAGTCATTGCCAATACC
ATTTATCGACCACTGCTGGAGTTGGCGATTGGAGAGACAGAGTTTATTTGCCTCAAGGCAATTATTTT
CTTGAGTGCGGGTCACCTTAACCTATCATCCAATGGTCGCCTCACCGTAGAAGCCTCACGGAGtcGGC
TTCAAATCGAACTAATGAACGTCATGAATGACAACCAATACCTCCCAGAGGGTCGATTCGGGGAGCTG
CTTCTTTTGGTGCCGACACTGCAACGGGTTTCAGGATTTCTTGTGGCCAGGATTGGAAGCGTTGCCAC
TACTTCTGCTGCTGCCGCCGCTGTTGCTGCAGCCAATAGCTCAGCCACGGCAGAGTCAGACGAGACTA
TCAATTCACTTAGACTGGATGATCTCCTGGGGGACATACTACTTTCAGGTCCAATGACCATGTTCGAT
GACCCCCAGGTAGAAACTAATGGCACTGTAGCTGTTCCTTTcGCCTATCTGCCATTCAGTCACAACAG
TCGATACAATGGGAACGGTGATACGATGTCTTGGCAACGCGAAGGACCTGCAAAACAGGGAATAACCA
TGGCTTTCCATCTCCAACCGTTGGCTACTACGTCTACATGTTACTCGCAGCAACAGCAACAAGGACAA
CAGCTCCAGGTTGCTCAAGAATCCATAAATTTCTTTGATAATGCATTCACCTATCAAGAGGACGTTGA
AAAGCAATGAAGGAGAGCCTACTGATGCTTCGACTCCTTCGTGCATTCAATTGGTCGATTTGAAGGTC
AAATTTGCTGCTCCTTTGGATGTGGGGGAGAACTTCTTCCTGCTCAATCACTAAATTATGACAAATGA
CAATGTCTTATGTATTGATTTTAAGTACCTGCATTATGAAGAATGTACGGAAGTA 
 
>Emhnf4b 
TGAGCCTCCAGAGTAGACATGAATCCACACAACTTTGAAATGGACCTCTACAATAGCAGCAGCGGTGG
CATCACCCAACCACGGCAACATGCACAACAATTCGTGAACACTTCAGGCGAGGAGTTCGAGGACGACT
CCTCCCTCCTCTTGCCAAGTCTCGTCGATACAAATTTTGTGGAGAGTGTTCCTGGAACCGCCTCCTAC
TACAATGGAACTCCCGCAACCAATCAGAATGGTGCATGGCTCACACCCCTCCCAACTTCATGTTCCAT
TGAACCGATACATTCAACCGACGTCTATAGACCCTATCTCCCAGATCAAACGCAGCTGCGATGGGAGA
CTCAGGTTGATCCAAATGTCGCCTACTATGCACCCGTTCTAGAGCCGATTGGATTCACCTGTGCGGAA
ACGTTAATTACCAACCACGAGGAGTATCGAAAGAAGATGAACTCAGAATCAGGAATCGCTGAAGGTGA
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GATGCTGACAGCTATTGTCAATGGTGACACCACAGCCAGTGGGTACTCTCAAACCCCTGAGGTGACCT
CTACTCCAAGGTCGCGTTGCCGTCGGGGTTCACAGAATGCCGTAAAGGGAGAGGCCaGCCTGGGGGGA
AGGAATCCCCATCAGGAGGATTCCCTGATGGCCTCTTTTGAAGTCAAAATCGACGACCGACCTCCCTC
GGGTTCTGCCTCTCTATCCATCTCCAACTGTCTTATTTGTGGAGACAAAGCAACGGGCAAACACTACG
GCGCATATTCATGTGACGGGTGTAAGGGGTTTTTCCGACGTTCTGTGCGTCGAAAACACACCTACAGT
TGTCGGTACAATCGAACTTGCACAATTGACAAAGACATGCGTAATCAATGCCGTTTTTGCCGCTGGAA
AAAGTGCTTTCCGGTGGGGCATGGAACCCGCGCAAGTCACCTTAACCTATCATCCAATGGTCGCCTCA
CCGTaGAAGCCTCACGGAGTCGGCTTCAAATCGAACTAATGAACGTCATGAATGACAACCAATACCTC
CCAGAGGGTCGATTCGGGGAGCTGCTTCTTTTGGTGCCGACACTGCAACGGGTTTCAGGATTTCTTGT
GGCCAGGATTGGAAGCGTTGCCACTACTTCTGCTGCTGCCGCCGCTGTTGCTGCAGCCAATAGCTCAG
CCACGGCAGAGTCAGACGAGACTATCAATTCACTTAGACTGGATGATCTCCTGGGGGACATACTACTT
TCAGGTCCAATGACCATGTTCGATGACCCCCAGGTAGAAACTAATGGCACTGTAGCTGTTCCTTTCGC
CTATCTGCCATTCAGTCACAACAGTCGATACAATGGGAACGGTGATACGATGTCTTGGCAACGCGAAG
GACCTGCAAAACAGGGAATAACCATGGCTTTCCATCTCCAACCGTTGGCTACTACGTCTACATGTTAC
TCGCAGCAACAGCAACAAGGACAACAGCTCCAGGTTGCTCAAGAATCCATAAATTTCTTTGATAATGC
ATTCACCTATCAAGAGGACGTTGAAAAGCAATGAAGGAGAGCCTACTGATGCTTCGACTCCTTCGTGC
ATTCAATTGGTCGATTTGAAGGTCAAATTTGCTGCTCCTTTGGATGTGGGGGAGAACTTCTTCCTGCT
CAATCACTAAATTATGACAAATGACAATGTCTTATGTATTGATTTTAAGTACCTGCATTATGAAGAAT
GTACGGAAGTA 
 
ATG/TGA: start codon/stop codon; 
_: polyadenylation site 
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7.3. LBD sequences of E. multilocularis NHRs from in silico analysis 
 
Table 4: LBD sequences of E. multilocularis NHRs  
 
Contig  Amino acid sequence of LBD 
1644 EMASRVLLVTVDWLKRCGPLDQLPSDLQNELIALSWVDLFMLGLCQMFGRRLGNLRMAFFGSN
QDDGCGVDAHPMKSDFNSIVSGFSRAEVTPEEYTYLRYMALFNSGGVRTNDATGLNRVREIEQKV
QVEFAGFLSESESQKVNDDGNQRPFEVQTASRGLQLMGLVCGLRRVT 
 
1680 NVIKSRILDVLSFAKFVPGFLLLSVRDQTRLLQSSLLDILTLRAVEALSRKMARSTINREEDDSESDNQ
SVTASKAYAFIARSADGNSKAIRDLARKVLLWKLDVTELALVASILLTSGNDVSDPGAVVAIETLLTN
VLVSHVMKGNMDGVKLRRLFSMFSEIHSIT 
 
1702 
 
SAMKIHLFRLINWARQLDCFVNLDMQDQLTLLRGNSGEMLLLSMVWQAICTSSQQIDEAGTFINL
FHRLNIAFMEVIKASGSGCNEFPAMPCCADDSKLDAILKVIANTIYRPLLELAIGETEFICLKAIIFLSAG
HLNLSSNGRLTVEASRSRLQIELMNVMNDNQYLPEGRFGELLLLVPTLQRVS 
 
1779 NHFHLHSQQVVQFAKLIPGFNQMSLSARGHLVRasLYSEVLLMLSRDYDAAEDRYNFLDFSPTERD
IVLRHFPIYNRVVEHLRISGRFFQQLNLTHTEFVYVCAIGILRYYYILANPAYTDARKLLLLARHSLLAT
MRSQNESQELVDHKWSRLEAMSEMLSSMSREY 
 
1798 
 
RQLLRTFLQPTTHSSTFQLTPREIARLMSTSWPRVFILEAIEVFLKGQDSKKLISFLAKLCSNGDATDF
DATERIESLTCALTHLQPSTEEFSLLKTLCLFSLGSESASQAEFEHLSSLCDLLHQNLSVYIQACFPTNM
EQKEGLLRCITAIKSIPDEMTCLIRRAFLKVFGCSMENIDRMIERM 
 
1872 
 
QRFEAHAHQIIRFARAIPGFCDLPRADTKFLLQASMYPIVLVQLSREALPGGDFNFYNFSPHERRHL
LAEFPQINPMVDHFYELTGFLGPLNLDNTEAALLCSIIFLRGSNQKLLEAEKIYEIYNHAASALQQYIT
VRYSSDERFTQLIKLLPSLSSMN 
 
 
2122 
 
PAISLHIQSVVEFAKAIPNFVSLAQPDQLALLKAAFPEVWVVQAARTISYPEQTIMLCNGHIICRTEL
DFIYTPQLTCAMFEFAAEFCALNLSDVEIGLFSAILLTKPSRHGLSDSAKVAVMQERFQAALSYQLAE
KHESVSDIMNKLALASSRLAQLSESM 
 
2681 
 
QFVSHTRMVVDFSKLIAGFNRLGINDRRQLIRAAMYPIMLIELSRDFQNNSSLSYNYFDFPEREKEVI
IQRFPPLAKMISHLVQSGKVLRRLKLDDIESTIICIQELLRHKNELEDPASCEHLFLLSMQALVNHEHQ
KSKSDAASERLTAFTQLLPILNQLN 
 
2822 FTSTAAIATHYVRWAKQLPFFNNIHKVDQMALLNDALCDIILLTLSQRLNYGIDLLKLHQHNDGEN
VKLNLRKLYENINQLTTLNLNFVECACLKAMLFFNVGK 
 
2878 TCFDRIMQDSVKFAKRIPGFSDLLPEDRMVLVQSGCFELACVIFSFYVDEESQTFCGPGNFTLSQSQ
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MWLTFPMSKKFVNLLFDFAFQVQSHRLEPLKLGLLLAVLLVTPIREGLTNREEVTWLRDLICQAFRF
QLMVTHSDGVGLFNHLVSSIREELQ 
 
3309 DTCIRRIIRVVKMLPYFNEIGKPAQLGLLRANIYGMIVLYSSFFFEREIRKLRYPVKRADGSLTTVTVS
MLDDLAPSVVSDEKAFSAFLSGKHRHAASAAAAAASLREDFELYKANTLAAFNHLEELTGEDDILR
MTLLAIKLFSDDSLSDELQSVVVSSKRVYLVFLWTYIRWRAGPKHLRQATELFARLHLAFIDLRSLEIR
MTEFAKLVSLEGLSPLMREI 
 
3395 
(EmNHR1) 
NTSGFLVRKFINFAKKLADFSVLGQEGQICLLKGVVLNALFIRSASHYDVIKDVWVTPKGEIPTSILKI
ATGMQNLYEEHAKYCRNFADVVKRDSHLVALMQVLCLFAPDRPRLSDRQSVSNIYDRYILLLKHYL
EARHGFTRGRTLLAAVLTNLAELQALT 
 
3400 SMLEDCLFHMVDWVNRTEIFRVIRVEDKMQLLYSSWSEVIVIEFLQCVILNLRTEDRSDIMKAGAG
SPREPSNRDLHYLVKELMEYLLPPDDENQRIRDLIARFNALNLSSHEFTCLKFLVIFNPYKHDVNLTSS
LEYVREVQADLCHFLLRAARRAIKQRPLPPPTFPTFPTHAASTLATIAASERLGRLLSHLTEVKHVA 
 
3425 
 
GESVEVIRQYADLVPGFSSLPEADREKIILLHSADLITFRMAFRTAKAAAERAQLNLIHPNTSQPNAY
FRSSTSADVSRTQQQTSTIMQHQQTGPFQSVENLSAWHTQPASLESSFRPFPHTPPLTPPPPSSW
LRGGSGGSVPRPANFEAEEEEGNITAWELALSTPTEPVYIFENGSIMTDEELIRAGLGSWIRALTWF
GWQLLELAMGDHSTIAGLSALVLINYQALSGRSDLENSSDIYTVHHRFVEMLKSHCCSPTSAVAIPT
GYPGCYVPEVDPAAATVATAATTTTMVPPARADSTYFSQVFKKKDTVHWIASQLLL 
 
3440 
 
TDIQESIINLLLWSQKIPLFSDFSDSDRFILLRAGCIELLLVHFISRLANSLTESHSPTSLRSSNPPLQESS
TSTSVTPIESTTTPPTPLNIPFVVVDVLFPFHSAPKDILFSQQAECDLRNADRWHESRVLMNILPVDV
DHHPISITGVPNELNAQCLSRRLILCRLFDLARLFKRLCLSVEAVGCLRMVILFNPDVPDLTEATRERV
ESRRDEAFICLEHTFLKADKKTALGRMAQMCLHLADLSFVA 
 
3442 NLADQRLYRIVRWSRALPVFSNLDTDDQILLLQNCWADLLCLDCCWKSLPTPTEIRLTSTKCINLDA
AREMGAEGLVDSLLRLTQDLKRLRFGLIDFACLKVFLLMQGDLTNLKAVRQVKQFQECVSQLLMD
YNSTSCADVPDKFTELLVRIPELQRTS 
 
A: For each NR, the encoding contig is depicted and the amino acid sequence of the LBD from N- to C-
Terminus.  
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7.4. Putative amino acid sequence of EmNDK 
MGSVSITASANVPVVGSHNRQVSLHVGDHLLLECPIWGSNEGPVHSEGESQPTSFLDGSLMNNVIYQWNIQGLPE 
YAVAMDTRFRFLEGGRVVELTQPVTKSDAGIYQCSGVTGFGQKKVDFEVHVAVLCLMNPNLRPDTIMTTEAELGS 
AIDLSCEAIGREPIKYLWFMGNAVADWISSSQGVRGPILHIERVGREHIGQYVCQVKNPIGTLNYTYRLTVKEPPSAIP 
RIIGEVENQTLIAGSSGVLTCRVKCSCSEPIIQWLKHVDPEDIDAYKAAGRSLVPLPAPRPAEAEEFYLALEKWEDAPA 
YMERTVVQLHRTTSITATAAAAGEITVPEREFLSSRHEGEAEERLFVSRLRLRGPVSVPLHAGKYVVMTMSRSNLKAI 
DYAVAYVHIVPKSFNVTVHNIMVYCVVPIALILLIAFVSLYCFLSRRNKDLEHPATRRGNVIFPPVVRGHSMSGVKKEY 
RPIVRQTPQSSVFSNGNTVSNGSKTSSRLPSYVAHSSPSQWNAATATASITSPSPHSNSFHNFQSHVSQPPTQLSPS 
PSTFYNYSGLQSLSNQPTYWHPPAPSVATETSFDQYSAIMGNPPSASGGLSVSHSASSSQRPQLSFPNVMGSVSITA 
SANVPVVGSHNRQVSLHVGDHLLLECPIWGSNEGPVHSEGESQPTSFLDGSLMNNVIYQWNIQGLPEYAVAMDT 
RFRFLEGGRVVELTQPVTKSDAGIYQCSGVTGFGQKKVDFEVHVAVLCLMNPNLRPDTIMTTEAELGSAIDLSCEAI 
GREPIKYLWFMGNAVADWISSSQGVRGPILHIERVGREHIGQYVCQVKNPIGTLNYTYRLTVKEPPSAIPRIIGEVEN 
QTLIAGSSGVLTCRVKCSCSEPIIQWLKHVDPEDIDAYKAAGRSLVPLPAPRPAEAEEFYLALEKWEDAPAYMERTVV 
QLHRTTSITATAAAAGEITVPEREFLSSRHEGEAEERLFVSRLRLRGPVSVPLHAGKYVVMTMSRSNLKAIDYAVAYV 
HIVPKSFNVTVHNIMVYCVVPIALILLIAFVSLYCFLSRRNKDLEHPATRRGNVIFPPVVRGHSMSGVKKEYRPIVRQT 
PQSSVFSNGNTVSNGSKTSSRLPSYVAHSSPSQWNAATATASITSPSPHSNSFHNFQSHVSQPPTQLSPSPSTFYNY 
SGLQSLSNQPTYWHPPAPSVATETSFDQYSAIMGNPPSASGGLSVSHSASSSQRPQLSFPNV 
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8. List of Abbreviations 
 
aa   amino acid 
AE   Alveolar Echinococcosis 
AF 1   Activation Function 1 
AF 2   Activation Function 2 
aFGF   acidic Fibroblast Growth Factor 
AKT   protein kinase B 
APS   ammonium persulfate 
Arg   arginine 
AR-Smads  TGF-β/activin receptor regulated Smads 
ATP   Adenosine triphosphate 
BCL2   B-cell lymphoma 2 
bFGF   basic Fibroblast Growth Factor 
BIBF1120  „Vargatef” (Z)-methyl3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido) 
phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate] 
BMP   Bone Morphogenetic Protein 
BMP2   Bone Morphogenetic Protein 2 
BrdU   5-bromo-2'-deoxyuridine 
BR-smad EmSmadE BMP receptor regulated Smads 
BS   bile salts 
C. elegans  Caenorhabditis elegans 
CA   cholic acid 
CAR   Constitutive Androstane Receptor 
CCND1   gene of G1/S-specific cyclin-D1  
CDA   chenodesoxy acid 
CDK inhibitors  Cyclin-dependent kinase inhibitors 
cDNA   complementary Deoxyribonucleic Acid 
CIP   calf intestinal phosphatase 
D. japonica  Dugesia japonica 
D. melanogaster Drosophila melanogaster 
DA   dafachronic acid  
DAF12   abnormal dauer formation 12 
DBD    DNA-binding domain 
DCA   desoxycholic acid 
DA   dafachronic acid 
DjFGFR1  Dugesia japonica Fibroblast Growth Factor Receptor 1 
DjFGFR1  Dugesia japonica Fibroblast Growth Factor Receptor 2 
DjNDK   Dugesia japonica nou-darake 
DMEM   Dulbecco’s modified Eagle’s medium  
DmHNF4  Drosophila melanogaster Hepatocyte Nuclear Factor 4 
DMSO   Dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DR5   Direct repeat 5 
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E. multilocularis Echinococcus multilocularis 
E2F1   human transcription factor E2F1 
EGF    Epidermal Growth Factor 
EGFR   Epidermal Growth Factor Receptor 
EGL-15   Caenorhabditis elegans fibroblast growth factor receptor 
ELISA   Enzyme-Linked Immunosorbent Assay 
EmABP   Echinococcus multilocularis Apolipoprotein A-I Binding Protein 
EmAlien  Echinococcus multilocularis Alien-like protein 
Emelp    Echinococcus multilocularis ezrin-radixin-moesin-like protein 
EmFR TkD-  Echinococcus multilocularis Fibroblast growth factor receptor tyrosine kinase 
mutant 
EmFR   Echinococcus multilocularis Fibroblast Growth Factor-like Receptor 
EmHNF4  Echinococcus multilocularis Hepatocyte Nuclear Factor 4-like 
EmMPK1  Echinococcus multilocularis Mitogen-Activated Protein Kinase 1 
EmMPK3  Echinococcus multilocularis Mitogen-Activated Protein Kinase 3 
Emndk   Echinococcus multilocularis nou-darake-like 
EmNHR1  Echinococcus multilocularis Nuclear Hormone Receptor 1 
EmNHRs   Echinococcus multilocularis Nuclear Hormone Receptors 
EmNIP1  Echinococcus multilocularis Normal Immunosuppressive Protein 
EmSkip   Echinococcus multilocularis Ski-interacting protein 
EmSmads  Echinococcus multilocularis Smads 
EmTR1   Echinococcus multilocularis transforming growth factor-β receptor 1 
Erk   extracellular signal-regulated kinases 
ERM    ezrin-radixin-moesin 
CESCKA   amino acid motif “Cysteine- Glutamic acid- Serine- Cysteine- Lysine- Alanine” 
EST   expresses sequence tag 
E-value   expect value 
FBS   fetal bovine serum 
FGF   Fibroblast growth factor 
FGFR   Fibroblast growth factor receptor 
FGFR-1, -2, and-3 human Fibroblast growth factor receptor-1, -2, -3 
FGFRL1   fibroblast growth factor receptor like 1 
Fig.   Figure 
FRS2   fibroblast growth factor receptor substrate 2 
Grb2   Growth factor receptor-bound protein 2 
GTP   Guanidine triphosphate 
GVBD   Germinal Vesicle Breakdown 
HNF1   Hepatocyte Nuclear Factor 1 
HNF4   Hepatocyte Nuclear Factor 4 
H. sapiens  Homo sapiens 
HR-96   Drosophila hormone receptor 96 
HREs    Hormone responsive elements 
Hs   Homo sapiens 
IC50   half maximal inhibitory concentration  
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Ig    immunoglobulin 
Igf   Insulin-like growth factor 
IR   Insulin receptor 
JM   juxtamembrane domain 
JNK   juxtamembrane domain (JM)  
LBD    ligand-binding domain 
LCA   lithocholic acid 
LXR   liver X receptor 
MAP   mitogen-activated protein 
MAPK   mitogen-activated protein kinase 
Mc   Metacestod vesicle 
MKK1   mitogen-activated protein kinase kinase 1 
NDK    nou-darake 
NHR   Nuclear Hormone Receptor 
NHRs   Nuclear Hormone Receptors 
NPC1   Niemann-Pick disease, type C1 protein 
NR1   Nuclear Receptor 1 subfamily 
Pa   activated protoscoleces 
PAA   polyacrylamide 
Pc   Primary cells 
PCR   polymerase chain reaction 
Pd   dormant protoscoleces 
PDGFR    Platelet Derived Growth Factor 
PIP3K/AKT  phosphatidylinositol 3,4,5-trisphosphate kinase/ protein kinase B pathway 
PLCγ   Phospholipase C γ 
PXR   pregnane X receptor 
RACE    Rapid amplification of cDNA ends 
Raf   rapidly growing fibrosarcoma or rat fibrosarcoma 
RAP250  nuclear receptor-activating protein 250 
Ras   Rat sarcoma 
RH- cells  Rat hepatoma cells 
RTK    receptor tyrosine kinases 
RT-PCR   Reverse Transcription Polymerase Chain Reaction 
RXR   Retinoid X receptor 
S. mansoni  Schistosoma mansoni 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
SER   Schistosoma mansoni epidermal growth factor receptor homologue 
siRNA   small interference Ribonucleic acid 
S. japonicum  Schistosoma japonicum 
SKIP   Ski-interacting protein 
SL   spliced leader 
Sm   Schistosoma mansoni 
SM   Skim milk 
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Sm2DBDba   Schistosoma mansoni nuclear receptor with 2 DNA-binding domains 
SMART   Simple Modular Architecture Research Tool 
SmDSF   Schistosoma mansoni homologue of Drosophila dissatisfaction gene 
SmFTZ-F1α  Schistosoma mansoni Fushi tarazu-factor 1 α 
SmHR96a  Schistosoma mansoni homologue of Drosophila hormone receptor 96 alpha 
SmNR1   Schistosoma mansoni nuclear receptor 1 
SmPNR   Schistosoma mansoni homologue of photoreceptor-specific nuclear receptor 
SmRAR-like receptors Schistosoma mansoni retinoic acid receptor-like gene 
SmRXR2  Schistosoma mansoni retinoid X receptor 
SmTLL   Schistosoma mansoni homologue of Drosophila tailless gene 
SmTRa   Schistosoma mansoni thyroid hormone receptor a 
SmTRb   Schistosoma mansoni thyroid hormone receptor b 
SNW/SKIP family SKI-interacting protein family 
SOS   Ras guanine nucleotide exchange factor SOS1/2 
Src   sarcoma proto-oncogene tyrosine-protein kinase 
SU5402 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone 
tBLASTN  Search translated nucleotide database using a protein query Basic Local 
Alignment Search Tool 
TEMED  N,N,N',N'-tetramethylethane-1,2-diamine (Merck) 
TGF-β    Transforming Growth Factor-β 
TM    Transmembrane Domain 
TyrKc   Tyrosine Kinase Domain 
VDR    Vitamin D3 Receptor 
VEGFR-1,-2, and-3,  Vascular Endothelial Growth Factor Receptor-1, -2, -3 
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